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ABSTRACT
Objectives: Rare prostate epithelial stem cells have been implicated in the 
aetiology o f prostate disease, yet are overlooked in studies on the whole tissue. 
When prostate epithelial cells are cultured at low density, two distinct colony 
types arise, postulated to represent the progeny o f stem cells (type II colonies) 
and committed ‘transit amplifying’ cells (type I). This project aimed to further 
characterize these rare colonies and confirm their position in the prostate 
epithelial cell hierarchy, in benign, and for the first time, malignant tissue.
Methods: Colonies derived from transurethral resection tissue were compared 
for proliferation, differentiation, colony self-renewal and gene expression. Paired 
benign and malignant radical prostatectomy samples were cultured. To confirm 
the benign / malignant nature o f individual colonies, loss o f heterozygosity and 
expression o f known prostate cancer markers were assessed.
Results: There was a trend to greater type II colony proliferation, but no 
difference in ability to differentiate into multi-layered acinus-like structures 
expressing early and late epithelial markers. When passaged, type II colonies 
never re-created themselves, but resembled type I colonies. Using cDNA 
microarrays, comparison o f  gene expression in the two colony types showed a 
limited magnitude o f differences, most notably in differentiation markers. 
Malignant tissue yielded both colony types, which were indistinguishable from 
their benign counterparts. Neither loss o f heterozygosity analysis nor prostate 
cancer marker expression distinguished benign from malignant colonies.
Conclusions: These colonies behave like differently-aged populations o f transit 
amplifying cells -  the committed offspring o f the stem cell. If a stem cell does 
generate type II colonies, it appears to lose self-renewal ability and differentiate 
in culture. Colonies derived from cancer tissue show neither a malignant 
genotype nor phenotype suggesting that malignant cells are not cultured in these 
conditions. This highlights the need to confirm malignancy in primary prostate 
cancer cultures, hitherto assumed by many authors.
[300 words]
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CHAPTER 1: INTRODUCTION
When freshly isolated prostate epithelial cells are cultured at low-density in 
serum-free medium, two distinct types o f colonies clonally expanded from single 
cells are obtained. It has been postulated that these colonies derive from stem 
cells or their progeny, transit amplifying (TA) cells. This thesis aimed to 
characterise these two colony types from both benign and malignant prostate 
tissue, and establish what differences in gene expression lay behind their 
different phenotypes, and behind the malignant or benign nature o f the prostate 
tissue that they derive from.
1.1 The clinical entity o f prostate disease
The prostate gland is situated below the bladder in the male urogenital tract, 
enclosing the urethra and ejaculatory ducts. Though small, it is responsible for a 
disproportionate amount o f morbidity and mortality. Adenocarcinoma o f  the 
prostate is the commonest non-cutaneous cancer o f Western males, with an 
annual UK incidence o f 93 men per 100,000 and a UK morbidity o f 27 men per
100.000 (http://www.statistics.gov.uk). In 2004, this equated to 9,163 men, or 
3.7% o f all male deaths. Additionally, it has been estimated that 50% o f males 
will develop symptomatic benign prostatic hyperplasia (BPH) in their lifetime 
and 50% will experience prostatitis (Partin and Rogriguez, 2002).
Both BPH and prostate cancer are diseases o f the prostate epithelium, albeit 
influenced by adjacent stroma. Elucidating the processes that govern the growth 
and turnover o f the normal and pathological prostate epithelium is therefore key 
to understanding and manipulating these diseases.
1.2 The normal prostate
1.2.1 The function o f the prostate
The prostate gland contributes 0 .5 -lml o f secretions to seminal fluid, with the 
remaining 80% o f the ejaculate deriving from the seminal vesicles, Cowper’s and
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Littre’s glands and the testes. The constituents o f semen have been widely 
studied, though the physiologic function o f many o f them is poorly understood 
(Aumuller and Seitz, 1990). Seminal plasma contains high concentrations o f 
fructose, zinc, citrate, spermine, prostaglandins as well as potassium, 
immunoglobulins, amino acids, seminogelin and enzymes such as prostatic acid 
phosphatase (PAP), proteases, esterases, a-amylase, p-glucuronidase and 
prostatic specific antigen (PSA) -  a serine protease. Together they optimise 
conditions for fertilization by providing a buffered environment for the sperm, 
improving sperm motility and extending viability. Seminogelin promotes 
coagulation o f the ejaculate, which subsequently liquifies, possibly due to the 
action o f PSA (Lilja et al, 1987). Prostaglandins suppress the female immune 
response to foreign sperm antigens; and spermine, spermidine and zinc have 
antibacterial properties (Aumuller and Seitz, 1990).
During ejaculation, the seminal vesicles, prostate and bladder neck contract 
forcing semen into the prostatic urethra. Subsequent relaxation o f the distal 
prostatic sphincter and rhythmic bulbocavernosal muscle contractions then expel 
the semen.
1.2.2 Human prostatic development
For the first six weeks o f gestation both sexes have a bipotential gonad. Under 
the influence o f the SRY gene on the Y chromosome, Sertoli cells within the 
primitive gonads secrete Mullerian Inhibitory Substance that causes regression o f 
the female genital precursors and stimulates testicular Leydig cells to produce 
testosterone (Thomas, 2002).
The male genitalia derive from the mesodermal Wolffian ducts (seminal vesicles, 
epididymes, vas deferens and ejaculatory ducts) and the endodermal urogenital 
sinus, (prostate, urethra, bulbourethral and periurethral glands, penis and 
scrotum). The prostate develops in the uppermost part o f the urogenital sinus 
where the Wolffian ducts open into the developing urethra, though the exact 
contributions o f each tissue type are not fully elucidated (Aumiiller et al, 1998). 
Testosterone enables Wolffian duct differentiation, however urogenital sinus
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differentiation is dependent on dihydrotestosterone (DHT) produced from 
testosterone by 5a-reductase enzyme in the urogenital sinus (Gilbert, 2000). The 
urogenital sinus mesenchyme is vital for the development o f the prostate and 
there is a complex interplay o f signals between the stroma, basement membrane 
and epithelium (see section 1.2.6).
The prostate develops between weeks ten and 22. Paired urethral epithelial buds 
invade surrounding urogenital sinus mesenchyme, radiating out in different 
directions to form the various zones o f the prostate. The buds branch out from 
their tips and cannulate to form ducts and acini. The surrounding mesenchyme 
develops into myoblasts and fibroblasts.
The prostate further matures due to the influence o f androgens at puberty until 
age 20. An increase in the number and complexity o f glands is seen, with 
increased secretory function (AumUller, 1983). Thereafter it remains dependent 
on dihydrotestosterone throughout life.
1.2.3 The anatomy o f the prostate.
The normal adult prostate volume is 20 ± 6ml (Berry et al, 1984). It is described 
as an inverted pyramid, with the base abutting the bladder and the urethra 
emerging just anterior and proximal to the apex. The prostate is surrounded by a 
thin capsule o f smooth muscle, collagen and elastin fibres, which blends 
internally with prostatic stroma and externally with pelvic fascia (Brooks, 2002, 
McNeal, 1998). The capsule is deficient where the prostate abuts the bladder and 
anterolaterally at the apex, where glands merge into the striated muscle o f the 
urethral sphincter. This is relevant in the histopathological assessment o f 
surgically removed prostates when determining whether cancer has grown 
beyond the gland, and whether the prostate has been removed intact.
At the midpoint o f  the prostatic urethra is the veru montanum, a protrusion o f 
tissue where the ejaculatory ducts from the seminal vesicles and vas deferens 
drain into the urethra alongside the prostatic ducts.
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The prostate tissue itself is comprised o f a branching arrangement o f glandular 
epithelial structures supported by contractile fibromuscular stroma that assists 
duct emptying during ejaculation. The internal anatomy o f the prostate was a 
subject o f debate for many years (McNeal, 1980). In 1968, after studying 
hundreds o f post-pubertal prostates sectioned in multiple planes, McNeal 
proposed four zones within the prostate, a model that remains widely accepted 
(McNeal, 1968). Zones were distinguished by differences in histology, duct 
architecture and sites o f urethral drainage; all thought to reflect different 
biological functions and account for different predilections to pathology 
(McNeal, 1988, McNeal et al, 1988). Figure 1.1 demonstrates how the separate 
zones fit together as a whole.
Figure 1.1: Zonal anatomy o f the prostate as described by J. E. McNeal (Am J 
Surg Pathol 1988; 12:619-33). A: Transition zone, B: Central zone, C: Peripheral 
zone, D: Anterior fibromuscular stroma.
1.2.3.1 The Transition zone
The transition zone in health represents 5% by volume o f the glandular prostate, 
but as the sole site o f BPH can grow to become the largest zone. It surrounds the
Transition zone
Central zone
Peripheral zone
Anterior fibromuscular strom a
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urethra proximal to the ejaculatory ducts and veru montanum, while its ducts 
radiate proximally from this level with the zone defined by a discrete 
fibromuscular margin. Histologically the acini and ducts are small, round, regular 
and smooth walled made up o f a simple columnar epithelium o f pale cells with 
basal nuclei (McNeal, 1988). Approximately 20% o f prostate adenocarcinoma 
arises here (McNeal et al, 1988).
1.2.3.2 The Central zone
Most o f the base o f the prostate is comprised o f this zone. Central zone ducts 
arise close to the ejaculatory duct openings and lead proximally. The ducts are 
typically large and irregular with septae projecting into the lumen. Cells are 
variable in length and extent o f  luminal border and nuclei are larger, paler and 
positioned throughout the cells. These histological appearances are reminiscent 
o f the seminal vesicles, suggesting a possible common derivation from the 
Wolffian ducts, supported by the fact that only up to 5% o f cancers arise here 
(Tisell and Salander, 1975).
1.2.3.3 Peripheral Zone
The peripheral zone represents around seventy percent by volume o f the 
glandular post-pubertal prostate constituting the bulk o f the posterior, apical and 
lateral prostate. Ducts radiate laterally and distally from the urethra distal to the 
veru montanum. Histologically, they are similar to transition zone ducts 
(McNeal, 1988). Seventy percent o f cancers arise in this zone and it is most 
commonly affected by chronic prostatitis (McNeal et al, 1988).
1.2.3.4 Anterior Fibromuscular Stroma
The anterior surface o f the gland is covered by stromal tissue extending from the 
bladder neck to the striated urethral sphincter, which contains no glandular 
tissue.
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1.2.4 Zonal variation within the prostate.
While the zones can be distinguished histologically and by their susceptibility to 
disease, their precise embryological, molecular and biological differences are 
less well established. Laczko et al (2005) compared the morphology, cell kinetics 
and immunohistochemistry o f  the three glandular zones. The peripheral zone and 
transition zone were comparable in appearance and rates o f proliferation and 
apoptosis while the central zone was distinct histologically, had half as many 
neuroendocrine (NE) cells and lower rates o f cell turnover. They found no 
differences in cytokeratin or androgen receptor (AR) expression, though 
lactoferrin was more frequent in the central zone and the stromal cells here 
expressed significantly more smooth muscle actin. Others have reported 
segregation o f  oestrogen receptor a  to peripheral zone stroma and greater 
expression o f stromal al-adrenoreceptors in the central and transition zones 
compared to the peripheral zone (Tsurusaki et al, 2003; Kobayashi et al, 1991).
The protein expression o f all three zones was compared by Lexander et al (2005) 
who found the peripheral and transition zones to have highly similar major 
protein expression profiles, but identified ten proteins differentially expressed by 
the central zone.
Van der Heul-Nieuwenhuijsen and colleagues explored peripheral and transition 
zone differences and their possible implications using DNA microarrays (2006). 
In all, 147 genes were more highly expressed in the transition zone, and these 
tended to overlap with those over-expressed in BPH and under-expressed in 
prostate cancer, while 199 genes more highly expressed in the peripheral zone 
were almost all known to be over-expressed in prostate cancer. As several o f the 
latter genes had been previously implicated in the origin and progression o f 
cancer, while some over-expressed in the transition zone are known to have anti­
tumour properties, the authors proposed that the zone-specific microenvironment 
o f the peripheral zone might support malignant transformation, while that o f the 
transition zone might be protective. As several o f the highly expressed transition 
zone genes are stroma specific it is possible that stromal-epithelial interactions 
help establish these different milieu.
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1.2.5 The histology of the norm al prostate
The prostate may be described as ‘normal’ for only a brief time window during 
life as prostate development is only complete after puberty, and prostate disease 
may commence as early as the 4th decade (Berry, 1984).
Figure 1.2: Haematoxylin 
and eosin (H&E) stained 
view o f a normal prostate 
acinus surrounded by fibro­
muscular stroma.
O  indicates a cell in the 
basal layer, and l£ a luminal 
cell.
The normal prostate is comprised o f epithelial ducts and acini surrounded by 
stroma (see figure 1.2). The epithelial compartment is believed to comprise stem 
cells, TA cells, terminally differentiated secretory cells and NE cells arranged as 
luminal and basal layers o f epithelium (De Marzo et al, 1998a). The relationship 
between these various epithelial cell types is discussed in more detail in section
1.3 below.
The luminal epithelial cells outnumber the basal epithelial cells by 2.7:1.0 
(Hudson et al, 2001). These terminally differentiated, functional cells form a 
continuous layer as tall, columnar cells with their apical borders defining the 
lumens of the prostate acini and ducts and their bases separated from the 
basement membrane by the basal layer (De Marzo et al, 1998a). Their cytoplasm 
is rich in secretory granules containing enzymes such as PSA and PAP. 
Secretions produced within the cells are secreted into the prostatic acini and 
ducts and ultimately drain into the urethra.
Small flattened basal cells with minimal cytoplasm rest on the basement 
membrane (Bonkhoff and Remberger, 1996; Rizzo et al, 2005). They may not be
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easily visible but can be demonstrated as a discrete layer by staining with the 
basal cell specific antibody 340-El 2 that binds to high molecular weight 
cytokeratins 1,5, 10 and 14 (Wojno and Epstein, 1995). TA cells and possibly 
prostate stem cells are thought to reside in this layer (Bonkhoff. 1998).
It has long been known that castration results in an almost complete involution o f 
the prostate epithelium, a fact utilised today in the treatment o f BPE1 and prostate 
cancer. Withdrawal o f androgens (either by castration or drugs) results in loss o f 
nearly 90% of the prostate epithelial cells (Staack et al, 2003). This cell loss 
occurs through apoptosis from the androgen dependent luminal cell layer, 
leaving the androgen independent basal layer and stroma intact (see section 1.3.1 
below, English et a l  1989). Restoration o f androgens results in epithelial 
regrowth until the gland reaches its previous size.
Terminally differentiated NE cells are scattered throughout the epithelium, again 
resting on the basement membrane. There are two types, ‘open’ NE cells which 
protrude apical microvilli into the lumen, and ‘closed' ones that send long 
processes to adjacent cells (diSant-Agnese and deMesy-Jensen, 1984; diSant- 
Agnese et a l  1985). Also inconspicuous, they are best demonstrated using stains 
for serotonin, synaptophysin or chromogranin A, but lack AR or PSA. Their 
nuclei are also negatively staining for Ki67, a proliferation associated antigen so 
they are thought to be terminally differentiated, post-mitotic cells (Bonkhoff and 
Remberger, 1996; Bonkhoff et a l  1995). NE cells are thought to help regulate 
prostate growth, differentiation and secretion through the paracrine and autocrine 
secretion o f neurotransmitters, hormones and bioactive molecules for which 
receptors have been demonstrated in the prostate (Vashchenko and 
Abrahamsson, 2005)
The surrounding stromal tissue is comprised o f smooth muscle cells, fibroblasts, 
myofibroblasts, nerves, capillaries and lymphatics. It supports the ducts, 
contracts to assist duct emptying during ejaculation and is important in directing 
epithelial function and growth (McNeal, 1998). An extracellular matrix o f 
collagens, elastin, fibronectin, laminin and glycosoaminoglycans, complex
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polysaccharide and glycolipids exists between the cells and forms the basement 
membrane (Aumuller, 1983).
1.2.6 Stromal-epithelial interactions
A complex interplay o f signals between the epithelium and the stroma across the 
basement membrane starts as early as the prostate itself and continues throughout 
life. The prostate develops under the permissive influence o f DHT. This activates 
mesenchymal AR resulting in the induction o f epithelial differentiation in the 
adjacent endoderm, through an unknown mechanism, which might involve the 
paracrine effects o f a diffusible growth factor, or alterations in the configuration 
o f insoluble extracellular matrix proteins (Cunha et al, 2002). The primitive 
epithelium lacks AR at this stage so must be influenced indirectly by DHT 
(Takeda and Chang, 1991).
The inductive ability o f mesenchyme was elegantly demonstrated by Cunha and 
colleagues (1983) using an assay system whereby embryonic tissue can be 
slipped under the renal capsule o f male nude mice, thereby providing an 
angiogenic and androgenic environment that supports further development. They 
demonstrated the ability o f rodent urogenital sinus mesenchyme to induce 
prostate development in various embryonic epithelia and even the non-glandular, 
AR negative adult urinary bladder.
In turn, prostate epithelium induces urogenital sinus mesenchyme to undergo 
smooth muscle differentiation. Co-culture o f urogenital sinus mesenchyme with 
adult prostate or bladder epithelium in male mice produces prostatic ducts 
surrounded by a-actin positive smooth muscle cells (Cunha et al, 1992).
Overall, it appears that stromal androgen sensitivity is essential for prostate 
proliferation and development, orchestrated via paracrine mechanisms, but 
subsequent differentiation into functional secretory epithelium requires epithelial 
expression o f AR and direct androgen effects (Cunha and Young, 1991). The 
situation is similar in adulthood, with stromal smooth muscle ARs maintaining a
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fully differentiated, growth quiescent gland, while epithelial ARs ensure 
secretory function (Cunha and Young, 1991).
1.2.7 Androgens and the prostate
Prostate growth, maintenance and function throughout life are dependent on the 
continued presence o f androgens. The testes produce >95% o f circulating 
androgens in the form o f testosterone with the remainder arising from adrenal 
secretion o f the weaker androstenedione, though only testosterone is biologically 
significant to the prostate. Only 2% o f  circulating testosterone is unbound to 
plasma proteins and thus available for conversion to DHT. This free testosterone 
is taken up by prostate cells and converted to DHT by cytoplasmic 5a-reductase 
enzyme. Within the prostate therefore DHT is present in five-fold greater 
concentrations and is 1.5 to 2.5 times as potent as testosterone (Veltri and 
Rodriguez, 2007a).
Inside the prostate cell, DHT binds to cytoplasmic ARs, activating them and 
causing their transport in pairs into the nucleus. Following the binding o f  other 
co-factors, the protein complex acts as a transcription factor at androgen response 
elements within the promoters o f various genes. A cell specific cascade o f gene 
and protein expression ensues (Veltri and Rodriguez, 2007b).
Castration results in a 90% decrease in total epithelial cell number and a slower 
40% decrease in stromal cell number (DeKlerk et al, 1976; Staack et al, 2003). 
Hours after withdrawal o f testosterone, the active and irreversible process o f 
apoptosis commences in the luminal cells, leaving only androgen independent 
cells surviving (Isaacs, 1984). In the rat ventral prostate this amounts to a 
subpopulation o f cuboidal cells in the luminal layer adjacent to an intact layer o f 
basal cells (English et al, 1987). Gerald Cunha and colleagues have again studied 
whether apoptosis is triggered by epithelial or stromal events and implicated the 
latter (Prins et al, 1991; Cunha et al, 2004).
When castrated rats are treated with androgens, there is an initial delay o f one 
day before the onset o f DNA synthesis, which peaks at two to three days then
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subsides to normal once the gland is restored to its normal size and function 
(Suffrin and Coffey, 1973). This cycle o f withdrawal and replacement can be 
repeated over 30 times, or over three years after castration suggesting the 
existence o f a long-lived, androgen-independent population o f stem cells in the 
basal layer (Isaacs and Coffey, 1989).
1.3 Epithelial cellular hierarchies.
All epithelial tissues within the human body are maintained throughout life by a 
constant process o f  cell turnover. The loss o f terminally differentiated cells must 
be balanced by the generation o f new cells. For some tissues, this requires a very 
high rate o f cell turnover throughout life, for instance in man, the entire outer 
layer o f the skin is shed each day (Dexter, 1987). This challenge is met by a tiny 
population o f epithelial stem cells responsible for tissue homeostasis and 
regeneration after tissue loss.
Epithelial stem cells, be they in gut, skin or breast tissues are rare, long-lived, 
infrequently dividing yet infinitely proliferative, tissue specific cells (Potten and 
Loeffler, 1990). They possess two defining characteristics -  pluripotency with 
the ability to generate differentiated progeny in a number o f different tissue- 
specific cell lineages, and the ability to self-renew such that stem cell mitosis 
results in one new stem cell and one daughter or TA cell.
TA cells have limited though significant proliferative potential, are committed to 
a certain cell lineage or subset o f lineages, and divide frequently to ensure the 
clonal amplification o f the initial TA cell into the differentiated cells that 
comprise the bulk o f the tissue. The TA cells divide until their proliferative 
potential is exhausted and they become post-mitotic, terminally differentiated 
cells. These specialised cells perform the function o f the tissues.
The traditional stem cell model therefore describes a linear and irreversible 
process o f differentiation (Morrison et al, 1997). There is an inverse relationship 
between proliferative potential (greatest in the stem cell) and differentiation 
(greatest in the terminally differentiated cells). Successive generations o f TA 
cells progressively lose the former and gain the latter. In some tissues, full
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function is clearly incompatible with mitosis (mature erythrocytes and cornified 
epithelial cells lose their nucleus, muscle filaments preclude cell cleavage) so the 
separation o f proliferation and terminal differentiation are essential.
1.3.1 Stem cell characteristics
Our understanding o f stem cells originated from studies on high turnover tissues 
such as the haematopoietic system, epidermis and intestinal mucosa. More 
recently stem cells have been recognised in other organs, such as liver, olfactory 
epithelium, breast and brain, and the prostate stem cell phenotype is now being 
approached (Houghton et al, 2007). Stem cells are typically classified by their 
specific pattern o f cell markers. However, their initial identification requires 
behavioural assays, most importantly o f the fundamental characteristics o f  self­
renewal and pluripotency.
Pluripotency is defined as the ability o f the undifferentiated stem cell to produce 
differentiated progeny for the full range o f  cell types in a specific tissue. 
Embryonic stem cells are described as totipotent, i.e., given the necessary signals 
they can give rise to any cell lineage within the organism. During development, 
these cells are progressively committed to an increasingly narrow repertoire o f 
cells until as adult stem cells they are ordinarily restricted to tissue specific 
lineages. Some stem cells such as muscle satellite cells are in reality unipotent, 
as only one lineage arises (Marshak et al, 2001). However bone marrow 
haematopoietic stem cells (HSC) produce all blood cell types: red blood cells, B 
and T lymphocytes, natural killer cells, neutrophils, basophils, eosinophils, 
monocytes, macrophages and platelets (Kondo et al, 2003). Isolated human bone 
marrow stem cells will repopulate the bone marrow o f a lethally irradiated mouse 
for all lineages for its life span and successful serial transfer into secondary 
recipients has demonstrated self-renewal properties (Larochelle et al, 1996). 
Self-renewal implies the generation o f at least one pluripotent new stem cell at 
mitosis. The lineage potential and properties o f a stem cell are determined by 
dynamic intracellular properties and/or cues from its microenvironment 
(Morrison et al, 1997). Following mitosis, the exact mechanisms whereby stem 
cells decide whether to self renew or differentiate are unknown (Sherley, 2002).
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Stem cells characteristically reside in specific niches within the tissue, 
surrounded by supporting cells that help maintain a stable microenvironment 
(Potten and Loeffler, 1990). In gastrointestinal mucosa, it has been proposed that 
daughter cells that migrate outside o f the limited space o f the mucosal crypt are 
released from the restraints o f the niche microenvironment and differentiate (Yen 
and Wright, 2006).
Control o f stem cell fate is critical to ensure a balance o f cell proliferation and 
loss. Division o f a stem cell may be asymmetric, resulting in one TA cell and one 
stem cell or symmetric, producing either two TA cells or two more stem cells 
(Morrison et al, 1997). These situations result in tissue maintenance, tissue 
depletion or tissue growth respectively. Tissue growth may be intentional after 
tissue loss, or represent unrestrained self-renewal as seen in cancer.
Controversially, it has been proposed that the same chromatids are retained by 
the new stem cell at each asymmetric division with the new chromatid copies 
inherited by the daughter cell (Cairns, 2002; Potten et al, 2002). This prevents 
the retention in the stem cell pool o f mutations caused by inaccurate DNA 
replication, which instead are inherited by cells committed to maturation and 
death. Additionally stem cells are deficient in some DNA repair mechanisms, so 
that damaged DNA is not subject to error prone repair, but results in sacrifice o f 
the stem cell by apoptosis. This could account for the sensitivity o f stem cells to 
DNA damaging agents (Cairns, 2002).
Intimately associated with self-renewal is the longevity o f stem cells. They 
divide rarely being predominately found in the G0/G1 phase at cell-cycle 
analysis, thereby minimising DNA replication related mutations though this 
alone does not confer immortality (Li et al, 1998). Every chromosome has 
telomeric DNA at its ends, some o f which is lost at every cell division. Most 
cells therefore, can only undergo about 50 cell divisions before their 
chromosomes are critically shortened, and they undergo apoptosis (Hayflick, 
1961). Telomerase is a riboprotein enzyme complex with reverse transcriptase 
activity that replaces lost telomere sequences after mitosis, thereby allowing 
indefinite cell division (Campisi, 2005). Telomerase has been reported to be
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expressed in longer living or immortalised cells (Kim et al, 1994). Other 
epigenetic processes are also thought to help prevent senescence. Genes such as 
B m il, which are involved in chromatin remodelling, are highly expressed in 
haematopoietic and neural stem cells (Lessard et al, 2003; Molofsky et al, 2003).
There has been much interest in assigning the cells in the prostate epithelium to 
this model, with particular reference to the location and phenotype o f the prostate 
stem cell, which has the potential to be the key focus o f intervention for the 
treatment o f prostate diseases.
1.4 Models o f prostate epithelial cell lineages
The different cell populations within the prostate epithelium have long been 
studied in terms o f their behaviour, phenotype and ultrastructural appearances, 
and more recently their intracellular and cell surface marker expression. In the 
1980’s and 1990’s, three models o f prostate epithelial maintenance were 
proposed to account for the three histologically distinct cell types (basal, luminal 
and NE cells) present in the two-layered prostate epithelium.
1. The luminal and basal layers represent discrete cell lineages with discrete 
stem cells, that divide when necessary to self renew and maintain the 
relevant cell layer. NE cells represent an entirely separate third lineage 
(Aumiiller, 1983; Evans and Chandler, 1987).
2. A basally located stem cell divides rarely, generating a stem cell and a 
basal TA cell. This TA cell can differentiate into two distinct lineages 
producing terminally differentiated luminal secretory cells after many 
divisions or rarer NE cells after fewer (Isaacs, 1987).
3. The progeny o f the stem cells in an intermediate location become 
committed to one o f two separate lineages, producing either basal cells or 
luminal cells (Wang et al, 2001).
In the 1980’s, from work in rat seminal vesicles and prostates, Aumiiller (1983) 
proposed the ‘homeostatic constraint mechanism o f accessory gland cell growth’, 
which stated that prostate secretory (luminal) cells in the normal prostate divide
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when the amount o f secretory product within them falls below a critical level. 
This mechanism depends upon the presence o f androgens, and stromal growth 
factors reaching the secretory cells via the basal cells (Aumiiller, 1983). In the 
absence o f the appropriate hormones, the basal cells are stimulated to proliferate, 
though their capability to differentiate is low.
In this model, NE cells represent a distinct lineage, derived from neural crest 
cells in periprostatic paraganglia (Aumiiller et al, 1999; 2001). During gestation, 
these invade into the developing prostate and distribute themselves throughout 
the gland. Accordingly there are fewer NE cells at the periphery, the number o f 
NE cells is stable throughout development and they reach maturity 15 years 
before the epithelial cells.
Evans and Chandler (1987) in agreement with Aumiiller, further proposed that 
basal and luminal layer cells were individually self-replicating cell types with 
discrete functions. During their study o f post-natal rat prostate development, they 
observed basal cells as small solid cords o f cells with a lumen and secretory cells 
appearing a few days later. Mitotic figures were seen in both cell layers even 
after they had acquired their characteristic luminal and basal ultrastructural 
features. Mitoses were seen more frequently in the luminal layer and the rate o f 
increase o f luminal cell number appeared more related to their own proliferative 
activity than the slower basal cell rate. No cells with intermediate ultrastructural 
characteristics were seen. However this work in the 1980’s distinguished cells 
only by their appearance and little corroborating evidence has emerged to 
support this model since its proposition.
An alternative stem cell organisation o f  the prostate was proposed by Isaacs 
(1987), based on the kinetics o f prostate growth. In this model, a small 
population o f androgen independent, basal stem cells generate TA cells which 
are committed to become either prostate luminal cells or more rarely NE cells. 
Basal TA cells are androgen independent for survival yet will proliferate in 
response to androgen to amplify the cell numbers derived from the slowly 
proliferating stem cell. During progressive divisions the TA cells migrate into the 
luminal layer where they become dependent on androgens for survival and
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undergo fewer divisions. Ultimately terminally differentiated secretory cells arise 
within the luminal compartment (see figure 1.3).
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Figure 1.3: Diagrammatic representation o f the cell populations within the 
prostate epithelium (Isaacs, 1987; Bonkhoff and Remberger 1996).
Evidence for this model derives from several sources. The prostate’s ability to 
reconstitute itself with androgen reintroduction after castration suggests the 
presence o f androgen independent stem cells in the basal layer (Isaacs and 
Coffey, 1989). Additionally, the identification o f cells with an intermediate 
phenotype between the basal and luminal cells allowed the definition o f the TA 
cell population. Thus the markers expressed by epithelial cells at different 
locations in the epithelium show a progression that fits with their postulated 
process o f differentiation.
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1.4.1 Basal, interm ediate and lum inal epithelial cell markers
Since the 1970 s, cells sharing m icroscopic features o f  both basal and secretory 
cell have been reported (Derm er, 1978). Immunohistochemistry and 
im m unofluorescence o f  m any other m arkers have better characterised the 
phenotypes o f  the basal, TA and luminal cells. More recently the phenotype o f 
the stem cell population has becom e m ore established (discussed in section 1.5 
below).
Cytokeratin expression varies betw een the epithelial layers. Keratins are one o f 
the five classes o f  interm ediate filam ent proteins within the eukaryote 
cytoskeleton in all epithelial cells. Tw enty keratins (K) have been documented 
but K l, 4, 6, 10 and 11 are not expressed in prostate epithelium (Moll, 1994).
Basal cells express K15, 5 and 14. Luminal cells express high levels o f K8 and 
K 18 (Sherw ood et al, 1991; N agle et al, 1991; Yang et al, 1997; van Leenders et 
al, 2000; Schm elz et al, 2005). Cells expressing combinations o f  these and other 
keratins are believed to be TA cells in transition between the two phenotypes. 
Num erous studies have identified interm ediate cell phenotypes, listed in table 1.1 
using a range o f  antibodies with d ifferent specificities for the keratin family.
Epithelial
layer
Phenotype Reference
Basal K14"K5+K18",
K 1 4 'K 5 +K I8 +
K14‘ K 1 5 \  K 14+K 15+, 
K14+K 1 7 \  K14"K 17+, 
K 15+K 1 9 \  K15+K19" 
K 14 'K 5+K 1 9 \ K 14+K 19+ 
K5+ K 6a+, K 6a+K19~ 
K8+K 18+
Verhagen et al, 1992; van Leenders et al, 
2000; Hudson et al, 2001 
Hudson et al, 2001
Verhagen et al, 1992; Hudson et al, 2001
Schmelz et al, 2005
Nagle et al, 1991; Yang et al, 1997
Luminal K5+K 18+
K 19+K8‘, K 19+K8+ 
K 6a^K 19\ K 6a"K 19f 
K 194K 7+
Verhagen et al, 1992; van Leenders et al, 
2000
Verhagen et al, 1992; Hudson et al, 2001 
Schm elz et al, 2005 
Hudson et al, 2001
Table 1.1: Interm ediate cytokeratin  phenotypes o f  cells in the basal or luminal 
prostate epithelium .
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So in summary, while K14 is only expressed in the basal layer, TA cells express 
a number o f keratins as they migrate from the basal to the luminal layer, 
ultimately retaining only K8 and K18. Early TA cells within the basal layer lose 
K14 expression and retain K15, K17, K19 and K5, later luminal TA cells 
continue to express K19 and K5 and gain K8 and K18 expression. After 
androgen ablation, K5+ and K5~ cells exist in the subpopulation o f remaining 
prostate cells suggesting that late intermediate K 5 ' cells within the luminal layer 
are still androgen independent (van Leenders and Schalken, 2003).
A number o f other differentially expressed markers have also been reported. 
Prostate stem cell antigen (PSCA) despite its title is thought to be a marker o f 
late TA cells in the basal layer that co-express K5/K14/K18 (Tran et al, 2002).
De Marzo et al (1988a) studied expression o f a cyclin-dependent kinase inhibitor 
p27K,pl, which is thought to prevent cell division and may signal exit from the 
cell cycle. Luminal cell nuclei stained strongly for p27K,pl, but this was strong to 
absent in basal cells. There was also an intermediate layer o f p27Kipl negative 
cells that were positive for the 34BE12 basal keratin marker (that binds K5 and 
K14). The authors postulated that absence o f p27Kipl correlated with rapid cell 
division such that slowly cycling p27Kipl positive stem cells produced p27Kipl 
negative TA cells that proliferate to amplify the epithelium prior to terminal 
differentiation and re-expression o f p27Kipl.
Other basal cell markers include p63, CD44, the transcription factor ETS-2 and 
EGFR (epithelial growth factor receptor) (Liu et al, 1997; Kellogg Parsons et al, 
2001; van Leenders and Schalken, 2003). The nuclear phosphoprotein pp32, 
found in self-renewing and long-lived cell populations is moderately expressed 
only in basal cells (Kadkol et al, 1998). The luminal layer also secretes PSA and 
PAP and expresses CD57 and greater quantities o f nuclear AR than basal cells 
(Ruizeweld de Winter et al, 1991; Liu et al, 1997).
As would be expected with Isaacs’ model, the distribution o f Ki67 suggests that 
80% o f proliferating epithelial cells are in the basal layer (Hudson et al, 2001). 
The antiapoptotic oncogene Bcl-2, expressed in stem cells and proliferation 
zones in the skin and gut, is also expressed in the basal cell layer, but
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downregulated in the luminal cells, while the pro-apoptotic protein CPP32 (a 
caspase protein that acts as an apoptosis effector molecule) is more highly 
expressed luminally (Bonkhoff and Remberger, 1996; Krajewska et al, 1997). In 
situ hybridisation has demonstrated telomerase exclusively in basal cells (Paradis 
et al, 1999). GST-rc, a member o f the it class o f glutathione S-transferases that 
protect against electrophilic carcinogens is also only basally expressed, perhaps 
implying greater protection o f the genome in the longer-lived stem cells 
(DeMarzo et al, 1998b).
In Isaacs’ stem cell model, the NE cells derive from division o f the same 
population o f stem cells, but the daughter cells differentiate into an alternative 
lineage. Cells have been reported that share epithelial cell and NE characteristics, 
which may represent the differentiating, proliferating cells o f the NE lineage. 
Cells co-expressing chromogranin A and PSA have been identified in 
hyperplastic prostates and adenocarcinomas, while occasional ‘closed’ NE cells 
positive for chromogranin A and basal cytokeratins have been seen in normal and 
hyperplastic glands (Bonkhoff et al, 1994a). Rumpold et al, (2002) reported the 
appearance o f K5/K14 and chromogranin A expressing ‘NE-like’ cells appearing 
de novo in cultures o f basal (positive for K5/14 and CD44) epithelial cells after 
three days. These cells were not however seen in the studies by Aumiiller et al 
(2001).
Cunha and colleagues however argued against this hierarchy based on their 
studies o f embryological cell characteristics (Wang et al, 2001). They reported 
that the cells o f the urogenital sinus epithelium, (that might be expected to be 
rich in prostate progenitor/stem cells) in mice, rats and humans all co-express 
luminal and basal cell markers. Exclusively luminal markers are seen only once 
prostate buds and ducts form at 10 weeks o f gestation and purely basal cells are 
first seen even later at week 18. They therefore proposed that basally located 
K8+/18+/14+/5+/19+, p63+, GST-7t+ cells represented the true stem cells. The 
frequency o f these cells decreases steadily through development, and represent 
only 0.59% of basal cells in the adult human prostate. Thus progeny from these 
stem cells differentiates into two separate lineages o f luminal or basal cells.
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Subsequent work by the same group addressed the origins o f NE cells and again 
supported this model (Kurita et al, 2004). In 2000, Signoretti et al reported that 
p63"/_ knockout mice (lacking the gene for the exclusively basal marker p63) 
failed to develop prostates suggesting that the p63+ basal cell population is 
critical for prostate development, and might contain stem cells, although it is 
difficult to identify the undeveloped prostate perinatally when p63-/" mice die. 
Kurita et al (2004) found that transplanting urogenital sinus tissue (mesenchyme 
and epithelium together) from p63_/“ mice under the renal capsules o f male nude 
mice produced prostate tissue with grossly normal ductal morphology 
surrounded by normal prostate smooth muscle. The ducts were lined by AR+ 
luminal cells, but no definable p63+/K14+/K19+ basal layer was present. Both 
p63"/_ and p63+/+ prostates contained equal numbers and distributions o f rare 
synaptophysin+ NE cells. Castration caused the entire p63"/_ graft to lose almost 
all luminal cells and duct complexity but they regenerated with re introduction of 
testosterone.
The authors concluded that p63 is essential for development o f the basal layer, 
branched ducts and secretory luminal cells, but not for differentiation o f  NE and 
smooth muscle cells. The basal layer does seem to play a role in normal luminal 
cell differentiation and secretion, perhaps by mediating interactions with the 
basement membrane.
While, Kurita et al (2004) concurred with Cunha’s model and suggested the 
presence o f a single p63" stem cell that chooses between luminal, basal or NE 
lineages, it is equally possible that three separate stem cells (p63~ for luminal and 
NE, p63+ for basal cells) exist in step with Aumuller’s model. It is also still 
possible that in the normal adult p63+/+ prostate, basal cells do develop into 
luminal cells as in Isaacs’ model. The debate over the developmental cell-linage 
relationships between luminal, basal and NE cells is as yet unresolved. However 
since 2000, a number o f  studies have progressively defined a population o f 
prostate epithelial cells that possess stem cell properties (though not all have 
been tested). Study o f  these stem cells promises to provide the answer.
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1.5 Defining the prostate stem cell
Recent work suggests that the prostate stem cell can be identified by its unique 
molecular expression profile: CD133+/ABCG2+/a2(31Hl/p637PSCA7AR7PSA" 
(Litvinov et al, 2006) though its location and relationship to basal and luminal 
cells remains uncertain. Identification lagged behind that o f other tissues due to 
inherent technical difficulties. As a solid tissue, extraction o f cells requires 
mechanical disruption and enzymatic digestion, which risks the very cell surface 
markers used to define them and adult stem cells are refractory to traditional 
methods o f cell culture as they tend to differentiate and senesce (Sherley, 2002; 
Dontu et al, 2003). A number o f extraction and isolation techniques used in other 
tissues have been applied with success to prostate tissue. Equally the search for 
specific markers has been guided by those found in other tissues suggesting that 
some determine the stem cell phenotype, while others determine tissue 
specificity (Gu et al, 2007).
Several studies have isolated populations o f primary epithelial cells that 
demonstrate some stem cell features. Primary culture o f prostate epithelial cells 
from explants and partially and entirely digested tissue yields tightly-packed 
cobblestone-like cells expressing mostly intermediate and some basal keratins, 
that form a monolayer (Merchant et al, 1987). Subsequently the cultures become 
multilayered with overlying luminal cytokeratin expressing cells containing 
secretory granules. Isolation and culture o f the upper layer o f cells demonstrates 
these cells to be viable, but have no mitotic activity (Merchant et al, 1987). This 
spontaneous differentiation in vitro in the absence o f androgens, serum and 
stroma has been taken as evidence that basal cells give rise to luminal cells 
(Robinson et al, 1998).
Hudson et al (2000) confirmed the proliferative heterogeneity o f primary prostate 
cells in low calcium, serum and androgen free culture o f dissociated epithelial 
cells and retrospectively isolated colonies from putative prostate stem cells. Two 
colony types were identified after two weeks culture o f prostate epithelial cells 
with an overall colony forming efficiency o f 5.8% ±1.8 (see figure 1.4).
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Type I colonies were up to 4mm across, and loosely packed with <30 cells per 
linear millimetre, they had irregular outlines, represented 89.5% o f all colonies or 
6.2% o f all plated cells and expressed either K8 and K14 or just K8 in the 
smallest colonies. Type II colonies were large, dense, round colonies, 3mm or 
more across, with 30-50 cells per millimetre. They formed 10.5% o f all colonies 
or 0.6% o f all plated cells, and almost exclusively expressed K14 only.
These type II colonies were proposed to be the progeny o f basal layer stem cells, 
while type I cells derived from TA cells. Furthermore, selection o f cells rich in 
integrins that adhered to type 1 collagen-coated dishes for five or twenty 
minutes, enriched five-fold for colony forming cells, but not for colony type.
This suggests that both stem cell and TA cells are adherent, while later androgen 
dependent TA and terminally differentiated cells within the primary epithelial 
cell suspension were not.
Type II colonies were also grown in three-dimensional Matrigel™ culture (an 
artificial basement membrane) and formed spherical structures connected by 
ducts reminiscent o f the two-layered architecture o f the prostate in vivo. The 
spheres consisted o f a basal layer o f cells expressing K5 and K14 and one or 
more luminal layers o f larger, flatter cells expressing weak K5 and K14 and 
strong K17, K19 and K8 arranged around a lumen. Shed cells within the lumen 
expressed AR, but no staining for PSA or PAP was seen in this androgen free 
culture.
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Figure 1.4: Colony types formed two weeks after plating 1000 freshly isolated 
epithelial cells from prostate tissue in a 5cm dish. Type 1 colonies (A and B) are 
relatively small, irregular and contain a mixture o f differentiated and 
undifferentiated cells, type II colonies (C and D) are large, regular and consist 
almost entirely o f small undifferentiated cells (Hudson et al, 2000).
Collins et al (2001) demonstrated that rapid type 1 collagen adherence is due to 
the high level expression o f a 2pi-integrins. They suspected that as integrin 
expression enriches for epidermal stem cells, it might do so for prostate stem 
cells that also rest on an integrin-rich basement membrane. Basal prostate cells 
(selected by their expression o f CD44) were plated onto type 1 collagen for five 
minutes. Adherent cells were a 2pi integrin bright and showed 3.8-fold greater 
colony forming efficiency compared to non-selected basal cells. In vitro 15% of 
basal cells showed strong a2Pi-integrin expression and high levels o f  a 2-integrin 
staining were also seen in 1.07% o f human basal cells in vivo (Collins et al, 
2001).
In agreement with Hudson et al (2000), different colony types were noted, 
however Collins et al (2001) reported three different morphologies after three 
weeks in culture. Collins’ type 1 (probably akin to Hudson and colleagues’ type 
II colonies after longer in culture) are large, circular, smooth edged colonies
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made up o f small cells with larger differentiating cells overlying them. Cells 
divided after an initial lag period o f seven days. Type 2 colonies (probably akin 
to Hudson type 1) grew more rapidly and could be larger than type 1 with an 
irregular perimeter and heterogeneous cell sizes. Type 3 colonies were <32 cells 
big and terminally differentiated (not scored by Hudson et al, (2000)). Selection 
for integrins could not influence the type o f colonies obtained. When implanted 
subcutaneously with stromal cells into male nude mice these rapidly adherent 
cells formed fully differentiated prostate tissue after six weeks. Acini were 
visible with basal and luminal cells that expressed PSA and AR.
Together these studies confirm that basal, androgen independent, a 2piHl integrin 
prostate epithelial cells comprise a mixed population o f highly clonogenic cells 
with variable proliferative abilities that can reconstitute both layers o f prostate 
epithelium (Hudson et al, 2000; Collins et al, 2001). These are likely to equate to 
stem and early TA cells but stem cell properties have not been demonstrated. 
Self-renewal was not tested and pluripotency was shown inasmuch as the 
Matrigel™ and mouse xenograft assays demonstrated differentiation, but 
generation o f the NE lineage was not achieved. The type II colonies appeared to 
differentiate between the second and third weeks in culture, suggesting that while 
stem cells may establish the colony, at an undefined point or number o f  cells 
some progeny commence differentiation as TA cells.
Selecting prostate epithelial a 2 p lHl basal cells for CD 133 expression further 
enriches for stem cells (Richardson et al, 2004). In the haematopoietic, 
endothelial and central nervous systems, CD 133, a five-transmembrane 
glycoprotein o f no known function has been used to isolate stem cells (Yin et al, 
1997; Peichev M et al, 2000; Uchida et al, 2000). It is expressed by developing 
epithelial cells, and is rapidly down regulated upon differentiation (Corbeil et al,
2000). Amongst isolated prostate epithelial cells, 25% o f  a 2 p lHl cells also 
express CD 133. The majority (75%) o f these a 2 p lHl CD 133+cells express basal 
cytokeratins (K14 and K5) but given that a minority (11%) express intermediate 
cytokeratins instead, CD133 may also be a marker o f early TA cells. No CD133+ 
cells express AR, PSA or PAP and they tend to be quiescent, expressing less
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Ki67 than CD 133 cells. Immunohistochemistry localized CD 133 expressing 
cells to clusters o f 1 to 5 basal layer cells.
When passaged to exhaustion, the CD133+ population generated over two-fold 
more cells than the CD 133” population. Equally, a2p 1H| CD 133+cells showed a 
10.6-fold greater colony forming ability, and the a 2 p lHl CD133” cells a 4.5-fold 
one than unsorted basal cells. This suggests the former are stem cell derived, 
while the latter are TA cell derived and the remaining non-adherent basal cells 
are TA cells nearing terminal differentiation. a 2 p iHl CD 133+derived colonies are 
also larger, and appear five days later, possibly due to the slow cell cycle time o f 
stem cells in vivo.
In vivo studies obtained two layer epithelial structures, with a K5 and K14 
expressing basal layer and a K18, PAP and AR expressing luminal layer when 
a 2 p lHlCD133+cells were injected subcutaneously with human stromal cells into 
male mice.
Richardson et al (2004) managed to demonstrate many features that would be 
expected o f stem cells in their a 2 p lHl CD133+ cell fraction. These cells are 
indeed quiescent, undifferentiated and rare - found in 0.75% o f the total basal 
cell population. However their niche environment is not apparent 
immunohistologically and far from showing indefinite proliferative potential, all 
cells senesced in culture after 55-75 days. Above all, neither true pluripotency 
nor self-renewal was demonstrated, though the former might have been had they 
stained the xenografts for NE cell markers. In effect these cells have not 
distinguished themselves from a population o f early, committed TA cells. When 
10,000 to 50,000 such cells are grafted it is possible that their residual 
proliferative activity is sufficient to generate the prostate epithelium seen here 
eight weeks later. Finally, these cells are still heterogeneous for cytokeratin 
expression, so these markers enrich for stem cells rather than isolate a pure 
population.
Breast cancer resistance protein (BCRP) also known as the G2 isotype o f the 
ATP-binding cassette (ABC) transporter family (ABCG2) is consistently 
expressed by adult bone marrow, skeletal muscle and neural stem cells (Bunting,
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2002). It transports from the cell chemotherapeutic drugs (thereby conferring 
resistance), steroids including androgens and experimentally the nucleic acid 
binding dye Hoechst 33342. Huss et al (2005) investigated the location, number 
and cell marker expression o f BCRP/ABCG2+ cells in benign prostate tissue, and 
a human prostate mouse xenograft model. In prostate tissue, 1% o f all epithelial 
cells were ABCG2+ and these appeared to be neither basal or luminal, being seen 
under the basal layer. Though close to basal cells expressing p63 and basal 
cytokeratins, NE cells expressing synaptophysin, AR+ luminal cells and a-actin 
expressing smooth muscle, they were negative for all these markers. Castration 
made no difference to the number o f ducts containing these ABCG2+p63”AR” 
cells in xenografts but a small proportion o f the immediate progeny o f these 
putative stem cells differentiated preferentially along a NE lineage (Huss et al,
2004). Reintroduction o f  androgens resulted in focal proliferative activity in the 
xenograft epithelial compartment with a cluster o f ABCG2"Ki67+ cells appearing 
around ABCG2+ cells, which themselves remained Ki67'. These proliferating 
cells were proposed to represent TA cells that had exited the ABCG2+ stem cell 
compartment.
Huss and colleagues’ ABCG2+p63~AR~synaptophysin"a-actin" stem cells are 
pluripotent, quiescent, undifferentiated and rare. Their lack o f p63 fits with the 
p63_/“ work o f Kurita et al (2004). They also appear to be a pure population as all 
ABCG2+ cells are homogeneously negative for other markers. Though self­
renewal was not demonstrated in this study, this phenotype has been further 
expanded upon since (Litvinov et al, 2006).
Bhatt et al (2003) also studied Hoechst 33342 dye exclusion by primary prostate 
epithelial cells but did not relate this to ABCG2 transporter expression. They 
identified two separate cell populations that together amounted to 1% o f all cells 
and 10% o f all a 2 integrin expressing cells. They differed in cell cycle position 
with the slightly more K14 rich population in GO and the slightly more K8 
expressing one in G l. Bhatt et al (2003) postulated that the former were stem 
cells and the latter TA. However further characterisation o f these cell populations 
was not reported, so it is difficult to relate them to the cells described by Huss et 
al, (2005). The ABCG2 transporter is expressed in several other cell types,
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including inflammatory cells and venous and capillary endothelium (Huss et al,
2005). Though a number o f extraction steps were taken, contamination might 
account for the difference.
Though Huss et al (2005) demonstrated the immunohistochemical location o f 
their prostate stem cell to be adjacent to but not within either the basal or luminal 
layer in human tissue, Tsujimura et al (2002) reported a small population o f 
slowly proliferating cells in both basal and luminal compartments o f proximal 
ducts in the mouse dorsal prostate. These putative stem cells retained 
bromodeoxyuridine when androgen was reintroduced after castration, could 
generate branching structures in collagen gels and were highly proliferative in 
vitro. When this cell population was dissected out and compared using a cDNA 
microarray to similar cells sourced from other regions o f the dorsal prostate.
CD 133 emerged as one o f the seven most upregulated genes, and CD133+ cells 
also stained for telomerase (Tsujimura et al, 2007).
These same dissected out proximal murine prostate cells, were then investigated 
using fluorescent activated cell sorting (FACS) for expression o f stem cell 
antigen-1 (Sca-1), a stem cell marker established in bone marrow and mammary 
tissue (Burger et al, 2005). Sca-1 was expressed more proximally and proximal 
Sca-1+ cells produced greater weights o f typical basal p63+, luminal AR+ prostate 
tissue than Sca-1~ or distal Sca-1+ cells when grown with urogenital sinus 
mesenchyme under mouse renal capsules. Though Sca-1 expression did enrich 
for prostate regeneration, some occurred in its absence, and with Sca-1+ noted 
distally it did not segregate for the proximal prostate only. Thus, alone it does not 
appear to define the murine stem cell. As with all murine studies, it is as yet 
unknown how this work correlates with the human prostate.
1.6 Characterising prostate stem cells
Bringing this work together, Litvinov et al, (2006) studied the prostate epithelial 
stem cell population in vitro that they defined as 
CD 133+/ABCG2+/a2p 1 Hi/p637PSCA~ /AR7PSA". Their working model 
describes a prostate epithelial differentiation process that sees cells proceed down
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a NE or luminal lineage. Cells destined for the luminal epithelium become TA 
cells with the phenotype CD 133' /ABCG2" /a2p 1 Hl/p63+/PSCA ' /A R '/PSA " as 
well as expressing K5 and K14 and amplify through a number o f divisions. At 
some point these cells acquire the ‘intermediate’ (TA) cell phenotype o f CD 133" 
/ABCG2" /a2p 110 /p63" /PSCA+ /AR" /PSA" expressing K8 and K 18 also. This 
transition was also noted by Tran et al (2002) studying PSCA who called these 
‘late’ TA cells. Finally the cells migrate into the luminal layer and complete 
their differentiation becoming post-mitotic, androgen sensitive, secretory 
CD 133"/ABCG27a2(31 Lo/p63'/PSCA"/AR+/PSA+ cells. Table 1.2 summarises 
the locations o f these markers.
A commercially available source o f non-immortalized second passage normal 
human
prostatic epithelial cells (PrEC) was cultured in low calcium, serum-free defined 
medium and the phenotype o f the constituent cells assessed. These cells will 
undergo ten passages before becoming quiescent. Almost all (98.9%) cells 
expressed a2pl integrins, and 1.3% o f cells expressed all three stem cell markers 
(CD133+/ABCG2+/a 2 p lHl). Over 80% o f these latter cells were negative for 
p63 with some positives appearing to arise from cells in mitotic telophase where 
one cell was negative and one was positive.
After less than six passages, p63 expression was apparent in a majority (90%) o f 
cells. O f the 10% negative cells, 1% were small and expressed stem cell markers, 
1% expressed chromogranin with NE cell morphology and the remaining 8% 
were larger cells and PSCA+ confirming their intermediate TA cell phenotype. 
When CD133+ cells alone were cultured at low density, amplification yielded 
predominantly small TA cells with no more than 20% progressing to become (as 
seen on time lapse photography) larger intermediate PSCA+ cells and none 
completing differentiation to AR+ PSA+ cells. NE cells also arose 1-3% o f the 
time. Addition o f  androgens to the culture media was not sufficient to assist the 
intermediate cells to full differentiation. This inability was correlated with the 
low calcium content in the medium, which activates the notch signaling pathway 
that inactivates AR and PSA expression. The down-regulation o f the notch-1
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receptor has been associated with the up-regulation o f AR and PSA and 
progression to a more differentiated state (Tran et al, 2002).
This study on a heterogeneous cell line in vitro has not demonstrated the two 
critical stem cell characteristics. Though self-renewal has not been convincingly 
displayed, asymmetric cell division was demonstrated immunohistochemically 
with a p63+TA cell separating from a p63” stem cell. Pluripotency was suggested 
by the two lineages generated by the CD133+ cells, however, the cells were only 
sorted for this single stem cell marker, and as Richardson et al (2004) 
acknowledged, CD 133 may also be a marker o f  early TA cells. Hence it would 
be interesting to see the outcome o f a truly pure population o f CD133+ /ABCG2+ 
/a 2 p lHl cells grown in a stromal / epithelial xenograft assay to determine whether 
one or more stem cells is required to obtain all three prostate epithelial lineages. 
Serial transplantation o f cell fractions from the xenografts with the generation o f 
a second generation prostate would also convincingly demonstrate self-renewal 
and though ideally this should be achieved from a single cell, mixtures o f  marked 
cells might also show clonally derived tissue (Houghton et al, 2007; Collins and 
Maitland, 2006; Lawson et al, 2007).
Currently, the prostate stem cell phenotype remains unconfirmed. Identification 
o f neural stem cells has been advanced by neurosphere culture (Rietze et al,
2001). When cultured in ultra-low adhesion dishes, neural stem cells will form 
nestin and CD133+ neurospheres. However plating onto poly-L-ornithine coated 
glass coverslips causes differentiation into one o f three lineages -  neurons 
recognisable by (3 tubulin type III expression, astrocytes expressing glial 
fibrillary acidic protein or oligodendrocytes expressing platelet derived growth 
factor receptor-a. Secondary neurospheres can be derived from a proportion o f 
single dissociated primary neurosphere cells, and this can be repeated through 
further generations (Gritti et al, 1996). Though ‘sphere’ formation is increasingly 
being reported, a distinction should be made between low-adherence culture that 
attempts to maintain cells in an undifferentiated state, and substances such as 
Matrigel™ that promote differentiation. There is evidence that human prostate 
epithelial cells will form spheres too in low-adherence culture, but none have 
been passaged as yet to confirm self-renewal (Gu et al, 2007; Miki et al, 2007;
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Tokar et al, 2005). Using a differentiation assay, Lawson et al (2007) have 
shown that mouse prostate basal cells will form sphere-like structures when co­
cultured with urogenital sinus mesenchyme in Matrigel™ and these can be 
passaged for six generations.
1.7 Summary of prostate epithelial markers.
Table 1.2 lists many of the markers discussed above. New markers for the 
epithelial components o f the prostate are being identified continually.
Histological
Location
Basal / sub-basal 
/ intermediate Basal epithelial Luminal epithelial
Cell type Stem cell Transit Amplifying Secretoryluminal
Marker CD133+ K14+ K8+ AR+
ABCG2+ K5+ K18+ PSA+
a 2 p lHi K15+ K5+ K8+
K17+ K15+ K18+
K19+ K17+ PAP+
p63+ K19+ PSA+
a2|31Hl K7+ CPP32+
CD44+ CD44+ CD57+
Bcl-2+ PSCA+ P21Kipl+
ETS-2+ p63+
pp32+,
Telomerase+
GSTP1 +
Ki67+
p63" CD133" CD133" CD133"
PSCA" ABCG2" ABCG2" ABCG2"
AR" PSCA" a 2 p lLo a 2 p lLo
PSA- AR" p63" p63"
PSA" AR" PSCA"
p 2 1Kipl" PSA" K5"
K8" p 2 1Kipl" K14"
K18"
Table 1.2: Summary o f cell marker expression by the different cell populations 
in normal human prostate epithelium.
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1.8 The prostate in disease
1.8.1 Benign prostatic hyperplasia (BPH)
The prostate epithelium is prone to pathology. BPH is a histological diagnosis, 
and is detected at autopsy in 25% o f men in their 40’s rising to 85% o f 80-year 
olds (Berry et al, 1984). Risk factors are aging, the presence o f androgens and a 
positive family history (Lepor, 2004). The hyperplastic process occurs in both 
the stromal and epithelial compartments in the transition zone so tissue 
architecture remains largely normal. Enlargement may be diffuse or comprise o f 
nodules o f predominantly stromal or epithelial tissue or a mixture o f both. 
Nodules in smaller prostates under 50g tend to be stromal suggesting that 
increased stromal activity secondarily triggers epithelial growth while epithelial 
nodules predominate in larger glands due to new budding and branching o f ducts 
(McNeal, 1990).
BPH is associated with a mechanical bladder outflow obstruction and/or lower 
urinary tract symptoms such as reduced flow, incomplete bladder emptying and 
voiding at night. However it can be asymptomatic, and the link between prostate 
enlargement and morbidity is a complex one. On average symptoms gradually 
worsen over time, though the experiences o f individual patients can vary and 
some men notice an improvement (Barry et al, 1997). Treatment amounts to 
lifestyle modification, a-adrenergic blocking drugs to relax bladder neck smooth 
muscle and 5a-reductase inhibitors to reduce intra-prostatic DHT levels and 
shrink the gland by 20-25%. Where medical therapy is insufficient, obstructing 
prostate tissue can be surgically removed by open, endoscopic or minimally 
invasive techniques (Desgrandchamps et al, 2006). Complications include 
urinary infections, bladder stones, acute urinary retention, haematuria and urinary 
incontinence. However these are rare events affecting about 5% o f men 
(McConnell et al, 2003).
It has been proposed that BPH arises when stem cells within the adult prostate 
are somehow reawoken, resulting in the growth o f new ducts to form an 
epithelial nodule (McNeal, 1978; Isaacs and Coffey, 1989). Alterations in the
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normal homeostatic stromal-epithelial interactions seem likely to play a role. In 
the normal adult prostate, the stroma and epithelium are essentially growth- 
quiescent with rates o f proliferation and cell death low and in balance. It appears 
that each tissue compartment keeps the other in check, as when both are cultured 
in isolation, their proliferative activity increases dramatically (Hayward and 
Cunha, 2000; Cunha et al, 2002). However, in dogs, androgen and oestrogen 
induced BPH is associated with reduced DNA synthesis suggesting that gland 
enlargement is due to decreased cell death rather than increased proliferation 
(Barrack and Berry, 1987). A number o f growth factors are emerging that may 
alter the balance between cell proliferation and death, with the most likely 
candidate being keratinocyte growth factor (Lee and Peehl, 2004).
1.8.2 Prostate Adenocarcinoma
1.8.2.1 The natural history o f prostate cancer
The aetiology o f  prostate cancer is not well understood, though a number o f  risk 
factors are recognised, such as increasing age, a positive family history, African- 
American ethnicity, and consumption o f a Western diet (Gronberg, 2003). 
Incidence is highest in the US, Canada and Scandinavia and lowest in China and 
Asia, likely reflecting the above factors and also variations in healthcare 
availability and cancer registration (Quinn and Babb, 2002). There is also a 
significant amount o f subclinical disease: the risk o f having pathological 
evidence o f prostate cancer in a 50 year old man is 42%, the risk o f symptoms is 
9.5%, and the risk o f mortality 2.9% (Scher et al, 2004).
Prostate cancer usually grows slowly, progressing from localised and 
asymptomatic disease, to locally advanced and/or metastatic cancer following 
lymphatic and haematogenous spread. Locally advanced cancer may invade the 
urethra, bladder, pelvic nerves or pelvic lymph nodes. Metastatic cancer spreads 
to the axial skeleton or long bones, and soft tissues such as lung or liver (Kirby, 
2000).
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Current clinical practice is to observe men with low grade, low stage disease and 
an estimated life expectancy o f less than 10 years. Others with clinically organ- 
confined disease may be offered active surveillance or radical prostatectomy, 
brachytherapy or external beam conformal radiotherapy with curative intent 
(Peschel and Colberg, 2003). For locally advanced or metastatic cancer, 
androgen withdrawal therapy offers symptomatic control, a delay in clinical 
progression (for a median o f 18 months in metastatic disease) and possibly 
increased survival (Robinson et al, 1995). Ultimately, hormone independent 
cancer emerges and though second line therapies such as oestrogens or 
chemotherapy are used, at this stage the disease is usually fatal.
1.8.2.2 Histological changes in prostate cancer.
There is a continuum o f histological changes seen within the prostate between 
benign and malignant states, and distinguishing some atypical lesions from early 
low-grade cancer is difficult. The identification o f pre-malignant lesions within 
the prostate is hampered by the fact that abnormal areas cannot be followed over 
time as it is impossible to reliably rebiopsy them. High grade Prostatic 
Intraepithelial Neoplasia (PIN) is the most likely precursor o f prostate carcinoma 
and is strongly predictive o f coexistent carcinoma. Like cancer, it is multifocal, 
commonest in the peripheral zone and its incidence increases with age though 
epidemiologically it predates cancer by over five years, (Bostwick et al, 1995). 
Low grade PIN cannot be reproducibly recognised and no clinical significance is 
attached to it. High grade PIN is architecturally benign with normal duct 
morphology but cytologically atypical. The basement membrane is intact, though 
the basal cell layer may show some disruption while the luminal cells 
demonstrate cytologic features that mimic cancer such as nuclear and nucleolar 
enlargement, variable nuclear size, hyperchromasia, mitotic figures and multiple 
nucleoli.
More than 95% o f prostate cancers are acinar adenocarcinoma and most are 
multifocal (DeMarzo et al, 2003). Architecturally cancer is defined by variable 
acinus sizes, haphazard directions o f infiltration with displacement o f stroma, 
back-to-back glands that share a basement membrane and increased cellularity.
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Perineural invasion is also diagnostic. The basal cell layer is absent in prostate 
adenocarcinoma, such that negative staining for basal cell-specific cytokeratins 
using antibody, 34p-E12 is used to help confirm a suspected diagnosis o f cancer 
(Allsbrook and Pfeifer, 1998).
The low-power architectural appearance also forms the basis o f the grading o f  
prostate cancer from 1 (least abnormal) to 5 (Gleason and Mellinger, 1974). 
Gleason grading accounts for the heterogeneity o f  prostate cancer by noting the 
two most common patterns by area, and is now widely accepted due to its 
simplicity, reproducibility and prognostic accuracy (Allsbrook et al, 2001).
Small cell carcinomas o f the prostate make up 1-2% o f all prostate malignancies 
and are thought to arise from the malignant transformation o f NE cells. These 
tumours are negative for PAP and PSA and may arise de novo but more often do 
so after hormonal treatment o f adenocarcinoma. They do not respond to 
hormonal withdrawal therapy and behave aggressively. Additionally most 
adenocarcinomas demonstrate some degree o f focal NE differentiation 
(diSant'Agnese, 1992). It has been postulated that NE secretions promote 
carcinogenesis in adjacent cells. Also, being androgen independent they might be 
expected to persist despite androgen withdrawal, and their numbers do increase 
in hormonally treated and hormone-refractory prostate cancer. In such cancers, 
treatments directed at the NE cells may have a role in the future (Huang et al, 
2007).
Stroma contains predominately smooth muscle cells and extracellular matrix, but 
stroma associated with prostate cancer is typically fibroblastic or 
myofibroblastic. Experimentally, such carcinoma-associated stroma induces 
cancers in the immortalized human prostatic epithelial cell line BPH-1, though 
not in normal epithelial cells. (Olurm et al, 1999). Thus it has been proposed that 
cancer initiating events within the epithelium result in altered stromal-epithelial 
signaling converting the normally repressive stroma into tissue that stimulates 
proliferation and carcinogenesis through paracrine means (Cunha et al, 2002). 
There is also evidence that unlike benign tissue, malignant prostate epithelium
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becomes stimulated directly by androgens through autocrine mechanisms (Gao et 
al, 2001).
Despite these histological changes, prostate cancers in their early stages at least 
show a cellular and structural organization reminiscent o f benign tissue. While 
stem cells maintain tissue growth in health, the concept o f cancer stem cells that 
perform this role in tumours has long been suggested (McCulloch and Till,
1964).
1.9 Cancer stem cells and the stem cell model o f cancer
There is good evidence for the existence o f cancer stem cells, or tumour initiating 
cells in some cancers. Tumours have long been recognised as heterogeneous in 
terms o f the differentiation o f their constituent cells and their proliferative ability. 
For instance, no more than 0.01 to 1% o f mouse myeloma cells will form 
colonies in vitro o f  which a small proportion showed ‘self-renewal’, in that they 
had the ability to be disaggregated and replated (Buick and Pollack, 1984). The 
reason for this may be that all tumour cells have equal but low proliferative 
abilities, or that a small subset o f tumour cells possess all the proliferative ability 
(Houghton et al, 2007).
The latter has been shown to be true for acute myeloid leukaemia (AML) and for 
an increasing number o f  solid tumours. HSC are CD34+CD38", while committed 
lymphoid precursors are CD34+CD38+. In acute myeloid leukaemia (AML), the 
only cells capable o f inducing human AML in mice was a small population with 
the HSC phenotype, while the more differentiated CD34+CD38+ cells that looked 
cancerous, could not in most cases (Bonnet and Dick, 1997). Furthermore, these 
cells could be passed from animal to animal and maintain the AML phenotype 
confirming the property o f self-renewal (Dick, 1996). In solid cancers, self- 
renewing tumourigenic human breast cancer cells have been sufficiently enriched 
so that as few as 200 CD44 /CD24 low tumour cells will consistently form 
tumours when injected into mouse mammary fat pads while 100,000 cells o f 
other lineages do not. Such tumours have been harvested and passaged into
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subsequent mice four times with no decrease in tumourigenicity (Al-Hajj et al,
2003). Using similar assays, the colorectal cancer stem cell is emerging as 
CD44 /epithelial cell adhesion molecule (EpCAM)hlgh/CD166+, the pancreatic 
cancer cell has been defined as C D 44/C D 24/epithelial-specific antigen (ESA)+, 
human brain tumour stem cells are CD133 /nestin+ and CD44 defines a 
tumourigenic self-renewing population in head and neck cancers (Dalerba et al, 
2007; Li et al, 2007; Singh et al, 2004; Prince et al, 2007).
Both cancer cells and stem cells have similar cellular properties. They possess 
limitless proliferative activity, can self-renew and are resistant to senescence and 
apoptosis (Hanahan and Weinberg, 2000). Tumour cells and tissue stem cells 
exploit many o f the same pathways, such as Wnt, Notch and Sonic hedgehog, to 
give them the capacity for and self-renewal (Reya et al, 2001). The classic 
tumour suppressor gene p53, lost in >50% o f human cancers, induces cell cycle 
arrest in the presence o f DNA damage to allow repair or apoptosis but has also 
been implicated in the regulation o f asymmetric stem cell divisions (Rambhatla 
et al, 2001). The transformation o f a cell must therefore involve the acquisition 
( if  not already possessed) and deregulation o f stem cell properties.
As in epithelium, the bulk o f the tumour is comprised o f terminally differentiated 
cancer cells upon which histological diagnosis and prognostication is based. 
However the stem cell model o f cancer states that tumour maintenance and 
expansion is driven by a few anonymous cancer stem cells. Frequently dividing 
cancer stem cells that favour self-renewal over generation o f a TA cell will 
produce a rapidly growing tumour. As cancers progress, they tend to lose their 
normal tissue specific appearance and become ‘less differentiated’. This may in 
reality reflect the expansion o f the undifferentiated stem cell compartment 
(Mackillop et al, 1983, Mackillop et al, 1985). In addition, the differentiating 
daughter cancer stem cells may follow aberrant pathways to different lineages, 
resulting in heterogeneous phenotypes such as NE differentiation in prostate 
cancer, or squamous differentiation in bladder cancer.
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This concept has far reaching implications. Studies o f whole tumour tissues will 
identify the characteristics o f the most predominant, terminally differentiated 
cells that are destined to die anyway, and shed no light on the most critical cells.
A successful cancer treatment is judged on its ability to reduce the bulk o f a 
tumour, however only a few cancer stem cells need survive for recurrence to be 
inevitable (Mackillop et al, 1983). This may also explain why small numbers o f 
disseminated cancer cells can be detected throughout the body in patients who 
never develop metastases. The aim o f treatment must be to identify and destroy 
the cancer stem cells. This will require isolation o f cancer stem cells from the 
bulk o f the tumour to allow prognostic markers and therapeutic targets to be 
found.
1.9.1 Stem cells as targets for malignant transformation.
The stem cell theory o f cancer states that the carcinogenic process probably starts 
in a stem cell. Theoretically, the exact target for transformation into a cancer 
stem cell could be a stem, TA or terminally differentiated cell. Stem cells are 
thought to be the most likely candidates. They already have the machinery for 
self-renewal activated, so maintaining and deregulating this activation may 
require fewer mutations that turning it on de novo within a more differentiated 
cell (so called ‘dedifferentiation’, Buick and Pollack, 1984). In addition, 
carcinogenesis is a slow process that may take years or decades, and it is the stem 
cells within a tissue that persist long enough to accumulate the necessary 
mutations (Fearon and Vogelstein, 1990; Hanahan et al, 2000). The commonest 
five human cancers (skin, lung, colon, breast and prostate) all develop in stem 
cell derived tissues. Radiotherapy o f skin cancers is successful with surprisingly 
low doses o f radiation, but this is understandable if the stem cells are 
preferentially destroyed (Mackillop et al, 1983). There is also evidence that 
leukaemias arise from mutations harboured by HSC. In addition to the 
CD34+CD38" AML cancer stem cell phenotype described above, other clonal 
markers such as the Philadelphia chromosome (9;22 chromosomal translocation) 
and isoenzymes o f glucose-6-phosphate dehydrogenase have been found in 
multiple cell lineages in patients with AML (R eyaef al, 2001).
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Alternatively, since every mutation that occurs within the stem cell is passed 
onto its progeny. It is possible that a TA cell that has inherited several mutations, 
could accrue one more that allows it to self renew in its own right and make the 
final step towards transformation. An example o f this mechanism occurring is 
again found in haematological cancers. The progeny o f HSC include common 
myeloid progenitors, granulocyte-macrophage progenitors, and megakaryocyte- 
erythroid progenitors. In patients with chronic myeloid leukaemia, granulocyte- 
macrophage progenitors have been found to have higher expression levels o f 
HSC self-renewal genes ((3-catenin and LEF-1) than normal granulocyte- 
macrophage progenitors. Unlike these normal cells, CML granulocyte- 
macrophage progenitors also formed self-renewing, replatable myeloid colonies 
in vitro, behaviour suggestive o f leukaemic stem cells (Jamieson et al, 2004).
The answer may be that all cells have the potential to transform, but will require 
different mutations to do so and the cell o f origin will differ from case to case 
(Signoretti and Loda, 2007). It is also possible that malignant transformation 
alters gene expression sufficiently to distort lineage relationships entirely and 
that disordered stromal architecture alters the actions o f the stem cell niche 
(MacKenzie, 2006). There is much that is unknown in this area, but it is likely 
that studies on cancer and on stem cells will increasingly share common ground.
I
1.10 Evidence for the prostate cancer stem cell.
It seems likely that in malignancy, the prostate tumour is still maintained as a 
stem cell structure. Like its benign counterpart, it remains heterogeneous in terms 
o f keratin marker expression, differentiation and hormone responsiveness
, suggesting the presence o f different cell populations. However the cancer stem
cell model is most convincingly demonstrated by its response to treatment. 
Therapeutic androgen withdrawal causes luminal cell apoptosis, serum PSA 
reduction and shrinkage o f the tumour mass. However some androgen 
independent epithelial and NE cells survive. Eventually, having acquired further 
mutations allowing them to recruit androgen independent growth pathways, the 
cancer stem cells proliferate in the absence o f androgen, repopulate the tumour 
and PSA rises again.
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1.10.1 The origin o f the cancer stem cell
As in benign tissue, the origin, location and phenotype o f the prostate cancer 
stem cell has been long sought, and remains equally unresolved. Several authors 
have nominated luminal cells (expressing K8, K18, PSA and AR), TA cells 
expressing intermediate keratins (K5 and K18) or as yet undefined normal stem 
cells. Their conclusions are based on the expression o f markers seen in prostate 
cancer, although o f course the phenotype o f a few cancer stem cells may be 
difficult to discern amongst their massively more represented progeny.
The histological appearance o f prostate cancer varies dramatically from that o f 
normal prostate epithelium, most markedly due to the loss o f the basal layer. PIN 
is widely accepted as a precursor to cancer, and the degree o f basal layer 
disruption increases from low grade to high grade PIN (Bostwick and Brawer, 
1987). Within PIN, proliferation o f luminal cells increases dramatically, such 
that whereas in normal prostate 70% of proliferating cells are in the basal layer, 
in high grade PIN 90% o f proliferation occurs in the luminal cells (Bonkhoff et 
al, 1994b). Expression o f  the apoptosis suppressing Bcl-2 oncoprotein mirrors 
the region o f proliferation in high grade PIN which may extend the lifespan o f 
these cells exposing them to further mutations. Telomerase expression is also 
seen (Paradis et al, 1999). The fact that the vast majority o f prostate cancer cells 
demonstrate a luminal phenotype with PSA, AR, K8 and K18 has lead to the 
proposition that luminal cells transform into cancers (Bostwick and Brawer 
1987).
In fact, in vitro, prostate cancer epithelial cells will express K5 and K14, and 
while basal cells are histologically absent, basal markers are expressed in cancer 
cells (Peehl, 2005). Based on cytokeratin expression, others contend that basally 
located, androgen independent, intermediate cells undergo carcinogenesis (Isaacs 
and Coffey, 1989; Bui and Reiter, 1999; van Leenders et al, 2001; van Leenders 
and Schalken, 2001; Schalken and van Leenders, 2003; Kellogg-Parsons et al, 
2001, Nagle et al, 1987). De Marzo et al (1998b) alternatively suggest that the 
intermediate cells in question reside in the luminal layer. Verhagen et al (1992) 
failed to identify any K14 expressing cells in primary and hormone independent
53
cancers but did identify K5+ cells in 25-35% o f primary cancers and 10-15% o f 
hormone independent cancers, while K19 was commoner in 50-75% and 25-90% 
of cells respectively, and all cancers stained for K18. Another analysis confirmed 
co-expression o f both keratins in androgen treated cancers, but found a reversed 
trend, towards a more basal K5 phenotype in more advanced cancers (Gil-Diez 
de Medina et al, 1998). A similar trend was noted by Lui and colleagues (1999,
2002) who found that while primary cancers predominately expressed a luminal 
cell marker CD57, advanced cancers and metastases expressed more CD44.
Nagle et al (1987) also reported a luminal phenotype in localised prostate cancer, 
but found this persisted in metastatic prostate cancer cell lines. A study o f 56 
prostate cancer metastases identified K18 in 100% and K5 expression that ranged 
from 29% in untreated cancers, to 75% after androgen withdrawal, and 57% of 
hormone escaped cancers (van Leenders et al, 2001).
The normal stem cell was implicated by Bonkhoff on the basis o f androgen 
insensitivity and that the increased prevalence o f post-mitotic NE cells in 
advancing cancers are derived from the pluripotent stem cell (1996, 1994a). 
Additionally, basal cell markers such as Bcl-2 and telomerase are increasingly 
overexpressed in PIN and prostate cancer (McDonnell et al, 1992; Paradis et al, 
1999). Overall, it seems that categorizing prostate cancer cells as basal or 
secretory is too simplistic, and other markers will identify the cancer stem cell.
As increasing numbers o f stem cell markers are identified in other tissues, more 
recent research has hypothesised that these might equally apply to the malignant 
prostate stem cell. Experience in malignant and benign stem cells from skin has 
shown the expression o f similar markers, while malignant and benign breast and 
neural stem cells will both grow in suspension culture, suggesting similarities are 
retained despite transformation (Mackenzie, 2006). However, studies so far have 
shown disagreement with the benign prostate stem cell phenotype as it is 
understood currently.
Sca-1 has been proposed as a stem cell marker in the murine prostate. Xin et al 
(2005) managed to make Sea-1 +cells tumourigenic using transfection o f a 
lentiviral vector to activate their PTEN/AKT1 signalling pathway, which has
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been strongly correlated with prostate carcinogenesis. When cultured with 
urogenital sinus mesenchyme under mouse renal capsules, such cells produced 
cancerous glands expressing intermediate cytokeratin. However histology alone 
was the determinant o f malignancy and no self-renewal was studied in the 
structures. Ultimately, though it may be possible to transform such a cell with a 
viral vector, this does not mean that this is the mechanism whereby cancer arises 
in vivo. p63 is not expressed in human prostate cancer, so might be expected to 
be absent in these ‘cancers’ though its expression in murine prostate cancer is 
unknown (Kellogg Parsons et al, 2001; Wang et al, 2006). In benign mouse 
prostates, p63 is a basal cell (but not stem cell) marker (Kurita et al 2004).
The same group subsequently studied cytokeratin and stem cell marker 
expression in the Pten-null prostate cancer model (Wang et al, 2006). These mice 
progress from prostate hyperplasia at four weeks, through PIN and cancer to 
metastases at twelve weeks. During this process, an increase in basal layer 
K5+p63+ cells was seen and there was an even greater proliferation o f 
intermediate K5 and K8 expressing cells. Sca-1 seemed to segregate to the basal 
cells, while Bcl-2 was expressed by the more proliferative intermediate cells. 
Both these populations were proposed as candidates for the tumour initiating 
cells, but again this work in genetically manipulated mice may not translate well 
to human prostate carcinogenesis.
Patrawala et al (2005) isolated the Hoechst 33342 excluding side population o f 
cells derived from a human prostate tumour xenograft (Klein et al, 1997). 
Comprising 0.07% o f the total cells, side population cells were 100-fold more 
tumourigenic in vivo, than non-side population cells. ABCG2 was more 
expressed in the side population, however when all cells were sorted for ABCG2 
expression, there was no difference in tumourigenicity between positive and 
negative cells. When injected into mice, ABCG2" cells produced tumours 
predominantly containing ABCG2+ cells suggesting differentiation from a stem 
cell to TA phenotype, and ABCG2+ derived tumours were also predominantly 
ABCG2+ though these cells could also generate a few ABCG2" cells. ABCG2" 
cells also expressed higher levels o f ‘sternness’ genes Notch-1, p-catenin and 
Oct-4 (an embryonic and adult stem cell transcription factor).
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The heterogeneity o f the side population has been recognised before, and side 
population cells may express other ABC transporters than the G2 isotype 
accounting for the ABCG2” cells within it. However, in benign tissue ABCG2+ 
cells have been proposed as stem cells, whereas ABCG2" cells behave more like 
cancer stem cells in this study. The differing findings o f Huss et al, (2005) and 
Bhatt et al (2003) suggest that these markers have more complex associations in 
benign tissue, and this seems no less true in malignancy.
The same group then performed very similar assays on CD44+ cells with more 
straightforward results (Patrawala et al, 2006). The CD44+ fraction o f prostate 
cancer cell lines and human prostate cancer xenografts exceeded the CD44" cells 
in terms o f clonogenicity, tumourigenicity and local tumour invasion. They also 
expressed higher levels o f stem cell genes N otch-1, p-catenin, Oct-4 and Bm il. 
Finally in vitro and in vivo, they differentiated into CD44” cells and expressed 
AR. Thus while not a pure population, CD44 does seem to enrich for prostate 
cancer stem cells.
Next they turned their attention to a2pl integrin expression in the same cells 
(Patrawala et al, 2007). In vitro a 2 p i+/Hl cells were more clonogenic than 
negative cells, however when cells were injected orthotopically into mouse 
dorsal prostate, no greater tumourigenicity -  the gold standard test for the cancer 
stem cell -  was seen between the two fractions. Co-localization 
immunohistochemistry showed that 70-80% o f cells expressed both a2p l and 
CD44, and all ABCG2 cells stained for these two markers. They devised a 
tumourigenic hierarchy with CD44+a 2 p l+/Hl and CD44+ a 2 p l '/Lo fractions being 
most tumourigenic, and CD44" a2pl /Lo cells the least.
Proof o f principle o f the prostate cancer stem cell has been demonstrated using 
human telomerase reverse transcriptase (hTERT)-immortalized primary prostate 
epithelial cells from radical prostatectomy specimens (Gu et al, 2007). A single 
transformed cell was able to establish an indefinitely proliferative cell line, which 
expressed stem cell (Oct4) and early progenitor cell markers (CD 133, CD44). 
These cells grew spheres in low adherence culture, glandular structures in
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Matrigel and recapitulated the tumour histology in mice complete with basal, 
luminal and neuroendocrine cells (though these tumours were not passaged on). 
As the authors recognized, immortalization is not equivalent to cancer stem cell 
isolation, but it confirms the potential o f such cells.
Finally Collins et al (2005) applied their experience from benign stem cells to 
prospectively isolate cancer stem cells from primary localised and metastatic 
prostate cancer tissue. All the tumours contained between 0.1 and 0.3% o f 
CD133+ cells. In colony forming assays, primary cultured CD44+a 2 p l+/Hl 
CD133+ cells represented the most clonogenic fraction, and uniquely, these 
colonies also formed secondary colonies when replated. These cells from 
tumours also showed greater proliferation in culture than similar benign cells 
(managing 25 population doublings compared to ~12). When in differentiation 
promoting culture, the CD44+a 2 p l+/Hl CD133+ cells regenerated phenotypically 
mixed populations o f nonclonogenic cells expressing AR and PAP.
Collins et al (2005) also attempted to confirm the malignant nature o f their 
histologically selected cancer cells. Cancer cells and cell lines demonstrated 
invasion in an invasion assay, while benign cells and a benign cell line did not. 
The cancer cells also grew better in semisolid methylcellulose. Genotype 
comparisons did not demonstrate mutations in all tumours though detected some 
microsatellite instability in two o f six compared to the patients’ lymphocyte 
DNA (but not benign tissue from the same prostate). CD133+ basal cells were 
nominated as the likely source o f prostate cancer.
Though this work is singular in its use o f primary cancer cells it has been 
criticized for its lack o f in vivo assays, which as shown above can result in 
different cellular behaviours (Patrawala et al, 2007). Litvinov et al (2006) have 
also questioned the low calcium culture medium used for the cancer cells, which 
according to their work promotes benign cell growth. They suggested p63 
negativity as a useful discriminator o f benign or malignant cells.
The target cell for transformation is still unknown, and will likely have to await 
definitive isolation o f the prostate cancer stem cell. A number o f candidate
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markers are under investigation, and though none have demonstrated 
transplantable tumourigenicity, considerable enrichment is being achieved. 
Current markers exclude >99% o f terminally differentiated or TA cells which 
should allow a closer inspection o f stem cell gene expression through microarray 
analysis to identify novel therapeutic targets. The identification o f the prostate 
cancer stem cell is a priority. Current therapies eradicate the bulk o f the tumour, 
but cannot prevent the emergence o f incurable androgen-independent disease. To 
achieve cure, treatments must selectively target cancer stem cells, either to kill 
them, or drive them towards differentiation and senescence, as a form of 
‘differentiation therapy’ (Cunha, 1994). Unlike many other cancers in stem cell 
tissues, any treatment targeted against the prostate would have to be organ 
specific, but need not be cancer specific. Complete obliteration o f all prostate 
stem cells and thus the entire prostate is not life threatening, and would be 
preferable to death from metastatic disease.
1.11 The aims of this project
Study o f the prostate epithelium should focus on the small population o f 
proliferative and regenerative cells rather than the heterogeneous whole. 
Techniques o f in vitro culture already select for androgen independent epithelial 
cells and against stromal cells by using a feeder layer and excluding androgens 
(Freshney, 2002a). Hudson et al (2000) reported that the cells that can grow 
generate two different colony types, demonstrating clearly that in culture, 
prostate epithelial cells still represent a heterogeneous population. The aim o f 
this project was to study and compare the cells within these two colony types 
both from benign and malignant prostate tissues.
Stem cells and TA cells are both highly proliferative, but differ in their self­
renewal abilities. While colony-forming assays are still used as a measure o f the 
proliferative ability o f a cell population, no studies have further refined on the 
heterogeneity o f  the colonies. Yet, the study o f  these two more homogeneous cell 
populations that self-segregate according to colony type represents an 
opportunity to better unravel the nature o f stem cells and their immediate 
progeny (albeit retrospectively). Studying such segregation also promises to be
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more biologically meaningful than sorting cells for a speculative marker, as 
colony morphology depends on the very characteristics in question -  the 
proliferation and differentiation o f the constituent cells.
Hudson et al (2000) postulated that type I colonies derived from the clonal 
expansion o f a TA cell, while type II colonies were stem cell derived. Working 
from this hypothesis, each colony type was assessed for various stem cell 
attributes with the lack o f them being TA cell attributes. Additionally, their gene 
expression profiles were compared using cDNA microarrays.
It was also hypothesized that the stem cell model o f cancer applied in prostate 
tissue. Thus is was proposed that low-density culture o f prostate cancer tissue 
would also demonstrate the proliferative heterogeneity o f two colony types 
derived from putative stem and TA cells. Parallel cultures o f benign and 
malignant tissue were compared, but further analysis o f the differences between 
their colonies was confounded by difficulties in confirming the malignant nature 
o f early prostate cancer cells in culture. The outcomes o f these enquiries are 
reported below.
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CHAPTER 2: 
MATERIALS AND METHODS
2.1 Culture media
2.1.1 Prostate Epithelial Growth Medium (PrEGM)
PrEGM, a selective medium with appropriate growth factors was used to 
preferentially culture primary prostate epithelial cells. Serum was excluded to 
eliminate transforming and platelet-derived growth factors that favour stromal cells 
(Freshney, 2002a). Nine aliquots o f additives o f  unknown concentration (PrEGM™ 
SingleQuots®) were added to 500ml flask o f PrEBM (Cambrex Bio Science Ltd, 
Wokingham, UK). These were 2ml bovine pituitary extract, 0.5ml transferrin, 0.5ml 
insulin (bovine), 0.5ml tri-iodothyronine, 0.5ml human recombinant epidermal 
growth factor, 0.5ml retinoic acid, 0.5ml epinephrine, 0.5ml GA-1000 (gentamycin, 
amphotericin B) and 0.5ml hydrocortisone. This medium was thus serum and 
androgen free and low in calcium (i.e. <300pmol/L Ca2+).
2.1.2 Dulbecco’s Modified Eagle's medium (DMEM)
F^ or culture o f 3T6 mouse fibroblasts, DMEM (Gibco BRL, Paisley, U.K.) was 
supplemented with 8% foetal calf serum (FCS, Sigma-Aldrich Company Ltd, 
Gillingham, UK).
2.1.3 Tissue Collecting Medium
Human prostate tissue was transferred from the operating theatre to the laboratory at 
room temperature in sterile tissue collecting medium consisting o f  RPMI-1640 
medium (Life Technologies, Paisley, UK) supplemented with 20mmol/l HEPES 
(Sigma Chemical Co., Poole, UK). 8% FCS, penicillin (lOOU/ml), streptomycin 
(lOOpg/ml), fungizone (Amphotericin B, 25pg/ml) and 2mmol/l L-glutamine (all 
from Life Technologies). 0.48g o f HEPES per 100ml collecting medium was 
dissolved in 10ml RPMI, then filter sterilized and added to the complete medium.
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2.1.4 Conditioned medium
Conditioned PrEGM culture medium was derived from flasks o f irradiated or 
mitomycin C treated mouse 3T6 fibroblast feeder cells at intervals o f 2, 3 and 4 days 
o f culture. After defrosting (see section 2.3), feeder cells were plated out in DMEM 
with 8% FCS and incubated overnight at 37°C. The following day, the layer o f 
adherent feeder cells was washed 3 times with PBS, then re-fed with PrEGM 
medium. This medium was pipetted o ff the feeder layer at intervals for up to 9 days 
after which the feeders were discarded. The conditioned PrEGM medium was 
centrifuged at lOOOrpm for 5 minutes to remove cell debris then filter sterilized prior 
to use. Aliquots were frozen at -80°C. pH was measured with a Hanna pH meter 
from Sigma-Aldrich.
2.1.5 Collagenase solution
2001 U/ml concentration o f  collagenase was obtained from desiccated type 1A 
collagenase powder, (Sigma-Aldrich, stored at -20°C) dissolved in collecting 
medium with low dose antibiotics penicillin (lOU/ml), streptomycin (lOpg/ml) and 
fungizone (Amphotericin B, 2.5pg/ml) or RPMI and 8% FCS, and filter sterilized.
At least 7.5ml o f solution was required for lg  o f  tissue.
I
/
2.2 Tissue Culture
All cells were cultured in a humidified incubator at 37°C in 5% CO2. Media was 
changed aseptically three times a week. Cells were grown initially on 6cm diameter 
Nunclon™ surface treated polystyrene dishes, then subsequently on similarly treated 
polystyrene flasks (Nunc, A/S, Denmark). All flasks were collagen coated with 
sterile rat-tail collagen type 1 (Vitrogen 100; Imperial Laboratories, Andover, UK) 
diluted in PBS (Gibco, Invitrogen Ltd., Paisley, UK) to 10fig/ml. Tissue culture 
flasks containing sufficient collagen solution to cover the base were incubated at 
37°C for at least 1 hour. The excess collagen solution was aspirated prior to use.
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2.3 Preparation of mouse 3T6 fibroblast feeder cell layer.
Feeder cell stocks were stored in 10% dimethylsulphoxide (DMSO, Sigma) at -80°C 
for use within a month, or at -180°C in liquid nitrogen for longer storage. Defrosted 
cells were immediately resuspended in DMEM with 8% FCS, and centrifuged once 
at lOOOrpm for 5 minutes and the supernatant aspirated to remove the DMSO.
Feeder cells were plated in DMEM with 8% FCS at densities o f 750,000-1 million 
cells per 25cm and incubated overnight at 37°C. Prior to seeding with prostate 
epithelial cells, the feeder cell layer was washed 3 times with PBS, then re-fed with 
PrEGM medium.
3T6 feeder cells were treated with either 40 Gray o f radiation or mitomycin C to 
obtain viable, metabolically active, non-dividing cells. For irradiated feeders, 12 
175cm2 confluent flasks o f  3T6 cells were harvested into a 30ml ‘universal’ tube 
(Sterilin Polystyrene tube, Barloworld Scientific, Stone, UK) which was irradiated 
on ice (40 Gray at 2.5Gy/min) for 16 minutes. The cells were then centrifuged at 
lOOOrpm for 5 minutes, resuspended in FCS with 10% DMSO and counted. Aliquots 
o f 20x106 cells were stored in 1ml cryotubes (Nunc) in liquid nitrogen at -180°C 
after initial cooling at -20°C overnight.
I
Mitomycin treatment o f 3T6 cells was performed on nine 80% confluent 175cm2 
culture flasks. Mitomycin C (Sigma) was dissolved in PBS to a concentration o f 
200pg/ml. 1.1ml o f this solution in 21ml o f  DMEM with FCS was added to each 
175cm2 flask, which were then incubated at 37°C for 2-3 hours. For smaller 25cm2 
flasks, 150pl o f Mitomycin C solution was added to 3ml o f DMEM with FCS. After 
incubation, the flasks were washed 3 times with PBS and the cells were harvested 
and counted. Aliquots o f  20x106 cells were stored in FCS with 10% DMSO in liquid 
nitrogen.
2.4 Acquisition o f prostate tissue
2.4.1 Acquisition o f benign hyperplastic prostate tissue
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Full ethical approval for the project design and patient information and consent 
forms was obtained from the ethical committees o f the institutions from where 
specimens were obtained (University College Hospital, Ref 01/0094, The London 
Clinic, Harley Street, London). Men due to undergo prostate tissue resection were 
approached preoperatively and asked for consent (see Appendix A for consent 
forms). Exclusion criteria were treatment with 5a-reductase inhibitors or a previous 
diagnosis of, treatment o f or a high clinical suspicion o f prostate cancer. If consent 
was given, 3-6 large, non-charred prostate chips comprising no more than 10% o f 
resected tissue were selected and transported in sterile collecting medium for 
immediate processing.
2.4.2 Acquisition o f paired malignant and benign prostate tissue samples.
Full ethical approval was obtained from the ethical committees o f the institutions 
from where specimens were obtained (University College Hospital, Ref 01/0094,
The London Clinic, Harley Street). Men with biopsy proven prostate cancer who had 
elected to undergo a radical prostatectomy were approached preoperatively and 
invited to participate in the research project. Those patients in whom pre-operative 
biopsies suggested involvement o f  a large number o f cores on one side o f the 
-.prostate were selected to maximise the likelihood o f a large area o f cancer to sample. 
Wh^re consent was given, the freshly excised prostate was immediately transported 
whole in sterile collecting medium from the operating theatre to the 
Histopathologist. The prostate was cut into several saggital sections and for earlier 
patients inked on its external surface. These cut surfaces were then inspected for any 
abnormal areas using the information from the digital rectal examination, biopsy and 
any prostate imaging to guide the site o f tissue sampling. Small samples o f cancer 
and benign tissue were excised from the peripheral zone using a sterile scalpel.
These samples were processed in parallel as soon as possible while the rest o f the 
prostate was fixed in 10% formalin for routine histological processing. Fixed 
haematoxylin and eosin (H&E) stained wholemount slides from the level o f the 
prostate where tissue was taken were assessed by the Histopathologist and areas o f 
cancer demarcated. Usually a defect was visible, indicating the site o f fresh tissue 
sampling. These slides gave an early indication o f the degree o f success with which 
areas o f cancer and benign tissue had been selected in the fresh prostate.
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2.5 Processing Prostate Tissue
All prostate tissue whether derived from trans-urethral resection o f the prostate 
(TURP) or radical prostatectomy specimens was handled similarly. In a laminar flow 
hood, tissue was washed 3 times with PBS to remove adherent blood cells, any 
charred areas o f  BPH were trimmed and the remaining tissue was weighed. After 
addition o f 0.5ml collagenase solution, the tissue was minced into <lm m  diameter 
pieces using fine scissors on a sterile culture plate resting on ice. These pieces were 
transferred to a 30ml universal container, resuspended in PBS and allowed to 
sediment for 5 minutes. The cloudy supernatant was aspirated and the step repeated 
until the supernatant was clear. The tissue was then digested with collagenase 
solution (7.5mls o f 200U/ml per gram o f tissue) to separate stromal cells from the 
still intact epithelial acini over 16 hours on a moving platform at 37°C.
After digestion, the tissue ‘broth’ was passed 10 times through a wide bore needle to 
produce a single cell suspension. This represented a modification o f  the protocol 
described by Hudson et al (2001), which used two brief 20-second centrifugations o f 
the broth then a 30-minute trypsin digestion step to separate acini into single cells. 
This modification was motivated by a wish to preserve cell membrane proteins for 
potential applications such as cell sorting. The digested tissue broth was centrifuged 
at 15(^0rpm for 20 minutes; the cells were washed once in PBS, then were 
centrifuged for a further 20 minutes. Finally the cell pellet was resuspended in 
PrEGM and a lOOpl sample, diluted 1:1 with 0.1% trypan blue to identify viable 
cells (Cambrex Bio Science Ltd, Wokingham, UK) was counted using a 
haemocytometer. Red blood cells, distinguishable by their biconcave shape were 
disregarded. The cells were plated at 103 cells/25cm2 onto collagen-coated flasks 
with a 3T6 fibroblast feeder layer in PrEGM. Colonies became visible from day 6, 
and cells were cultured for 2 weeks.
2.6 Sampling Type I or Type II prostate epithelial colonies.
At two weeks, flasks were scored for colony number and type. The plated epithelial 
cells show proliferative heterogeneity, such that clonal expansion o f a single cell
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results in two distinct colony morphologies, as described by Hudson et al (2001). 
The characteristics o f these colonies are as shown in Table 2.1, and colonies were 
typed accordingly under direct vision or xlO low power magnification (though 
immunocytochemistry was not performed). On the few occasions where a colony 
was difficult to type or appeared to have merged with another, the colony was not 
harvested.
The colony cell density was measured by placing the flask on a clear acetate grid 
colony on the microscope stage. For cell number, the density o f cells was squared, 
and multiplied by the number o f grid squares under the colony. Using cell number, 
the number o f doublings was calculated from its log2 and rounded up.
Type 1 colony Type 2 colony
Size Small (max 4mm) Larger (>3mm)
up to 8500 cells 8 0 0 0 -4 0 ,0 0 0  cells
(5 -12  doublings) (12-14 doublings)
Density Loosely packed Denser
(<30cells/mm) (30 -  50 cells/mm)
Frequency 90% 10%
Outline Irregular Regular
Immunocytochemistry K8 or K 8 & K 1 4 K 14 only
Table 2.1: Characteristics o f  BPH derived type I and type II prostate epithelial 
colonie^ after two weeks in culture.
Colonies were harvested either by ring cloning, scraping with a cell scraper (Nunc) 
and immediate aspiration o ff the plate (see below) or by trypsinization o f flasks in 
which all colonies o f one type were first scraped up and washed off with PBS three 
times leaving only the other type o f colonies for collection.
2.6.1 Ring cloning o f colonies.
The top surface o f a culture flask containing colonies for harvesting was removed 
with a hot scalpel, and the flask washed three times with PBS leaving only a thin 
layer o f PBS. Rings were cut with a hot scalpel from the sterile threaded top o f a 7ml 
‘bijou’ tube (Sterilin Polystyrene tube, Barloworld Scientific) or 30ml universal tube 
depending on the size o f  the colony to be cloned. Using forceps, one ring edge was
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coated with sterilized silicon vacuum grease (Dow Corning®, GBR Technology Ltd, 
Reading, UK) and this was pressed to obtain a water-tight seal onto the surface o f 
the culture flask, centred over the colony. Fifty to lOOpl o f 0.25% trypsin/versene in 
buffered saline (Invitrogen) was added into the ring and cells were incubated within 
the laminar flow hood at room temperature for 3-5 minutes until the cells had 
rounded up and aggregated in the centre o f the ring. Cells were then repeatedly 
flushed o ff the flask with PBS and pipetted into a sterile 15ml centrifuge tube (CLP 
Ltd, Northampton, UK). The tube was centrifuged at lOOOrpm for 5 minutes and the 
trypsin containing supernatant aspirated off. The pellet was resuspended in PrEGM 
and the cells counted then transferred to a new collagen coated culture flask or into 
Matrigel™.
2.6.2 Harvesting o f passaged colonies for RNA extraction.
Individual ring cloned colonies were transferred into collagen coated 25cm2 tissue 
culture flasks with a feeder layer. Cells were expanded in culture for 1 to 2 weeks 
prior to harvesting, counting and RNA extraction. Cells were harvested when 
approximately 75% confluent by eye, while they were actively dividing, rather than 
when confluent which would trigger a change in gene expression. At harvesting, any 
remaining adherent feeder cells were first rinsed o ff with a brief trypsin solution 
incubation followed by three PBS washes. The still adherent prostate epithelial cells 
were then incubated in 1ml o f trypsin solution at 37°C until detached. The cells were 
transferred to a 15ml centrifuge tube, centrifuged at lOOOrpm for 5 minutes and the 
pellet was then resuspended in PBS for counting prior to RNA extraction.
2.6.3 Harvesting o f single or multiple colonies for RNA extraction.
Where DNA or RNA from a single type II colony was required, the top o f the flask 
was removed using a hot scalpel and all other colonies were scraped off. The 
remaining colony was harvested using trypsin solution, and the cells suspended in 
PBS. The cells were counted and 90% were allocated for DNA extraction and 10% 
for RNA extraction. These latter cells were centrifuged at lOOOrpm for 5 minutes 
and the cell pellet resuspended in 1ml RLT buffer (a highly denaturing guanidine
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isothiocyanate containing lysis buffer, Qiagen Ltd, Crawley, UK) prior to RNA 
extraction.
Colonies were closely adherent to the plastic and colonies o f different types often 
grew close together. Where multiple colonies o f  one type were to be harvested 
together, a vacuum device was used to allow harvesting o f selected colonies under 
x4 magnification (figure 2.1).
MICROSCOPE
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used to lift o ff & \
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Figure 2.1: Apparatus for selective harvesting o f type I or type II colonies for total 
RNA extraction.
The top surface o f the flask to be harvested was removed, and the colonies washed 
three times with PBS leaving a thin layer o f PBS. Colonies were selected and areas 
containing each type were segregated using a liquid repellent ‘PAP’ pen (Invitrogen) 
on the base o f the flask. This prevented the thin layer o f PBS flowing beyond the 
marked boundaries. Under xlO magnification, type I colonies were first elevated off 
the plastic surface using the sterile bevelled tip o f some sterile flexible, 1mm 
diameter PTFE tubing (Extruded Plastics Ltd, Macclesfield, UK); and immediately 
aspirated with the PBS into an RNAse-free 15ml centrifuge tube (CLP Ltd). The 
amount o f fluid aspirated with the cells was kept as low as possible to avoid
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excessive dilution o f RNA prior to extraction. Cells were aspirated straight into RLT 
buffer containing 1% 14.3M P-mercaptoethanol (Sigma Chemicals). The ratio o f cell 
aspirate to RLT buffer was kept below 1:3.5 (personal communication, Qiagen 
helpdesk). After all type I colonies were harvested, the flask was washed a further 
three times with PBS, and type II colonies were similarly harvested into a new 
container. Not all colonies in a flask were harvested, as overlapping or inaccessible 
colonies were sacrificed.
2.7 Three dimensional culture in Matrigel™
Matrigel™ basement membrane matrix is a solubilized basement membrane 
preparation derived from mouse sarcoma. It contains laminin, collagen IV, heparan 
sulfate proteoglycan, entactin and fibroblast growth factor, TGF-beta, tissue 
plasminogen activator and other growth factors. 1ml o f Matrigel™ (Promega, 
Southampton, UK.) was defrosted overnight at 4°C, mixed with 1ml o f chilled 
PrEGM on ice, and then 200pl aliquots were pipetted into a 24 well plate. The 
solution solidified after 30 minutes at 37°C, and a further 1ml o f PrEGM was 
carefully pipetted onto the Matrigel. 10,000 pooled type I or type II colony cells 
were added onto the Matrigel and cultured at 37°C for 14 days prior to harvesting, 
fixation and paraffin embedding for immunohistochemistry. Photographs o f the 
structures obtained were taken at intervals using a microscope mounted Nikon 
Coolpix 995 digital camera.
2.8 Preparation o f histological sections.
The tissue or cells for sectioning were wrapped in tissue paper inside a plastic 
fenestrated cassette and soaked overnight in 10% formaldehyde (VWR International 
Ltd, Poole, UK). It was next dehydrated over 24 hours in 70% ethanol, and then 
embedded in paraffin. The chilled paraffin block was sliced with a microtome into 
4pm sections using a microtome which were mounted on glass microscope slides at 
40°C and incubated at 60°C for 20 minutes to attach the specimen to the slide.
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Flasks with colonies were fixed and permeabilized for staining. After aspiration o f 
the culture medium and two PBS washes, 5ml o f chilled 1:1 Methanol: Acetone 
(VWR International Ltd) were added to the flasks on ice for 10 minutes. Flasks were 
washed a further two times before staining. Colonies were stained with Rhodanile 
blue (Sigma-Aldrich Company Ltd, Gillingham, UK) by immersing them in the dye 
at room temperature for five minutes, then rinsing with tap water and leaving to air 
dry.
2.9 Immunohistochemistry
The primary antibodies used are given in table 2.2. Unlabelled primary antibodies 
were detected with an immunoperoxidase method using a standard avidin-biotin- 
complex kit (Vectorstain Elite ABC kit, Vector Laboratories, Peterborough, UK). 
Antibody binding was visualized using 3,3’-diaminobenzidine tetrahydrochloride 
(DAB; DAB substrate kit for peroxidase, Vector Laboratories).
Paraffin-embedded sections were de-waxed in xylene (VWR International Ltd, two 
times 3 minutes) then were rehydrated in 100%, 70% and 70% alcohol for 1 minute 
each and then rinsed in distilled water. Formalin fixation involves the formation o f 
cross-links between molecules that alter the structure o f proteins and affect their 
recognition by antibodies (Macintyre, 2001). Reversal o f this process, so called 
antigen retrieval was performed by microwaving in 1600ml o f boiling distilled water 
containing 15ml citrate-based antigen unmasking solution, (Vector Laboratories) for 
30 minutes, then washing twice in PBS. Thereafter both fixed culture dishes and 
paraffin-embedded sections were treated similarly.
Endogenous peroxidase was quenched by incubating cells with 0.3% peroxide in 
70% methanol for 30 minutes. After two 5 minute PBS washes non-specific protein 
binding was blocked using 1.5% normal horse serum in PBS for 20 minutes. The 
primary antibody diluted as required in 0.1% bovine serum albumin in PBS was then 
applied to the sections for 1 hour at room temperature. After three 5 minute PBS 
washes, lOOpl o f biotinylated secondary antibody (horse anti-mouse IgG diluted 
1:100 in 1.5% normal horse serum in PBS) was added to the sections and incubated 
for 30 minutes. Following three further 5-minute PBS washes, the sections were
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incubated in Vectastain ABC reagent (an avidin and biotinylated horseradish 
peroxidase macromolecular complex) for 30 minutes then washed twice more. 
Finally lOOpl DAB peroxidase substrate solution was added to the slides for 10 
minutes, which resulted in the release o f  oxygen, which then combines with DAB to 
form a brown end product.
The sections were counterstained in M ayer’s haematoxylin for about 10 seconds, 
washed then dehydrated in 70%, 70% and 100% alcohol each for 1 minute, then 
twice in xylene. Coverslips mounted on DPX (Merck) were set, then allowed to dry.
Antigen Clone Species Isotype Dilution Source
Androgen
Receptor
MU256-
UC
mouse IgGl 1:250 Affinity
Biogenex1
K14 LL002 mouse IgG3 1:10 Gift from 
EB Lane
K8 35bHl 1 mouse IgM 1:40 Dako2
AC 133 AC 133 mouse IgGl 1:100 Miltenyi
Biotec
K5,K6 & 
K18
1 . r-r- ■.
LP34 mouse IgGl
i ------
1:10 Dako2
A ffinity B iogenex, Launch D iagnostics Ltd, Kent, UK; Dako UK  Ltd, Cam bs, UK; M iltenyi Biotec  
GmbH, 51429  Bergisch G ladbach, G erm any.
Table 2.2: Antibody Reagents
2.10 Genomic DNA extraction from large and small tissue samples.
Genomic DNA was obtained from a number o f tissue sources. Histologically 
confirmed malignant and benign areas o f the paraffin-embedded radical 
prostatectomy specimen were sampled either by scraping cells with a sterile scalpel 
blade off sections using a drop o f 100% alcohol on the slide, or by taking thin cores 
o f the paraffin block from within the cancer / benign areas with a 5mm skin biopsy 
punch (Stiefel Laboratorium, Offenbach am Main, Germany). Often a defect was 
visible, indicating the site o f  fresh tissue sampling, so cells immediately adjacent 
were harvested as a source o f  corresponding DNA. Baseline normal benign DNA 
from the same patient was obtained from paraffin embedded negative lymph node 
samples as cores o f the paraffin block (see figure 2.2).
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Figure 2.2:
Sourcing DNA 
from the prostate 
blocks. A shows a 
haematoxylin and 
eosin stained 
section from the 
paraffin embedded 
prostate block 
shown in C. The 
histologically
confirmed focus o f cancer was marked on slide A with the defect due to fresh tissue 
sampling visible within it (*). A core o f the cancer focus in the paraffin block was 
taken and DNA extracted (►). It was hypothesized that colonies derived from the 
fresh cancer tissue would show the same genotype as those from the original cancer 
focus. B shows a wholemount slide with a defect at the site o f benign tissue 
sampling (*). In D, adjacent tissue has been scraped off to obtain representative 
‘benign’ DNA.
DNA was obtained from colonies derived from fresh tissue by scraping the whole 
colony using a scalpel blade for fixed cells or a 200|il Gilson pipette tip for cells 
where the medium had just been removed. Larger, denser type II colonies were 
harvested preferentially when available. Cell line DNA was obtained from near 
confluent flasks o f cells that were trypsinized, removed from the flask then 
centrifuged into a cell pellet for DNA extraction.
For paraffin embedded tissue samples the Qiagen DNeasy™ kit was used to lyse 
cells and bind DNA to a silicone membrane, from which proteins and divalent 
cations are washed before eluting DNA as 30-50kb fragments. Paraffin embedded 
samples were incubated overnight with 180pl o f buffer ATL (an enzymatic buffer 
containing sodium dodecyl sulphate) and 20pl o f proteinase K in eppendorfs at 55°C 
in a humidified chamber to chemically and enzymatically lyse connective tissue. 
Subsequently, 200pl o f buffer AL, a chaotropic salt was added which dehydrated the 
DNA to optimise binding o f the exposed negatively charged phosphate backbone to
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the positive silicon membrane o f the column. It also inactivated proteins and 
carbohydrates in the solution. The eppendorf was vortexed and incubated at 70°C in 
a water bath for 10 minutes. 200pl o f 100% ethanol was then added, to further 
dehydrate the DNA, and the solution was pipetted onto the DNeasy spin column and 
centrifuged at 8000rpm for 1 minute. The column membrane with bound DNA was 
washed twice with 500pl o f buffer AW1 (a dilute chaotropic salt solution that 
removed residual protein and carbohydrate), then 500pl o f buffer AW2 (dilute 
ethanol solution) with intervening 1 and 3-minute 8000rpm centrifugation steps. 
Finally the DNA was eluted in 80pl buffer AE after one minute’s room temperature 
incubation by centrifugation at 8000rpm for a minute. Buffer AE was a simple 
alkaline buffer (pH 8-9), which bound the acidic DNA. The 160pl DNA sample was 
stored at -20°C.
For small samples, where the column would dilute the DNA excessively an 
alternative method was used. Sterile DNA extraction buffer (50mM KC1, lOmM 
Tris-HCl pH 8.0, 2.5mM MgCE, 0.1 mg/ml Gelatin, 0.45% NP40, 0.45% Tween 20 
and water) and lOmg/ml o f  desiccated Proteinase K enzyme (Sigma) in deionised 
water was used to make a 1:20 Proteinase K: Buffer solution. 50pl was added to the 
cell sample in an eppendorf, which was incubated overnight at 55°C in a humidified 
chamber. The proteinase K was then inactivated by heating at 95°C for 10 minutes 
and the DNA was stored at -20°C.
DNA concentration and purity were measured using the Genequant Pro (Biochrom 
Ltd, Cambridge, UK) ultraviolet spectrophotometer with an absorbance o f 1 at 
260nm equating to 50pg/ml o f genomic DNA and a ratio o f absorbance at 
260nm:280nm o f 1.8 denoting pure DNA.
2.11 Polymerase Chain Reaction (PCR)
Amplification o f specific regions o f genomic DNA and cDNA was performed for 
loss o f heterozygosity (LOH) and gene expression analysis following reverse 
transcription o f mRNA. The PCR is an in vitro cyclical process o f heating and 
cooling to denature, anneal and enzymatically amplify DNA. Specific DNA 
sequences can be multiplied exponentially using a system that combines a thermal
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cycler with a heat stable enzyme (Taq polymerase). The reaction used two 
approximately twenty oligonucleotide long primers that were complementary to and 
hybridised with opposite DNA strands flanking the region o f interest in the target 
DNA. The reaction consisted o f the following steps with steps 2 to 4 repeated 35-45 
times depending on the quality and length o f the DNA used and the efficiency o f 
primer annealing.
1 Initial denaturing  at 94°C for 5 minutes.
2 template denaturation  at 94°C for 45 seconds to separate the DNA strands.
3 prim er annealing  at 52-62°C for 45 seconds; the primers annealed to the 
template at an optimum temperature determined by the nucleotide composition 
o f the primers.
4 extension at 72°C for 1 minute; the new DNA strands were synthesized from 
the primers, complementary to the single-stranded template DNA to which the 
primer had hybridised.
5 fina l extension at 72°C for 10 minutes.
The cycling meant that the newly synthesized DNA strands could themselves act as 
templates for further rounds o f  DNA synthesis in the subsequent cycles o f  the 
reaction. DNA amplification was theoretically 2” times where n was the number o f 
cycles, although in practice the efficiency is not 100%. The primers were 
incorporated into the new DNA strands, so were added to the reaction mixture at 
concentrations in excess o f  the final DNA concentration.
PCR was performed using the Qiagen Taq PCR Master Mix kit which provided a 
ready mixed solution o f  Taq DNA polymerize, Buffer, M gCh and equal quantities 
o f deoxyribonucleotides; dATP, dCTP, dGTP and dTTP. The final concentrations in 
the 20pl reaction mix were:
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Taq PCR Master Mix lOpl 0.5 units o f Taq Polymerase
lx  Buffer 
1.5mM MgCl2 
0.2mM o f each dNTP
Sense Primer 
Antisense Primer 
DNA
Distilled water 
Total reaction mix
l.Opl 0.25 pM
l.Opl 0.25 pM
1.5-5.0pl 0.2-0.5pg total, 100-250ng/pl
3.0-6.5 til
20pl
All reagents were defrosted on ice and vortexed well before use. Each PCR 
contained a negative control lacking DNA to identify contamination and a positive 
control where possible depending on the parameter being optimised. All primers 
used are listed in Appendix B. Each primer was optimised before use to determine 
the best annealing temperature. The highest annealing temperature between 50-62°C 
that gave the best PCR product was used.
Primers for LOH analysis were those used by Bott et al, (2006) which were directed 
at the most commonly reported sites o f  LOH in prostate cancer. These loci are 
widespread throughout the genome on chromosome arms lq, 2q, 3p, 5q, 6q, 7q, 8p, 
9p, lOp, lOq, l ip ,  1 lq, 12p, 13q, 16q, 17p, 17q, 18q and 21q. LOH primers were 
fluorescently labelled, 18-21 nucleotides long and had a Guanine-Cytosine (GC) 
content o f 40-60%. The fluorochromes attached to the reverse primer o f  each pair 
were FAM, HEX or TET dye. All LOH analysis primers were ‘blasted’ using the 
‘Basic Local Alignment Search Tool’ on the NCBI website
(http://www.ncbi.nlm.nih.gov/BLAST/) to confirm that they would not amplify any 
contaminating mouse DNA, given the necessity o f culturing prostate cells on a 
mouse fibroblast feeder layer.
Unlabeled primers for reverse transcription PCR were designed with similar 
properties as above at www.veastgenome.org using published sequences o f the 
genes o f interest.
DNA quantities for LOH analysis were often limited. During primer optimisation 
when lOOng o f DNA template was used in the reaction mix the PCR product was 
often only barely visible. Using 200ng yielded easily visible results and this amount
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was used thereafter. Colony DNA was often in too limited a supply to allow 
estimation o f DNA concentration. 2.5pl o f colony DNA was amplified for GAPDH, 
and those that demonstrated a visible band on gel electrophoresis were used for LOH 
analysis.
2.12 Semi-quantitive reverse transcription PCR (RT-PCR)
The relative expression levels o f  different genes can be assessed by reverse 
transcription PCR. Using a known amount o f total RNA, DNA copies o f all mRNA 
transcripts are synthesized with highly expressed genes being represented in higher 
abundance than weakly expressed genes in the DNA sample. PCR o f equal amounts 
o f the DNA sample directed at specific genes produces quantities o f PCR product in 
proportion to the abundance o f the mRNA transcript in the initial total RNA. This 
does not reflect any post-translational modification or variations in protein 
transcription occurring downstream so may not accurately reflect the quantity o f 
functional protein within the tissue.
Reverse transcription involves the synthesis o f single stranded complementary DNA 
(cDNA) from mRNA by reverse transcriptase enzyme. The antisense cDNA strand 
is produced by RNA-dependent DNA polymerase activity following the annealing o f 
oligo-dT primers to the mRNA poly-A tails. The bound RNA template is then 
digested by a hybrid dependent exoribonuclease activity also demonstrated by the 
enzyme. The resulting cDNA sample is then used for PCR o f sequences o f  interest.
The Qiagen Omniscript Reverse Transcription kit which uses an E coli derived 
Reverse Transcriptase enzyme was used. RNase inhibitor (Qiagen Ltd) was added to 
minimise RNA degradation during the reaction. All reagents were defrosted on ice 
and vortexed well before use. The 20pl reaction mix was made up with the 
concentrations below and incubated at 37°C for 1 hour. The resultant cDNA was 
stored at -20°C.
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lOx Buffer RT 2pl
2pl
2|il
lf.il
1 x Buffer
dNTP mix 0.2mM o f each dNTP
Oligo dT primer 
RNAse inhibitor
lpM  
10 units
Omniscript Reverse Transcriptase lpl 4 units
Total RNA l-3pl 0.5pg total, 0.17-0.5pg/pl
9-1 lu l
20pl
RNase-free water
Total reaction mix
2.13 Loss o f Heterozygosity (LOH) Analysis.
LOH analysis is a well-established technique to identify areas o f chromosomal 
deletion from 2 to hundreds o f bases long within cells. Such loci may indicate the 
sites o f tumour suppressor genes. By definition both alleles o f these genes must be 
disabled for loss o f  function. Typically this occurs through a point mutation in one 
allele and DNA deletion at the other, so loci that consistently show LOH in cancer 
samples are likely to be near important tumour suppressor genes.
Within the 97% o f  the human genome that is non-coding, are areas o f repeated DNA 
sequences known as tandem repeats. These areas vary in size from over 1Mb to less 
than 150 base pairs (bp), and are termed satellites, mini satellites or microsatellites in 
decreasing size order. M icrosatellites (also called short tandem repeats (STRs) have 
repeated sequences o f  1 to 6 base pairs, making up regions o f DNA up to 150bp long 
and may be found both between and within genes. The number o f these repeats is 
polymorphic, so that they usually differ between maternal and paternal alleles. 
Microsatellite DNA is likely to have arisen through strand misalignment or slippage 
during replication, recombination or repair. PCR amplification o f a specific stretch 
o f DNA that contains an area o f  microsatellite DNA, would be expected to yield a 
heterogeneous product containing two different lengths o f amplified DNA, one 
derived from each parent. These may vary by only 2 base pairs in length but can be 
distinguished using high-resolution electrophoretic techniques. Where only one band 
is obtained, this is for one o f  three reasons.
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1 DNA deletion o f one allele has occurred at this locus. This is characteristic o f 
cancer and implies truncation or loss o f part o f a chromosome within the 
tissue. Thus LOH or allelic imbalance has occurred.
2 The degree o f polymorphism at different microsatellite DNA loci varies with 
an average heterozygosity rate o f 70% (Dib et al, 1996). Thus, both parents 
will be homozygous at about 30% o f loci, having the same number o f 
microsatellite repeats within the amplified segment and yielding only one 
length o f PCR product. This locus is therefore ‘non-informative’ for that 
particular individual. For this reason, LOH analysis in a malignant tissue 
requires a benign control sample from the same patient to distinguish 
between lost and non-informative loci.
3 The non-informative locus with one allele only present in both benign and 
malignant tissue may represent a germ line mutation, carried by all cells.
In some instances, subtler changes than complete deletion may be identified, where 
mutations have resulted in an increase or decrease in the number o f repeats within 
the cancer tissue due to strand misalignment during replication, recombination or 
repair. When both benign and malignant specimens yield two PCR product each, but 
with different lengths this demonstrates ‘microsatellite instability’. Microsatellite 
instability arises spontaneously, but more often reflects reduced function o f certain 
DNA repair pathways (Figure 2.3).
LOH analysis was used in this project as a means o f differentiating between benign 
and cancer colonies. The method o f tissue acquisition and the multifocal nature o f 
prostate cancer made it possible that within each sample were contaminating benign 
or malignant cells that might have produced colonies derived from a cancer cell 
amongst benign colonies and vice versa. Thus the nature o f each colony had to be 
determined individually. In general it is not possible to reliably differentiate between 
primary cultures o f benign and malignant prostate tissue at the microscopic level 
(Bright et al, 1997). LOH analysis therefore aimed to distinguish cells in terms o f 
their chromosomal deletions.
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Figure 2.3: The underlying genetic differences in microsatellite instability and 
LOH. (from Pharoah & Caldas, 1999).
Up to 55 regions o f polymorphic genomic DNA that had previously been reported as 
lost in prostate cancer were analysed in prostate block or colony genomic DNA 
using PCR. For each locus for each colony any differences in PCR product length 
were detected by the ABI Prism® 3700 DNA analyser, an automated, high- 
throughput, capillary electrophoresis system. This contains fine glass capillary tubes 
containing a stationary polymer. Each PCR product generated using fluorochrome 
labelled primers is drawn up into one o f the capillary tubes and a 1000-volt charge 
applied across it. PCR products migrate along the capillary, with smaller and more 
negatively charged products moving faster. As the fluorochrome-containing DNA 
fragments leave the capillary, an argon laser excites them and their emitted
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fluorescence is measured. An electropherogram is constructed for each capillary 
sample using GeneScan analysis Software (Applied Biosystems, Foster City, CA, 
USA). The electropherograms show the length and relative concentration o f the PCR 
products within the sample and LOH is identified by comparing electropherogram s. 
The fluorochromes were FAM or HEX, which appeared blue on the analyser or 
TET, which showed green.
PCR products o f  different lengths and different coloured fluorochromes could be 
pooled for running in one capillary. PCR products were analysed in 96 well plates 
after dilution with de-ionized water to concentrations o f 1:40, 1:80 or 1:120. In each 
well, 2pl o f diluted pooled PCR product was combined with lOpl o f Hi-Di 
Formamide (Applied Biosystems) and 1.5% Genescan 400 High Density (ROX) size 
standard (Applied Biosystems) no more than 24 hours prior to analysis as the 
formamide slowly breaks down DNA. The resultant mixtures were denatured at 
95°C for 5 minutes just prior to 3700 analysis. ROX size standard consisted o f  21 
50-400bp single stranded DNA fragments labelled by a red fluorophore. The 
migration times o f  these known fragments allowed the machine to size the unknown 
PCR products in the same lane.
3700 data was imported for analysis into the Genotyper software. Individual labelled 
electropherograms portrayed the DNA within each well with size in base pairs 
plotted against the amount o f  fluorescence (measured in arbitrary fluorescence units) 
and therefore product. Peaks relating to each DNA product were quantified by the 
software. The highest peak was chosen for each allele, though there were often a 
number o f adjacent smaller peaks a few base pairs longer or shorter caused by 
slippage o f the Taq polymerase enzyme during DNA amplification. The longer allele 
was always present in lower quantities than the shorter allele but this difference in 
peak heights was assumed to be constant. LOH was present where the change in 
peak height o f the two alleles in the malignant specimen was significantly greater 
than that o f the benign specimen. This standardized for PCR amplification 
differences and loading variability between the two and was calculated as:
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peak height o f  lower allele in malignant specimen
peak height o f higher allele in malignant specimen
peak height o f lower allele in benign specimen 
peak height o f  higher allele in benigp specimen
The amount o f  DNA in each PCR product varied, so all samples were first analysed 
at the 1:80 concentration. When PCR products were too concentrated then the 
excessive fluorescence (levels over 10,000 arbitrary fluorescence units) saturated the 
detector and electropherogram peaks were blunted. If  they were too dilute, peak 
heights less than 200 were indistinguishable from baseline noise and disregarded. 
Samples were re-run at 1:40 or 1:120 as necessary. The definition o f  a significant 
difference varies throughout the literature from 0.8 to 0.2 (Canzian et al, 1996; 
Barratt et al, 2002; Narla et al, 2001, Gray et al, 1995). The likelihood o f  true LOH 
being detected depends on the purity o f  the cancer sample, which is in turn 
dependent on the origin o f  the tissue and the means o f  obtaining the DNA. For 
heterozygous alleles where one allele has been lost in the cancer, there should in 
theory be only one allele present in the cancer sample compared to two in the benign 
sample. However in practice, few primary tissue samples are not contaminated with 
benign cells or perhaps different cancer clones. Thus the two alleles contained in 
these contaminants are detected and contribute to an albeit smaller peak in the 
cancer sample. In this project, loci were considered positive for LOH when the 
calculated difference was <0.5 (though a threshold o f  <0.3 was also considered) 
given the likely presence o f  contaminating non-epithelial tissue such as stroma and 
vessels in the prostatectomy block samples.
DNA obtained from the malignant or benign areas o f  the whole mount radical 
prostatectomy specimen was screened for LOH using 55 microsatellite markers. 
Lymph node DNA represented the benign control. DNA from colonies grown from 
the fresh malignant or benign tissue was then screened at loci showing LOH. This 
aimed to identify whether the colony matched the LOH pattern of the area o f  
malignant prostate that it came from thus confirming that cancer colonies had been 
cultured. Cell line DNA from paired benign and malignant prostate cell lines as
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described by Bright et al (1997) were similarly compared for 29 markers to act as 
control samples. Figure 2.4 shows typical electropherograms.
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Figure 2.4: Electropherogram pairs demonstrating A) a homozygous, non- 
informative locus and B) LOH with 81% loss o f  the shorter allele in the upper 
specimen. The peaks that are compared are indicated ( ^ ) .
2.14 RNA extraction
Total RNA was extracted at room temperature using the Qiagen RNeasy™ midi kit. 
RNA isolation entails initial lysis and homogenisation o f cells which are passed 
through a silica-gel membrane by centrifugations at 3000 x g. The membrane 
selectively binds total RNA, allowing other molecules to be washed through. An 
eluting step releases this RNA providing a sample for further applications. All RNA 
molecules longer than 200 nucleotides are isolated, thus the procedure enriches for 
mRNA since most RNAs <200 nucleotides (such as 5.8S rRNA, 5S rRNA, and 
tRNAs, which together comprise 15-20% o f total RNA) are selectively excluded.
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Cell pellets for RNA extraction were immediately resuspended in 1ml o f  RLT buffer 
to lyse cell membranes and inactivate RNases and ensure isolation o f  intact RNA. 
Type I and II BPH colony cells were harvested directly into RLT buffe r and the 
paired samples processed in parallel. Where a large volume o f cell lysate  existed, 
several columns were used for the same colony type in parallel, and e lu ted  total 
RNA handled separately thereafter despite being derived from the sam e lysate. Lysis 
aimed to completely disrupt cell and organelle membranes to release all the RNA 
within the sample. The lysed sample was then homogenized by passing the lysate ten 
times through a syringe and fine-bore (21G) needle to reduce viscosity and create 
the homogeneous lysate necessary for optimal RNA binding. At this point, any RNA 
samples that were not for immediate extraction were stored at -70°C.
An equal volume o f  100% ethanol was then added to the hom ogenized lysate and 
mixed to promote selective binding o f  RNA to the RNeasy silica-gel m em brane. 
Aliquots o f sample were applied to the RNeasy-midi column up to th ree  tim es and it 
was centrifuged for 5 minutes, after which the flow through was discarded. Further 
columns were used if  lysate remained.
On-column DNase digestion was next performed to wash through any residual DNA 
(Qiagen RNase-Free DNase Set). The column was washed with 2ml buffer RW1 (a 
guanidinium thiocyanate containing buffer) spun through for 5 m inutes. Then 160pl 
o f buffered DNase I (0.34 Kunitz units/pl in RDD buffer) was applied to  the RNA 
bound to the silica-gel membrane at room temperature for 15 minutes. A fter 
incubation in buffer RW1 for 5-minutes, centrifugation as above w ashed the DNase 
o ff the column.
Prior to RNA elution, the column was washed again with 2.5ml o f  ethanol-based 
buffer RPE with a 2 minute centrifugation and then 2.5ml o f RPE buffer w as spun 
through for 5 minutes. Finally the RNA was eluted into an RNase-free eppendorf 
(Ambion Europe Ltd, Huntingdon, UK) using 30-100pl o f RNase-free w ater 
(depending on initial number o f  colonies harvested) with a 3-minute centrifugation 
after 1 minutes incubation. A second elute into the same eppendorf was perform ed 
similarly. RNA solutions were immediately frozen at -80°C.
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2.15 Quantification and quality assessment o f RNA samples
Two methods o f RNA assessment were used. The Genequant Pro (Biochrom Ltd) 
ultraviolet spectrophotometer assessed the quality and quantity o f RNase-free water 
diluted total RNA samples drawn into glass capillary tubes. Absorbance at 260nm 
wavelengths allowed calculation o f  concentration where an absorbance o f 1 equates 
to 40pg/mL o f RNA, and the ratio o f  absorbance at 260nm / 280nm gave a measure 
o f  purity with 2.0 implying pure RNA.
For total RNA for application onto gene chips, the RNA 6000 Nano LabChip Kit 
and the 2100 Bioanalyser from Agilent Technologies UK Ltd, West Lothian, UK 
was used. In this lab-on-chip procedure, the denatured RNA sample combined with a 
marker dye is drawn along a fine gel-filled capillary by electrophoresis. RNA 
molecules o f different lengths travel at different speeds allowing the quantity and 
relative abundance o f  different sizes o f RNA to be measured. A ladder allows 
standardization o f the RNA run in each capillary. Each single use chip allows the 
analysis o f  12 samples simultaneously in 30 minutes. Only lp l o f  total RNA is 
required to quantitate concentrations o f 25-500ng/pl to an accuracy o f  ±  50% 
(manufacturer’s specifications). The LabChip was first primed with 9pl o f  a gel 
matrix and dye mix. lp l o f  heat denatured (70°C for 2 minutes) sample RNA and 
5 pi o f  RNA 6000 Nano Marker (Ambion) was added to each well with denatured 
RNA 6000 ladder (Ambion) placed in a separate well. The chip was vortexed and 
placed in the Agilent 2100 Bioanalyser. Sample quality and quantity was 
demonstrated by a gel image, electropherogram, rRNA signal height ratio (28S/18S) 
and calculated RNA concentration.
In addition, the electropherogram plot data for each sample was run through the 
Degradometer program (from www.dnaarravs.orgl devised by Auer et al (2003).
This program sought to improve on the rRNA ratio calculation used by the 
Bioanalyser software as a measure o f RNA integrity. The ratio is determined by the 
relative area under the 18S and 28S peaks, however the start and end o f  these are not 
easily defined. In addition, other assessments o f quality such as the appearance o f 
the gel or electropherogram are amenable only to subjective evaluation. The 
degradometer program provides a single figure -  the ‘degradation factor’ - that
84
allows direct comparison and ranking o f samples, and also bands them into five 
quality ranges from black (worst) through red, orange and yellow to no colour (best). 
The degradation factor figure increases as quality worsens. As degradation occurs, 
the rRNA peaks are seen to diminish and a greater number o f shorter RNA 
molecules cause degradation peaks. The degradation factor is calculated using the 
ratio o f the average RNA peak height to the 18S peak height to account for this. All 
these RNA measures were considered together to select the best quality RNA 
samples for further analysis.
2.16 Concentration o f RNA samples
Given the difficulty selectively harvesting colonies, and the need to maximize 
harvested cell numbers, the resultant RNA solutions were often too dilute. 
Concentrations o f 500ng/pl or at least lOOng/pl with an amplification step were 
required for downstream application onto Affymetrix® GeneChips® (Eberwine et 
al, 1992). When required, RNA samples were therefore concentrated within the 
eppendorf on ice at 4°C, by evaporation under a flow o f  nitrogen gas directed at the 
surface o f  the sample using a sterile glass pipette (figure 2.5). Concentration was 
stopped when the volume o f liquid had reduced sufficiently depending on the known 
starting concentration, and the sample concentration and quality was rechecked 
using the Agilent RNA 6000 Nano LabChip Kit and 2100 Bioanalyser.
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N 2 gas under sufficient pressure to 
agitate meniscus o f RNA sample
Sterile glass pipette with tip puncturing 
laboratory film covering eppendorf
Loosely applied film to catch splashes
Eppendorf containing RNA sample for 
concentration
Ice bucket. Procedure performed at 4°C
Figure 2.5: Concentration o f RNA samples using N2 gas.
2.17 Agarose gel electrophoresis
Total RNA samples and PCR products were assessed for integrity, size or 
concentration using agarose gel electrophoresis. Two percent agarose gels were 
used. These were made from powdered agarose (Invitrogen) added to Tris Acetate 
Electrophoresis buffer (TAE buffer: 4.84g Tris base, 1.142ml glacial acetic acid,
2ml 0.5M EDTA pH 8.0, made up to 1000ml with distilled water), covered and 
heated until it had dissolved. The agarose solution was allowed to cool, then mixed 
with 0.5pg/ml o f ethidium bromide and left to set in a gel tray with combs in situ. 
Gels were loaded while immersed in TAE buffer in the gel tank with 5 pi o f total 
RNA or 6pl o f PCR product with 2pl o f  loading dye per well. Where required 1 pi o f 
a lkb DNA ladder (GeneRuler™, Fermentas Life Sciences, Germany) in 5pl o f  gel 
loading buffer was also loaded. A 120-volt charge was applied and negatively 
charged DNA migrated through the gel. Gels were viewed on a GeneFlash UV 
imaging system at 254-300nm (Syngene Cambridge, UK). UV fluorescent images 
were captured using the GeneFlash system and GeneSnap image acquisition 
software (Syngene Cambridge, UK). For RT-PCR band intensity measurement,
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images were analysed using GeneTools software (Syngene Cambridge, UK) and 
data exported to Excel (Microsoft, Berkshire, UK) for statistical analysis.
2.18 Total RNA processing, amplification and application onto oligoarrays to 
obtain raw gene expression data.
The expression o f  many thousands o f genes can be studied simultaneously using 
DNA microarrays or oligoarrays. Thousands o f  DNA fragments or oligonucleotides, 
each known to correspond to a specific gene, expressed sequence tag or other DNA 
sequence are bound in a set pattern to a glass slide or silicon wafer. Processed 
mRNA is incubated as cDNA fragments with the array, and any mRNA fragment 
that hybridises to the complementary DNA probe is detected. From the position on 
the slide, semi quantitative and qualitative information regarding the expression o f a 
specific gene is obtained. Developed in the 1990s, microarray technology has 
opened up a new era in high throughput expression analysis, and allowed an 
understanding o f the global gene expression patterns underlying cell behaviour.
2.18.1 Transcription o f total RNA and hybridisation onto the Affymetrix 
GeneChip® array
Affymetrix GeneChip Human Genome U133 Plus 2.0 (Affymetrix UK Ltd, High 
Wycombe, UK) oligoarrays were used. This high-density array allows genome-wide 
expression analysis o f the known human transcriptome on a single microarray.
Each chip is a thin coated quartz wafer upon which millions o f  DNA fragments have 
been chemically bonded and extended using a photolithographic manufacturing 
process. Each chip is divided into over 1.3 million 11pm squares called features. 
Each feature contains millions o f  copies o f a specific 25-nucleotide long DNA probe 
bound to it at one end to which cDNA target fragments will bind if  complementary. 
Along with various control sequences, the expression level o f >47,000 transcripts 
and variants, including approximately 38,500 well-characterised human genes are 
demonstrated by >54,000 sets o f  probes on the chip. Each gene, expressed sequence 
tag or other sequence (termed ‘gene’ hereon) is specifically represented at 11 
different features by 11 different unique 25-mer probes.
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These sequences were derived from the most appropriate sequences on a number o f 
databases in the public domain (dbEST, NCBI, Feb. 2003; GenBank®, NCBI, Feb. 
2003 Release 134; RefSeq, NCBI, March 2003 and a draft human genome assembly, 
NCBI, November 2002, Build 31), avoiding those that might fold in on themselves 
or cross hybridise. Sequences were also selected from within 600 bases o f  the 3' end 
o f each mRNA transcript as RNA degradation starts at the 5' end.
For any probe there will be a degree o f  non-specific binding causing background 
noise. To control for this, each o f  the 11 probes representing each gene has a further 
11 features dedicated to it which contain very similar 25-mer probes, but with one 
different base pair in the middle o f the sequence. This is sufficient to destabilize 
specific binding, while non-specific binding is unchanged. This ‘perfect 
match:mismatch’ system allows the quantification o f  non-specific binding for each 
probe, and by subtraction, the quantification o f  true specific binding to the perfect 
probe. The use o f probe sets containing 11 pairs o f probes increases the sensitivity o f 
a chip for detecting the expression o f the gene to a resolution o f  1 in 200,000 total 
transcripts in a sample. All probes have to be hybridised in the same conditions, and 
will differ in their affinities due to their different sequences. This means a scaling 
process is required to normalize all signals to a common base line, but increases 
sensitivity, as a low abundance transcript will be detected by a high affinity probe 
while plentiful transcripts which saturate high affinity probes can still have 
differential expression demonstrated by low affinity probes.
Variations in microarray expression data may be technical or biological. Throughout 
the process o f patient selection, tissue culture, sample acquisition and microarray 
application standard protocols were followed to minimize technical variation. 
Affymetrix GeneChip Human Genome U133 Plus 2.0 arrays were used as in a 
comparison o f six commonly used gene expression analysis platforms, these 
demonstrated low levels o f  technical variability (Yauk et al, 2004). Twelve arrays 
analysed the five selected sample pairs and the reserve pair which was required as 
high background in the prostate I Type II chip might have lead to reduced detection 
o f low level expressed genes. All GeneChips were from the same batch and were run 
in succession. Sample amplification, labelling and gene chip hybridisation were all
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performed by Dr N. Jina at the Institute o f  Child Health, University College London. 
Figure 2.6 shows the steps within this process, which are further elaborated below.
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Figure 2.6: Human prostate epithelial target amplification and labelling for 
Affymetrix GeneChips from the GeneChip Expression Analysis Technical Manual. 
(www.affvmetrix.com)
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2.18.2 Selectively amplifying mRNA
Total RNA is comprised o f  messenger RNA (mRNA), ribosomal RNA (rRNA), 
transfer RNA (tRNA), small nuclear RNA (snRNA), small nucleolar RNA 
(snoRNA) and other non-coding RNA. The majority o f cellular RNA is rRNA, with 
mRNA contributing 3-5% . After transcription, mRNA is modified before 
translation. This includes RNA splicing to remove introns, capping o f  the 5 end and 
polyadenylation o f the 3* end. The poly-A tail present on all mRNAs can be used to 
selectively copy these RNA molecules using complementary primers with a built in 
promoter sequence. Here a modified oligo(dT) primer with a 5' T7 RNA polymerase 
promoter was used (5'-
GGCC AGTG A ATTGT A AT ACGACTC ACT AT AGGG AGGCGG-(dT)24-3').
2.18.3 Amplification of small target RNA samples: First cycle o f cDNA  
synthesis
In general, the standard RNA processing and hybridisation protocols as 
recommended by Affymetrix in the GeneChip Eukaryotic Small Sample Target 
Labelling Assay Version II were followed in this study; these protocols are available 
in the GeneChip Expression Analysis Technical Manual (see www.affVmetrix.com). 
The steps are described below.
1. Hybridisation of primer involved incubating the total RNA sample at 70°C 
for 6 minutes with a modified oligo(dT) primer with a 5' T7 RNA 
polymerase promoter (Affymetrix).
2. First (antisense) strand cDNA synthesis was performed by reverse 
transcription using Superscript II Reverse transcriptase enzyme (Invitrogen) 
incubated at 42°C for 1 hour then heat inactivated at 70°C for 10 minutes.
3. Second strand (sense) cDNA synthesis was performed by incubating DNA 
Polymerase I, E. coli (Invitrogen) at 16°C for 130 minutes, adding T4 DNA 
polymerase (Invitrogen) for the last 10 minutes.
4. Double-stranded cDNA clean up used overnight ethanol precipitation.
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5. In-vitro transcription o f the second (sense) strand o f cDNA produced 
antisense cRNA using the Ambion MEGAscript T7 Kit and unlabelled 
ribonucleotides.
6. Antisense cRNA clean up used Qiagen RNeasy mini columns.
2.18.4 Second cycle o f cDNA synthesis to produce biotin-labeled cRNA
7. First (sense) strand cDNA synthesis from antisense cRNA used a 10 
minute 70°C incubation to anneal random hexamer oligonucleotides 
(Invitrogen ). These primed the cDNA strand from random 3' binding 
locations on the cRNA and were extended from 5' to 3', ending in the 
synthesis o f  a 3' poly-A tail. The first strand cDNA were therefore shorter 
than the template antisense cRNA.
8. Second strand cDNA synthesis was primed using the T7-(dT)24 oligomer 
primer again.
9. Clean up o f double-stranded cDNA used the GeneChip® Sample Cleanup 
Module (Qiagen Ltd).
10. In-vitro transcription of first (sense) cDNA strand used biotinylated UTP 
and CTP ribonucleotides to produce biotinylated antisense cRNA (ENZO 
Diagnostics, Farmingdale, NY, ENZO® Bioarray™ HighYield™  Transcript 
Labelling K it).
11. Labelled cRNA clean up used the GeneChip® Sample Cleanup Module 
(Qiagen Ltd).
12. cRNA quality assessment by Agilent RNA 6000 Nano LabChip Kit and the 
2100 Bioanalyser (results not shown).
2.18.5 Fragmentation, hybridisation, array processing and scanning
13. Full length cRNA fragmentation into 35-200bp fragments by metal 
induced hydrolysis using the GeneChip Sample Cleanup Module (Qiagen 
Ltd).
14. GeneChip hybridisation involved the preparation o f a hybridisation 
cocktail including the fragmented target cRNA, probe array controls, bovine 
serum albumin and herring sperm DNA derived from the GeneChip
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Hybridisation, Wash, and Stain Kit (Affymetrix). It was then hybridised to 
the Affymetrix GeneChip cassette during a 16-hour incubation. Premixed 
control cRNA molecules were added from the GeneChip Eukaryotic 
Hybridisation Control Kit (Affymetrix). These were a mixture o f biotinylated 
and fragmented cRNA o f  bioB, bioC  and bioD  from E. coli, and ere from PI 
bacteriophage in staggered concentrations with corresponding probes 
represented on Affymetrix Eukaryotic expression probe arrays.
15. Processing o f hybridized a rra y s  involved washing and staining with 
phycoerythrin-conjugated streptavidin in an Affymetrix Fluidics station.
16. Raw  D ata gathering. Images were scanned with a Hewlett-Packard 
GeneArray scanner / Affymetrix GeneChip Scanner 3000 7G. A YAG laser 
is directed onto the chip and the amount o f  light emitted at 570nm is 
proportional to the bound target at each location on the probe array. This 
process bleaches the fluorophore by 3-5% such that the data is best captured 
on the first scan.
2.19 B uilt in controls fo r G eneC hip expression analysis.
Several quality control parameters are built into the Affymetrix GeneChip system to 
allow monitoring o f  assay data quality. Detailed information is available in the 
GeneChip Expression Analysis Data Analysis Fundamentals manual. These 
parameters were assessed across all GeneChips analysed.
2.19.1 Visual a rra y  inspection
At the most basic level, the probe array is inspected for any image artefacts such as 
high or low intensity spots, scratches and overall background levels.
2.19.2 B2 Oligo Perform ance
Just prior to hybridisation a number o f  labelled transcripts from the Affymetrix 
GeneChip® Eukaryotic Hybridisation Control Kit were added to the labelled target 
to serve as hybridisation, washing and staining controls. These included 50 pM o f  a
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synthetic biotinylated control oligo B2 which is used by the software to align a grid 
on the probe array prior to image analysis.
2.19.3 Average Background and Noise Values
The average background level on the chip is recommended to fall between 20 and 
100. A high background implies that sample impurities are binding non-specifically 
which can obscure genes at very low levels o f  expression leading to an overall loss 
o f  sensitivity. Noise is a measure o f pixel-to-pixel variability within a probe cell and 
is a feature o f the scanner and the sample. Replicates should ideally have 
comparable noise levels.
2.19.4 Poly-A Controls
The efficiency o f  the labelling o f the cRNA target was assessed using the Poly-A 
RNA Control Kit (Affymetrix) which contains sense RNA strands synthesized from 
four B. subtilis genes {dap, lys, phe  and thr) modified by the addition o f  poly-A tails 
and then amplified with T3 RNA polymerase. A mixture o f these 4 exogenous 
cRNAs is added to the target cRNA sample at known concentrations {lys 1:100,000; 
phe  1:50:000; thr 1:25,000 and dap 1:7,500). For amplified samples efficient target 
labelling should result in all lys being called ‘present’ on the chip in >70%  o f  arrays 
, with the other controls always being present at increasing intensities. An estimation 
o f assay sensitivity is thus also possible.
2.19.5 Hybridisation Controls
The GeneChip Hybridisation Control Kit also contains staggered concentrations o f 
biotinylated fragmented antisense cRNA o f  bioB, bioC  and bioD  from the biotin 
synthesis pathway o f  E. coli, and ere from the recombinase gene o f  bacteriophage 
PI. Their corresponding probes are included in Affymetrix Eukaryotic expression 
probe arrays. These controls are added to the target cRNA prior to hybridisation.
The concentration o f bioB is lowest at 1.5pM and should be detected in 50% o f 
arrays, while the other controls at 5pM, 25pM and lOOpM respectively should 
always be detected.
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2.19.6 Internal Control Genes
By comparing the signal values o f  probes for the 3’, middle and 5’ ends o f  p-actin 
and GAPDH, RNA sample and assay quality can be assessed. In general the 375 ’ 
ratio is <3 for the standard protocol. When samples are amplified, the use o f  random 
primers during the second amplification cycle means that it is inevitable that the 5 ’ 
end is not represented in all cDNA transcripts, so ratios tend to be >3 and the 3’ to 
mid-transcript ratio (3’/M) is a better guide. A high ratio may indicate degraded 
RNA or inefficient first strand cDNA synthesis and/or cRNA transcription.
2.19.7 Percent Present calls
The number o f probe sets called “Present” relative to the total number o f  probe sets 
on the array is dependent on multiple tissue, sample and chip factors and should be 
similar across samples.
2.19.8 Scaling Factors
For global scaling, the average overall array intensity was calculated and the 
deviation from this for each GeneChip was measured as a scaling factor. This 
variability in overall intensity was most likely due to assay factors, which were then 
controlled for by adjusting individual signal intensities by the scaling factor. Scaling 
factors should ideally not vary more than 3-fold.
2.20 Analysis o f GeneChip expression data.
Data from the scanned array was stored as a *.dat file by the GeneChip scanner. A 
*.cel file was derived from this, which contained a single intensity value for each 
probe cell. The probe cells were then grouped into their perfect match:mismatch 
pairs and their relative intensities compared. The true intensity level was assigned a 
detection p value and called present, marginal or absent in relation to a predefined 
threshold intensity. The relative proportion o f these three states for all 11 probe sets 
was combined into an overall p value for likelihood o f expression for the gene along
95
with the mean intensity o f expression. This data was expressed in a *.chp file and 
exported as *.txt file into the expression analysis software.
Using Genespring GX, Version 7.2 (Agilent technologies UK Ltd) the data was 
further transformed to focus on biological variation. First the data was normalised. 
All measurements less than 0.01 were set to 0.01 to remove all negative expression 
levels and other biologically irrelevant and unacceptable values. The intensity o f 
each gene on one chip was then normalised to the 50th percentile o f all gene 
intensities on that chip to standardize for variations in hybridisation and array 
performance and allow comparison between arrays. Finally all genes across all chips 
were rescaled to the median value o f  all genes so that genes with similar expression 
patterns would now look similar. These normalization steps assumed that the overall 
gene expression profile was similar on all chips (which was reasonable as they 
contained >1000 genes covering a wide range o f  biological functions). Each gene 
now had an assigned value for raw signal, control signal and a normalized value 
along with its t-test p-value expressing the likelihood o f  expression.
The data was viewed and manipulated using the natural log o f  the normalized 
values. This made the data more symmetrical and reduced the influence o f  outliers 
allowing better estimates o f variance. Thus equal emphasis could be given to up and 
down regulation o f genes and the data more closely approached a normal 
distribution (Morrison and Ellis, 2003). The cross gene error model was also 
employed to compensate for the limited number o f replicates (Rocke and Lorenzato, 
1995). This used details o f  the overall variability o f  the data and applied this to 
individual genes. It assumed that the expression o f a gene within type I or II colonies 
was normally distributed, that most genes were not differentially expressed and had 
a mean o f 1 and that genes expressed at a similar level had similar variances. This 
made gene selection more stringent when activated.
This transformed data contained readings for all 54,675 genes on the Affymetrix 
Human Genome U 133 Plus 2.0 array. Those genes showing significantly different 
expression between type I and type II colonies were obtained through a series o f 
filtering and statistical steps.
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First a step ‘filtering by fraction Present’ was performed as recommended by 
McClintick and Edenberg (2006) to exclude most non-expressed genes and reduce 
the false discovery rate associated with later statistical selections. Genes that are not 
detectably expressed nevertheless generate signal values and contribute 
disproportionately to the false discovery rate. These usually low, random 
fluctuations can still often produce apparently large fold-changes. By retaining only 
those genes which were called present in at least 3 out o f the 12 chips (i.e. 50% o f 
one experimental arm of 6) this excluded the majority o f non-expressed genes while 
retaining highly significant genes and interesting transcripts that were turned on or 
off. McClintick and Edenberg found this filter to exclude 92% of absent probe sets 
while removing 4.2% present probe sets in their data. This filtering step was useful 
as the data did not tolerate later multiple testing corrections that also aimed to reduce 
the false discovery rate.
It is generally accepted that fold change alone is not a valid test for differential 
expression (Morrison and Ellis, 2003; Allison et al, 2006). Therefore a one-sided 
analysis o f variance (ANOVA) with no multiple testing correction steps was used at 
a p-value o f 0.05 to identify those remaining genes that were significantly differently 
expressed between the two colony types. This level o f significance was chosen as a 
compromise between type 1 error (finding false positive genes) and type II error 
(excluding false negative genes). No post-hoc tests were necessary as only two 
groups were being compared and no multiple testing corrections were included as 
these were too stringent, excluding all remaining genes.
The ANOVA identified those genes that were significantly differentially expressed. 
Next those genes with a t-test p-value o f >0.05 in one o f the two experimental arms 
-  type I or II were excluded. This retained genes whose expression was similar 
between replicates and therefore probably more meaningful.
A cluster diagram as first described by Eisen et al in 1998 was constructed. Using 
hierarchical clustering, genes and samples showing similar expression patterns were 
grouped closest together with the branch lengths on the dendrogram reflecting the 
degree o f similarity between each one.
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K-means clustering was also explored as an alternative to the two-dimensional gene 
tree, to further categorize the final gene list (Hartigan and Wong, 1979). This 
clustering algorithm aims to group genes with similar expression patterns together. 
The default number o f starting clusters, 5, was used and genes were assigned in the 
order o f the gene list to one o f these 5 clusters which were plotted in ‘expression 
space’ with the centre o f each representing the average location. Each gene was then 
reassigned to the cluster with the centre nearest its position and the centres’ locations 
were recalculated. After 100 iterations the clusters were defined.
This is one o f several available unsupervised clustering tools. However there is no 
clear consensus as to which clustering algorithms are most biologically useful or 
reproducible, and for K-means clustering, how many starting clusters are required 
(Allison et al, 2006). K-means clustering can produce different outcomes each time 
it is run on the same data if the starting cluster allocations are random (not the case 
in Genespring 7.2) which can be expressed as its stability. In a comparison study o f 
several different clustering models, K-means was found to be more stable than some, 
though only with a 55% stability at best (Garge et al, 2006).
The genes listed in each cluster were then examined in context o f their biological 
functions with the help o f the Netaffx™ Analysis Center hosted by 
www.affvmetrix.com and databases curated by or accessed via the National Centre 
for Biotechnology information at http://www.ncbi.nlm.nih.gov/.
2.21 Statistical analysis.
All statistical analysis was performed using Microcal Origin 4.0 (Microcal Software 
Inc., Northampton, MA, USA), Excel (Microsoft, Berkshire, UK) or the online 
statistical calculators available at http://www.phvsics.csbsiu.edu/stats/. Expression 
array analysis was performed using Genespring GX.
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CHAPTER 3:
ACQUISITION AND ANALYSIS OF EPITHELIAL COLONIES FROM  
BENIGN PROSTATIC HYPERPLASIA TISSUE.
3.1 Morphological characteristics o f primary prostate epithelial colonies
Fresh primary prostate tissue from TUR specimens was collected and processed 
according to the protocol described above. After 14 days in monolayer culture type I 
and type II colonies were distinguishable. Such colonies had previously been 
characterised by Hudson et al (2000) in terms o f their frequency, size, morphology, 
cell density and cytokeratin expression. The colonies obtained in this study were 
similarly assessed to confirm the reproducibility o f the technique. The colony 
forming efficiency o f  the prostate cells is given for all dishes from ten experiments 
in table 3.1. Figure 3.1 shows the distribution o f colony size and type derived from 
ten dishes from each o f  three experiments.
Experiment No. o f  dishes scored
Mean total 
% CFE 
(>32 cells)
Mean % 
type II CFE
% total 
colonies 
type II
1 20 0.45 0.06 13.3
2 20 0.48 0.17 35.4
3 17* 0.36 0.05 13.9
4 23* 0.20 0.04 20.0
5 24 0.27 0.02 7.4
6 15* 0.03 0.00 0.0
7 18* 0.15 0.05 33.3
8 20 0.13 0.03 23.1
9 23* 0.48 0.09 18.8
10 25 0.10 0.00 0.0
mean 20.5 0.27 0.05 16.5
s.e.m. - 0.05 0.02 3.87
CFE = colony forming efficiency, s.e.m. = stanc ard error o f the mean, *excludes
dishes lost to infection that were not scored.
Table 3.1: Colony forming efficiencies o f primary prostate epithelial cell cultures.
100
■  Type I colonies 
□  Type II colonies
32-6 3 (5) 64-127 128-255 256-511 512- 1024- 2048- 4096- 8192- 16384- 32768- 65536- 131072- 262144->524287
(6) (7) (8) 1023 2047 4095  8191 16383 32767 65535 131071 262143 524287 (19)
(9) (10) ( 11) (12) ( 13) (14) (15) ( 16) (17) (18)
Colony size in cell number (cell doublings)
Figure 3.1: Distribution o f  prostate epithelial cell colony size by type. Error bars 
show the standard error o f the mean over 10 dishes from 3 experiments.
Colonies were typed primarily on their morphology and overall appearance under 
direct vision. However four other criteria were also recorded: colony diameter, 
number o f cells across 1mm (cell density), total colony cell number and the number 
o f cell divisions this reflected. All these criteria were significantly different between 
the two colony types (pO.OOOl, Students t-test, data shown above for colony cell 
number only) and were useful objective discriminators alongside the more subjective 
assessment o f morphological appearance. A typical dish and magnified views o f 
both colony types are shown in figure 3.2.
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Figure 3.2: A Representative 
collagen coated dish seeded with 
1000 primary prostate epithelial 
cells, cultured for 14 days then 
stained for K 5/6/18. B&C The 2 
colony types are distinguishable by 
eye. ‘Stranded’ feeder cells (*) are 
visible within the colonies. > * 7
Vi*
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Hudson et al, 2000 Present study
Colony type I II I II
Diameter 
(mm, mean)
< 4 >3 0 .5 - 1 6
(4)
9 - 2 0
(ID
Cell number 
(mean)
< 8,500 8,000 -  
40,000
40 -  48,000 
(8300)
i 28,000 -  
607,000 
(169000)
Number o f doublings 
(mean)
5 - 1 2 12 - 14 5 - 1 6
(11)
15 -  19 
(17)
Density
(cells/mm, mean)
<30 3 0 - 5 0 7 - 3 2
(19)
3 3 - 5 9
(40)
Outline Irregular Regular Irregular Regular
Frequency o f colonies 90% 10% 83% 17%
Incidence o f colony 
forming cells
1/17 1/185 1/377 1/1961
I m m unocy toe hem i stry K8 or 
K 8& K 14
K14 only not
assessed
not
assessed
Table 3.2: Characteristics o f the two colony types obtained from primary prostate 
epithelial cell culture by Hudson et al, (2000) and in the present study.
To summarise, the characteristics o f the colonies as defined by Hudson et al (2000) 
are given in table 3.2 alongside those o f the colonies obtained for this study. Both 
series describe colonies that are similar in appearance. Type I colonies tended to be 
smaller with fewer, more loosely arranged cells, while type II colonies were less 
common but larger and more dense. In both studies, type II colonies were grown in 8 
o f 10 experiments.
Unlike the previous report, in this study both colony types were far rarer, 
particularly type I colonies even though initial plating density was the same. Those 
colonies that were obtained were larger both in diameter and cell number, while 
density was more consistent. Colonies were derived from fresh prostate tissue using
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a very similar protocol to that described by Hudson and tissue was sourced from the 
same London population. However, the modifications made to the protocol as 
described in section 2.5 account for the observed differences. The replacement o f the 
trypsin and two brief 20 second centrifugation steps by mechanical tissue disruption 
and a longer spin would result fewer cells being lost with the discarded supernatant 
in this study. The resultant ‘cell rich’ single cell suspension was counted prior to 
plating at 1000 cells/25cm2 dish. It appears most likely that a greater number o f  non- 
epithelial cells were included in the count. All viable cells were counted excluding 
recognisable red blood cells, which could include a greater proportion o f leucocytes 
and stromal cells. Certainly the longer spin did not increase the yield o f prostate 
epithelial cells. Thus fewer than 1000 true prostate epithelial cells could have been 
plated, with reduced colony yields.
The larger size o f colonies may relate to more favourable growing conditions and 
less competition for resources given the lower colony numbers. The Hudson series 
used irradiated mouse fibroblasts whereas a mitomycin treated feeder layer was used 
in this series, purely because these feeders could be generated ‘in house’. Both 
feeder layer treatments are well established, though neither is known to confer a 
growth advantage (Ponchio et al, 2000). The individual epithelial cells that form the 
largest colonies must divide at least daily, and even a slight variation in time on the 
day o f  scoring the colonies (that were not fixed for this study) would cause 
exponential increases in cell number.
3.2 Growth characteristics of type I and type II colonies
Hudson et al (2000) suggested that the two colony types formed by the clonogenic 
fraction o f human prostate epithelial cells reflected different cell subpopulations. 
They suggested that the rarer type II colonies might be clones o f  stem cells, having 
indefinite proliferative capacity while being undifferentiated, while type I colonies 
might derive from transit amplifying cells as they were more differentiated and less 
proliferative. Thus type I colonies would be expected to reach replicative senescence 
sooner than type II cells. The proliferative potential o f cells ring cloned from type I 
and type II colonies was assessed. Growth curves are shown in figure 3.3.
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Figure 3.3: Proliferation of type I and II colonies. After 14 days in culture, 10,000 
pooled type I or type II colony cells were cultured in 25cm2 collagen coated flasks 
for 28 days. Flasks were counted when nearing confluency and 10,000 cells were 
passaged on. The mean total cumulative cell number for 2-5 flasks over days in 
secondary culture are shown for three separate patient prostate samples. Error bars 
show the standard error o f the mean.
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These growth experiments were terminated after 28 days due to attrition with 
infection. Three to four passages were necessary over this time. In some experiments 
the flasks were cultured for up to a further 2 weeks and none o f these flasks 
approached confluency or required further passaging, though cell numbers were not 
counted in such dishes. Both colony types demonstrated significant proliferative 
ability, even though these cells were derived from primary colonies at 14 days that 
had already divided a mean o f 11 times for type I colony cells and 17 times for type 
II colony cells. In secondary culture, each type I colony cell yielded between 1,300 
and 168,000 cells (10 -  17 further doublings) and each type II colony cell between 
2,900 and 253,000 cells (11 to 21 further doublings). Thus the most proliferative 
type I cells demonstrated 27 doublings in total from the time of initial plating to 42 
days later, and type II cells demonstrated 38 total doublings. In each o f the three 
samples, type II cells appeared more proliferative, though the few data points were 
not amenable to statistical comparisons so significance cannot be proven.
In 1961, Hayflick and Moorhead determined that human diploid cells underwent a 
total o f 50 population doublings before undergoing growth arrest, termed cellular 
senescence (Hayflick and Moorhead, 1961). This Hayflick limit is thought not to 
apply to telomerase expressing cells such as stem cells and cancer (Rubin, 2002). 
Cells that are dividing have exponential growth curves, but as they senescence the 
curve plateaus, creating a sigmoid shape. Some o f the cells in these experiments are 
approaching their Hayflick limit, and on the strength o f the few data points here, 
there is a suggestion that the growth rates o f type II cells in the first prostate and 
both types in the third are starting to slow down. It is not possible to comment on the 
other cells and a longer period in culture would have been desirable. The fact that 
the last passages failed to reach confluency suggests that a degree o f senescence was 
occurring. In line with the hypothesis o f Hudson et al, (2000), the TA cells in the 
type I colonies would be expected to senesce in contrast to self-renewing type II 
stem cells that should proliferate indefinitely. Given that these too appear to slow 
their growth, suggests either that these cells are in fact even earlier TA cells, or that 
the conditions o f growth favour proliferation over self-renewal.
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There is also extreme biological variation between these three patients with the cell 
yields differing by orders o f magnitude. Such variation is already apparent in the 
colony forming abilities o f different patients that differ 16-fold amongst ten patients. 
Formal quantification o f these colonies proliferative abilities will require greater 
patient numbers and a longer duration in culture.
3.3 Three-dimensional culture o f type I and type II colonies
Hudson et al (2000) demonstrated that ring cloned type II colonies produced three- 
dimensional structures in Matrigel culture, consistent with the differentiation that 
would be expected o f possible stem cell derived colonies (though this assay does not 
conclusively demonstrate pluripotency). The ability o f the type I colonies to form 
such structures was not explored.
In this study, ten thousand pooled type I or type II colony cells were cultured in 
Matrigel. After two weeks the resulting structures were harvested, paraffin 
embedded and stained for various cell markers. Figure 3.4 shows the microscopic 
appearance o f the ducts and acini obtained and figure 3.5 the distribution o f basal 
and luminal cell marker expression.
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Figure 3.4: Appearances o f acini and ducts obtained from pooled type I (A, C & E) 
or type II (B. D & F) colonies in Matrigel culture at 4 (A & B) and 14 days (C to F). 
Clumps of cells developed First with branches emerging after 6 days. These branches 
then formed an inner core structure, suggestive o f a lumen after 10 days.
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Figure 3.5: All scale bars are 100pm. Expression o f prostate epithelial basal 
markers K14 and CD 133, and luminal markers K8 and AR in monolayer primary 
and three-dimensional Matrigel secondary culture.
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There was no difference in the number or appearance o f structures formed by each 
colony type, with far more spherical acinar structures than ducts seen. Some cells 
added onto the Matrigel migrated to the base o f the well and grew in monolayer 
culture so the yield o f each structure from total cells added could not be assessed.
Monolayer expression patterns were as expected (Fry et aU 2000; Hudson et aL 
2000; Hudson et al, 2001). K14 showed little expression in type 1 colonies in 
monolayer, but was moderately expressed in type II colonies. K8, expressed by 
transit amplifying and differentiated cells was strongly expressed in type I primary 
colonies but not in type II. Neither CD133 nor androgen receptor were expressed in 
monolayer culture.
Immunohistochemistry o f the acinar and duct structures better demonstrated their 
cellular arrangement as different layers were picked out by different markers. Three 
layers could be discerned: a continuous single cell outermost layer that stained for 
basal and stem cell markers K14 and CD133, further similar layers within this that 
were similarly tightly packed and positive for basal marker K14 and then multiple 
further layers o f larger flattened cells that defined a lumen that also contained cells. 
Luminal markers K8 and androgen receptor were expressed only in this last layer. 
Cell surface marker CD 133 has been proposed as a prostate stem cell marker and 
was the most exclusive o f the basal markers, being expressed in a subset o f those 
expressing K14. The appearances o f several CD 133 positive layers in the type I 
structure shown in figure 3.5 may reflect an early ‘acinus’ in the process o f forming 
a lumen, or a cross-section taken through the edge o f an ‘acinus’. K14 expression 
was seen to a lesser extent in the luminal layers, which may represent a high 
background given the strong basal staining seen, as this marker has been described 
as exclusively basal (Hudson et al, 2001).
N Three dimensional secondary culture did produce heterogeneous structures with 
basal and luminal layers typical o f prostate epithelium in vivo from a type I or II 
colony cell population, though there were no distinguishing features between them. 
This alone does not give sufficient evidence for self-renewal as both transit 
amplifying cells and stem cells would be expected to demonstrate such proliferative
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abilities. Such proof would require a second generation Matrigel structure derived 
from selected cells o f the first.
Matrigel also induced the expression o f markers not seen in monolayer culture. 
These were early basal markers such as CD 133 and markers o f terminal 
differentiation such as androgen receptor (Richardson et al, 2004). The cells 
comprising each colony type were therefore sufficiently undifferentiated to express 
this marker o f stem and early TA cells. It can only be assumed that the fact that they 
did not do so in monolayer culture (where they were surely no more differentiated) 
is due to the culture environment. The in vitro expression o f CD 133 in prostate 
epithelial populations has not been reported, as it is usually sought in freshly sorted 
cells or prostate tissue sections.
Less clear, is why apparently more differentiated type I colony TA cells that express 
K8, lose this in Matrigel culture and express CD 133 instead. The process o f prostate 
differentiation is assumed to be one-way and irreversible, so type I cells should only 
be able to generate later basal layers and luminal ones. An explanation may be that 
the type I colonies are not as homogeneous as thought, and contain less 
differentiated cell within them. Type II cells may have contaminated the 10,000 
ring-clone selected, pooled type I cells from the same dish, though no fewer 
structures were seen. There may have been luminal cell only structures within the 
Matrigel culture that were not recognized against a noisy background o f cell debris. 
Alternatively, Matrigel may have the ability to induce basal marker expression in 
such cells, which either implies that keratins are not as indicative o f the level o f 
differentiation as previously thought, or that dedifferentiation has occurred. 
Dedifferentiation does occur and is driven by external signals, the ultimate example 
being the successful cloning o f “Dolly” the sheep by implanting the nucleus o f  an 
adult mammary gland cell into an enucleated sheep oocyte. Here the nucleus o f a
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terminally differentiated cell regained complete embryonic stem cell abilities 
(Wilmut et al, 1997). Lang et al (2001) studied the ability o f seven-day-old cultured 
prostate epithelial cells to form ‘spheroids’ in Matrigel. They reported that CD44+ 
cells did form structures, but CD44" cells did not. If dedifferentiation did not occur 
in that case, then it may be that type I colony cells do not need to dedifferentiate as 
they are sufficiently undifferentiated in themselves and will express a range o f
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markers dependant on their position within the structure and interactions with 
surrounding cells.
3.4 Comparison of gene expression profiles o f type I and type II prostate 
epithelial colonies.
3.4.1 Optimising samples for gene expression analysis.
To compare the gene expression profiles o f type 1 and type II prostate epithelial 
colonies it was important to ensure that the cells harvested were as representative 
and uniform as possible, both within and between patient samples. Ultimately, a 
total o f six patients were used providing six paired type I and type II cRNA samples 
that were used for microarray analysis. A number o f  issues were addressed before 
the final experimental design was established.
3.4.1.1 Use o f a single representative colony per patient versus pooling of cells 
from several colonies.
For gene chip analysis, the initial RNA requirement for application onto an
Affymetrix gene chip was 20pl o f 500ng/pl total RNA, equivalent to lOpg o f sample
in total. Alternatively, the incorporation o f a double linear amplification step into the
protocol reduces the minimum sample size required to 2pl o f lOOng/pl total RNA, or
200ng o f sample. It was therefore necessary to ensure sufficient RNA was
obtainable from both colony types for every patient. While type I colonies are more
frequently obtained than type II, they are less dense in cell number so total RNA
yield is correspondingly lower per colony. To obtain enough total RNA either a
single selected colony had to be further cultured until it yielded sufficient cells, or a
number o f representative colonies o f the same type from the same patient could be 
\
harvested and the cells pooled.
Both these options were studied for three prostate samples.
A number o f type I and type II colonies were ring cloned after 2 weeks in primary 
monolayer culture and the morphologies o f cells and colonies during secondary
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culture on feeders (the first passage o f these cells) was assessed over the following 
1-2 weeks. For one prostate, flasks were harvested for total RNA extraction once 
approximately 75% confluent. The results are shown in table 3.3.
\
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Patient Colony No. o f Colony morphology No. cells Total
type cells when 75% confluent in on day 12 RNA
transferred secondary culture. (xlO3) yield (pg)
#1 I 5200 Loose type I colonies and 284 26.9
scattered cells
3300 66 100 10.9
1700 66 522 36.8
2700 66 106 11.5
8100 66 163 15.4
900 66 122 8.9
II 50000 Loose type I colonies and 689 30.6
scattered cells, no type II
58000 66 490 32.1
2200 66 233 26.1
2800 66 228 17.0
3200 66 344 37.4
2100 66 552 39.4
#2 I 42000 Loose type I colonies and - -
scattered cells
21000 66
25000 66
10000 66
2500 66
45000 66
II 1100 Loose type I colonies and _ _
scattered cells, no type II
20000 66
91000 66
27700 66
7000 66
7700 66
#3 I 1800 Loose type I colonies and - -
scattered cells
1900 66
6200 66
8200 66
II \ 15400 Loose type I colonies and _ _
scattered cells, no type II
23200 66
Table 3.3: Outcome o f ring cloning and passaging o f individual type I and type II 
colonies.
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There was a wide variability in cells transferred by ring cloning (table 3.3). In some 
cases the ring did not form a watertight seal with the flask leading to a leak o f 
trypsin or the silicon grease used spread inwards to cover some cells. Some cells did 
not survive this traumatic procedure so only viable cells as assessed by trypan blue 
exclusion were counted, though the proportion o f dead cells in a ring cloned cell 
suspension was from 0 to 29% (data not shown). Type I colony cells took longer to 
reach 75% confluence at around 11-14 days while type II took 9-11 days (data not 
shown). However in secondary culture (1st passage) the morphology o f the loose 
colonies and scattered cells derived from type I and II colonies were 
indistinguishable. The typical appearances o f  a type I and a type II colony 
immediately prior to ring cloning and in secondary culture on feeders over 11 days is 
shown in figure 3.6. No type two colonies were seen in any o f these or subsequent 
passages o f primary epithelial cell colonies.
Though this experiment was intended to assess RNA yields, it was also a colony 
self-renewal assay. It is significant that putative type II colony stem cells were 
unable to recreate themselves a second time. In some cases, all cells from a primary 
colony were transferred, so even if  a small population o f stem cells remained in the 
type II colony at 14 days culture these should have been present in the first passage 
(barring traumatic cell death).
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Figure 3.6: All scale bars are 100pm. The appearance o f two colonies from prostate 
2 in table 3.3 before ring cloning and at intervals during secondary culture on a 
feeder layer. The type I colony with a cell density o f 27 cells/mm yielded 42,000 
cells o f which 10,000 were passaged. A type II colony with cell density 42 cells/mm 
yielded 7000 cells. At near confluence, the most compact areas o f cells had a cell 
density o f 20 cells/mm (see lowest panels) regardless o f originating colony type.
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Though the yield o f total RNA from a single colony expanded by secondary culture 
was adequate for application onto a gene chip (average 24.4pg), the fact that no 
recognisable type II colonies were seen and that these passaged cells have not been 
previously characterised confirmed that this method could not be used to obtain total 
RNA for comparison o f gene expression between these two morphologically defined 
primary colonies.
The alternative approach was to pool primary colonies o f a similar type after two 
weeks in monolayer culture to obtain sufficient RNA. This would also allow an 
averaging out o f morphologically similar colonies so that the characteristics o f each 
type would be more likely to emerge from gene expression analysis. The RNA 
yields for three prostates are shown in table 3.4.
Patient Colonies
harvested
Mean harvested 
colony diameter 
in mm (s.d.)
No o f cells 
harvested 
(xIO3)
Total RNA 
yield (pg)
R NA/  
colony (pg)
I II I II I II I II I II
1 35 9 3.1
(4.0)
14.9
(4.3)
281 1990 2.6 27.6 0.07 3.07
2 32 4 4.8
(2.9)
10.8
(1.0)
571 249 8.6 3.78 0.27 0.95
3 18 9 5.4
(2.0)
14.1
(3.2)
- 10.5 74.5 0.58 8.28
s.d. = standard deviation
Table 3.4: Total RNA yield from pooled type I or type II primary colonies
Not all colonies were useable, depending on their location in the flask and relation to 
other colonies. The type I colonies obtained were not infrequently larger than those 
described by Hudson et al though they demonstrated typical type I morphology and 
cell density, and contrasted clearly with type II colonies within the same flask. The 
smallest colonies harvested contained 40 cells and had a diameter o f 0.5mm. Pooling 
o f like colonies provided sufficient total RNA for use on gene chips, though in all 
three patients the yields from one or both colony types were lower than the lOpg 
required to avoid an amplification step in the generation o f cRNA for use on gene 
chips. Amplification has been shown to produce high fidelity microarray expression
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data o f comparable quality to non-amplified sample analysis (Jenson et al, 2003; 
King et al, 2005,).
3.4.1.2 Culture o f prostate epithelial cells in the absence o f a feeder layer.
The use o f a feeder layer o f mitotically arrested yet metabolically active cells has 
long been used in cell culture (Rheinwald and Green, 1975). Feeder cells promote 
proliferation o f cells at low density through secreted conditioning factors; direct cell- 
surface contact and contributions to the basement membrane (Miller et al, 1982; 
Blacker et al, 1987). Irradiated or mitomycin C treated mouse 3T6 fibroblasts are 
used as standard in prostate epithelial cell culture. After two weeks o f culture, the 
feeder cells were generally sparse, and it was possible that a few remained after 
rinsing o ff briefly with trypsin. It was felt preferable to grow cells without a feeder 
cell layer to avoid contamination o f prostate colony RNA with feeder cell RNA and 
it was anticipated that conditioned PrEGM would at least contain the secreted 
molecules provided by the mouse fibroblasts. A number o f different feeder-free 
culture conditions were tested (table 3.5).
CONDITIONS
Flasks with colonies / total flasks 
(total colony number)
1 2 3 4
Collagen + mouse 3T6 feeder layer 19/20 1/5 4/4 4/5
(107) (1) (17) (22)
Collagen + PrEGM - 0/5 0/4 0/4
Collagen + 2 day Conditioned 
PrEGM
- 0/4 0/5 0/5
Collagen + 2 day Conditioned 
PrEGM (frozen & defrosted)
- 0/5 - 0/4
Collagen + 3 day Conditioned 
PrEGM
3/5
(8)
0/4 “ 0/4
Collagen + 4 day Conditioned 
PrEGM
- 0/5 0/5 0/4
Collagen + 4 day Conditioned 
PrEGM (frozen & defrosted)
- 0/4 - 0/4
Table 3.5: Colony yield in alternative feeder-layer free culture conditions.
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The pH o f  these media remained within physiological levels ranging between 7.55 
for PrEGM, and 7.22 for 2 day conditioned PrEGM (data not shown). All colonies 
obtained had typical appearances.
A feeder layer was essential for the primary culture o f prostate epithelial cells. 
Colonies grown in such conditions had to be used as a source o f RNA for use on 
gene chips, and type I cells due to the larger numbers harvested and their more 
sprawling morphology would be more likely to be contaminated. The sequences on 
the Affymetrix chip do have a degree o f  cross-reactivity with mouse sequences when 
the two genomes are compared.
3.4.2 Acquisition o f total RNA from pooled type I and type II prostate 
epithelial colonies.
A series o f patient prostate samples were cultured on collagen coated flasks with a 
feeder layer for two weeks. Colonies o f each type were harvested separately and 
total RNA extracted as described. The patient characteristics, histological findings, 
colony yields and RNA extracted are given in table 3.6. In five out o f nine patients, 
the RNA yield from one or both colony types was less than 10pg so a double linear 
amplification step was necessary, and used across all samples.
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No. Patient
age
Clinical details PSA
(ng/dl)
Histology Tissue
weight
Acquired  
cells 
x 106 / g
Cells
plated xlO 3
C olonies
grown
C olonies
harvested
Total RNA  
yield (pg)
1 II I II I II
1 77 Moderate LUTS, on 
prazosin 2.1 BPH 0.2 0.72 24 35 10
34 9 2.6 27.6
2 73 Catheterized unknown
BPH & chronic 
inflammation
1.4 3.40 28 59 5 32 4 8.6 3.78
3 57
LUTS, failed m edical 
management 4.5 BPH 0.6 1.55
24 57 12 18 9 10.5 74.5
4 80
Re-do TURP previous 
TURP 1992
2.0 BPH 0.5 4.90 28 111 13 14 7 2.9 24.0
5 68 Catheterized unknown
BPH with foci o f  
fibrosis
0.3 0.28 24 21 5 11 5 1.5 14.3
6 61 LUTS on tam sulosin 0.8 BPH 0.7 2.80 25 54 9 36 8 15.3 25.5
7 60
m ild/m oderate LUTS on 
tam sulosin
2.2 BPH 0.4 0.11 27 90 20 35 12 6.2 27.1
8 58 LUTS 1.6 BPH 0.3 0.33 25 62 10 22 10 13.5 82.7
9 71 Catheterized 7.4 BPH 0.6 6.10 27 86 14 30 14 38.3 31.0
Mean 67 2.9 0.6 2 .20 26 63.9 10.9 25.9 8.8 11.0 34.5
s.d. 8.6 2.3 0.4 2 .20 1.7 27.9 4.6 9.8 3.2 11.3 26.4
LUTS -  lower urinary tract sym ptom s, TURP = transurethral resection o f  the prostate, BPH = benign prostatic hyperplasia, s.d. = standard deviation
Table 3.6: Culture o f primary prostate epithelial cells: patient characteristics, histology, and colony and total RNA yields.
3.4.3 Concentration of dilute total RNA samples
For each sample, total RNA was extracted from type I and II colony cell lysates in 
parallel. The RNA quality was expressed as the 28S/18S rRNA signal ratio; the 
degradation factor and the colour o f  the quality range it fell into; and visually as an 
electropherogram and gel image. All samples contained sufficient total RNA, but 
nine were too dilute at <100ng/pl. These were concentrated by nitrogen gas 
evaporation and then reassessed. Table 3.7 shows the concentration steps and 
characteristics o f the nine samples.
Patient RNA sam ple
Volum e
(pi)
Concn
(ng/pl)
Total
RNA
yield
(Pg)
28S/18S
rRNA
ratio
Degrad­
ation
factor
Quality
range
colour
1 I eluted 150 17 2.6 2.0 12.79 yellow
concentrated x l 10 76 0.8 1.5 8.61 yellow
concentrated x2 5 169 0.8 2.0 6.07 none
3 I eluted 500 21 10.5 1.5 9.78 yellow
concentrated 47 641 30.1 1.6 14.99 yellow
lib* eluted 500 72 36.0 1.6 11.22 yellow
concentrated 45 1225 55.1 1.2 14.94 yellow
4 la* eluted 90 26 2.3 1.5 17.24 orange
concentrated 20 114 2.3 2.1 12.33 yellow
5 lb eluted 50 17 0.8 1.3 9.63 yellow
concentrated 10 135 1.4 1.7 14.11 yellow
6 la eluted 70 84 5.9 2.0 9.51 yellow
concentrated 25 206 5.2 1.8 10.92 yellow
7 la eluted 85 47 4.0 1.8 11.92 yellow
concentrated 30 181 5.1 2.1 9.70 yellow
9 I eluted 500 77 34.3 2.1 4.55 none
concentrated 20 1831 36.6 2.0 2.33 none
11 eluted 500 62 31.0 1.8 9.05 yellow
concentrated 22 1476 29.5 1.8 9.76 yellow
* a and b denote first and second elution o f  RN A through the sam e extraction colum n collected  as 
separate samples.
Table 3.7: Concentration o f RNA samples by nitrogen evaporation. The degradation 
factor and the quality range (denoted by colours from none, through yellow, orange, 
red and black) are objective measures o f RNA sample integrity as devised by Auer et 
al (2003, see section 2.15).
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Concentrating the samples did alter 28S/18S rRNA ratios and degradation factors 
though not in a predictable way. The ratio is a less accurate measure o f RNA 
integrity as equal degradation o f both rRNAs would lead to a worsening in 
degradation factor while the ratio would remain unchanged. There can be no 
improvement in RNA integrity by this evaporation process but the improved signal 
to noise ratio o f a more concentrated sample may lead to more accurate measurement 
by the bioanalyser. In general, no sample was ruined by the process and all remained 
suitable for use on a gene chip (see figure 3.7).
At times evaporation appeared to increase total RNA amounts in the sample. This 
enigma relates to the degree o f error in measuring small volumes. In the Agilent 
process, accuracy when quantitating 25-500ng/pl RNA concentrations is o f ± 50% 
(manufacturer’s specifications).
■Pli
Figure 3.7: Agarose gel electrophoresis o f total RNA samples before and after 
nitrogen gas concentration. lOpl o f total RNA solution was run with 5pl gel dye 
buffer and a lkb ladder on a 1% agarose gel. The more concentrated sample 
appeared to retain the desired relative 2:1 intensity o f the two 18S and 28S rRNA 
bands suggesting little degradation occurred.
1 2 2
3.4.4 Choice o f RNA samples for gene chip analysis
All RNA samples ultimately obtained from nine patients are shown in table 3.8. Five 
paired samples (patients 1,4,6,7 and 9) were chosen with a sixth reserve sample 
(patient 5). A degradation quality range o f none or yellow was required, and where 
possible an rRNA ratio >1.6. Figure 3.8 shows the electropherograms and gel 
appearances o f the ‘worst’ sample; patient 3 colony type II, and the ‘best’; patient 9, 
colony type I.
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Patient Colony
type
Volum e
(pi)
Cone"
(ng/pl)
Total
RNA
yield
(Pg)
28s/18s
rRNA
fatio
Degradometer
factor
Colour
o f
quality
range
U sage o f  
sam ple
1 I 5 169§ 0.8 2.0 6.07 none used
II 50 552 27.6 1.8 2.70 none used
2 I a* ■600 9 5.5 1.1 25.24 red discarded
I b* 170 18 3.1 1.2 17.03 orange discarded
II 180 21 3.8 1.2 23.17 orange discarded
3 I 47 641§ 30.1 1.6 14.99 yellow not used
II a 500 77 38.5 1.5 9.63 yellow not used
11 b 45 1225* 55.1 1.2 14.94 yellow not used
4 l a 20 114s 2.3 2.1 12.33 yellow used
I b 50 12 0.6 1.3 unrecordable black discarded
II a 50 182 9.1 2.1 6.66 none not used
II b 90 166 14.9 2.1 6.48 none used
5 1 a 80 9 0.7 0 unrecordable black discarded
I b 10 135s 1.4 1.7 14.11 yellow used in 
reserve
II 120 119 14.3 2.2 5.61 none used in 
reserve
6 I a 25 206s 5.2 1.8 10.92 yellow used
I b 100 94 9.4 1.0 24.48 red discarded
II a 90 227 20.4 3.0 3.71 none used
II b 60 85 5.1 2.3 4.96 none not used
7 I a 30 181s 5.1 2.1 9.70 yellow used
I b 95 23 2.2 1.0 unrecordable black discarded
II a 75 253 19.0 2.3 9 .27 yellow used
II b 70 116 8.1 2.1 10.01 yellow not used
8 I 155 87 13.5 1.9 25.35 red discarded
II a 90 766 68.9 2.2 2.07 none not used
II b 35 395 13.8 2.3 2.03 none not used
9 I 20 1831s 36 .6 2.0 2.33 none used
II 22 1476s 29.5 1.8 9.76 yellow used
•  a and b denote first and second elution o f  RN A through the sam e extraction colum n collected  
as separate sam ples, § = these sam ples were concentrated using nitrogen evaporation prior to 
being used, Cone" = concentration
Table 3.8: Characteristics o f paired colony total RNA samples (chosen 6 in bold)
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30
25 Patient #3 Colony type II
20 R N A  concentration: 1225ng/ul 
28S /18S  rRNA Ratio 1.17 
1 5  D egradation factor: 14.94 (Y ellow )
a: 10
5
19 24 29 39 54 59 6434 44 49
Time (seconds)
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R N A  con centration . 1831 n g /u l 
2 8 S /1 8 S  rR N A  R atio  1 .96  
D egrad ation  factor: 2 .3 3
<D
<2 75
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- I ---------- f -
59 6439 6919 24 29 34 44
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49 54
Figure 3.8: Agilent bioanalyser electropherograms and gel images for two total 
RNA samples for GeneChip analysis. A & B: gel image a from patient #3 sample 
showed some degradation in comparison to gel image B, from patient #9. C & D: 
corresponding electropherograms for these two samples. As total RNA degraded, 
strands were shortened. The ratio between the 28S and 18S rRNA peaks reduced and 
a higher baseline level o f smaller RNAs was seen as shown by C in comparison to D.
3.5 GeneChip Quality control param eters
Quality control measurements are shown in table 3.9. There were high background 
(ideally 20-100) and noise (ideally <4) readings on the first type II chip which 
obscured low-level gene expression and lead to correspondingly fewer probe sets 
being detected (% present should have been similar for all chips). Hybridization was 
universally successful, however the desired >70% detection o f the B. subtilis lys 
probe set was not achieved (58% present), suggesting reduced efficiency o f the poly-
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A primer binding and possibly reduced sensitivity. The 37M ratio o f the GAPDH 
gene was well preserved though values for p-actin suggested some degradation, even 
allowing for the fact that it is a longer gene. In an investigation o f the quality control 
criteria o f Affymetrix gene chips, Dumur et al (2004) found that the recorded 
intensities o f the 3’ p-actin probe set were sensitive to experimental variations such 
as day to day variability and RNA source, while other probe sets were not. They 
suggested that these changes might be related to a rather less robust probe design 
than actual differences in the concentration o f that particular transcript, so the 
GAPDH results here may be more accurate.
Overall, all chips were o f acceptable quality and could be analyzed, though the 
potential reduced sensitivity o f some chips was noted. In reality, the implications of 
variations in quality control parameters and therefore their usefulness in 
distinguishing between analytical and biological variability remains unsubstantiated 
(Allison et al, 2006; Dumur et al, 2004).
Type I colonies Type 11 colon ies
Prostate # 1 4 5 6 7 9 1 4 5 6 7 9
Mean
background
56.3 44.9 56.2 42.2 45.0 44.3 101.9 43.7 55.8 34.3 35.8 45.3
Mean noise 1.9 1.5 1.9 1.4 1.6 1.5 4.9 1.4 1.9 1.1 1.2 1.5
B. subtilis 
lys present No Yes N o Y es Yes N o N o Yes Y es Yes Y es N o
E. coli bioB  
present 
% probe 
sets present
Yes Y es Y es Y es Y es Y es Y es Yes Yes Y es Y es Yes
35 41 40 41 38 33 28 40 39 38 37 35
GAPDH  
37M  ratio
1.2 1.2 1.2 1.2 1.5 1.5 1.2 1.4 1.1 1.3 1.3 1.5
P-actin 
37M  ratio
3.7 2.0 3.2 3.7 5.5 4.0 4.3 4.0 3.4 3.5 6.2 4.5
Scaling
factor
1.1 1.3 0.8 1.3 1.7 1.7 1.2 1.5 1.0 2.5 2.3 1.4
Table 3.9: Quality control parameter outcomes for each GeneChip
The inherent variability between replicates was also assessed using logistic 
regression. When the raw data from two type I or type II samples was plotted against 
each other the line o f best fit correlated with R values between 0.64 and 0.80 (see 
table 3.10. Both type I and II replicates were similarly variable. One such plot is
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shown in figure 3.9. Such variability was expected in a small experiment based on 6 
individual patients but will result in more subtle differences in gene expression being 
overlooked.
-2 0 0  H 1---------1---------1---------1---------1---------1---------1---------1---------1---------1---------1---------1---------1---------1
-200 0 200 400  600  800  1000 1200
Raw data for Prostate 1 Type I
Figure 3.9: Graph o f Prostate 1 type I colony raw signal intensity data plotted 
against Prostate 4 type I raw data.
Type I Colonies 1 4 5 6 7 9
1 1 0.71 0.80 0.72 0.77 0.70
4 0.71 1 0.73 0.80 0.75
5 0.80 0.73 1 0.74 0.79 0.70
6 0.72 0.80 0.74 1 0.76 0.71
7 0.77 0.75 0.79 0.76 1 0.68
9 0.70 0.64 0.70 0.71 0.68 1
Type II colonies 1 4 5 6 7 9
1 1 0.70 0.71 0.72 0.70 0.72
4 0.70 1 0.76 0.77 0.77 0.71
5 0.71 0.76 1 0.74 0.80 0.72
6 0.72 0.77 0.74 1 0.72 0.67
7 0.70 0.77 0.80 0.72 1 0.79
9 0.72 0.71 0.72 0.67 0.79 1
Table 3.10. Logistic regression values o f R when type I or type II sample raw signal 
intensity data is compared.
1 2 7
3.6 Validation of cDNA m icroarrays using RT-PCR
The expression array findings were validated using semi-quantitative RT-PCR o f the 
same RNA samples and primer sequences equivalent to those on the GeneChip.
There was insufficient remaining RNA from prostate #5 so this was omitted. Five 
genes were chosen that were present on all sample arrays and showed a large fold- 
change which was also statistically significant. The RT-PCR results are shown in 
figure 3.10.
Type I Type II
1 4 6 7  9 1  4 6 7 9
KLK12 
PIM1 
BRPF1 
ZBTB10 
SNX10 
KLK12 
PIM1 
BRPF1 
ZB TB10 
SN X10 
G A PD H
for five
The heatmap squares were coloured red for those genes upregulated compared to the 
median value o f all genes on all chips and green for those downregulated. The 
intensity o f the colour was determined by the extent o f upregulation and also the 
degree o f ‘trust’ i.e. statistical significance that could be attributed to the result. The 
intensity of the RT-PCR product bands compared reasonably well to the expression 
levels suggested by the GeneChips for genes KLK12. PIM1, BRPF1 and ZBTB10. 
Even where gene products were seen in specimens in which they were
Figure 3.10: Validation o f expression levels on GeneChip using RT-PCR 
genes with GAPDH control.
1 2 8
downregulated, the band was more intense in the opposite colony type confirming 
the correct differential gene expression. The RT-PCR results were poorly 
representative o f the GeneChip results for SNX10, and the prostate sample 9 most 
often contradicted the array results.
The underlying variability o f expression levels for individual genes between samples 
is clear both from the RT-PCR and the heatmap appearances, though not always 
appreciated when comparing the two colony types on the basis o f their overall 
expression level and p-value. Some disagreement was to be expected. Due to the 
small number o f specimens in the experiment, the identification o f significant results 
could not incorporate a multiple testing correction step as these were too stringent. 
As such corrections aim to reduce the false discovery rate, without them some genes 
may be false positives. Finally, though genes showing the highest fold-change 
difference are often selected for validation, it has emerged more recently that this is 
not always optimum as ‘regression toward the m ean’ by such outlying results tends 
to underestimate overall agreement levels between microarrays and validation 
samples (Dhanasekaran et al, 2001; Miron et al, 2006). On the basis o f these results, 
further expression array analysis was undertaken but with the exclusion o f sample 9.
3.7 Identification of differential gene expression between type I and type II 
colonies using cDNA microarrays.
This relatively simple experiment consisted o f 2 conditions (RNA from type I or II 
colonies derived from the same patient) with 6 biological replicates. Initial filtering 
by fraction Present reduced 54,675 genes to 22,486. An ANOVA at p<0.05 with 
cross gene error model applied further reduced this to 874 genes. The hierarchical 
cluster diagram o f these is shown in figure 3.11.
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Figure 3.11: Normalised dye intensities for 874 genes significantly (p<0.05 ) 
differentially expressed between type I and type II colonies. Red denotes up- 
regulation or increased expression relative to the global mean level o f dye intensity, 
while green denotes down-regulation or reduced gene expression. A hierarchical 
clustering algorithm was used to group genes and samples on the basis o f similarities 
o f gene expression. The relationship between the genes or samples were 
demonstrated by the arrangement and length o f the branches o f the dendrograms.
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From these 874 genes, a list o f the 200 most significant genes (with a p value cut off 
o f <0.0126) and a list o f the 200 genes with the greatest difference in expression 
(with a fold-change o f >2.88) was generated. Ninety-three genes common to both 
lists were chosen for further consideration. The distribution of these genes is 
demonstrated in a ‘Volcano Plot’ in figure 3.12. Thirty-six genes were upregulated in 
type 1 and 57 were upregulated in type II colonies. A hierarchical cluster diagram of 
these genes suggested six main clusters, so k-means clustering was performed using 
6 starting nodes. The processing o f the normalized expression data is shown in a 
flow diagram in figure 3.13. The clusters generated are shown as a scatter diagram in 
figure 3.14. The genes are listed in their clusters in table 3.11.
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Figure 3.12: Volcano plot o f all 874 selected genes showing their degree o f 
differential expression (fold change or ratio o f type I to type II) and their significance 
(as the p value derived from the ANOVA). A log2(ratio) o f -1 is equivalent to a two­
fold higher expression o f the gene in type II colonies compared to type I. Blue and
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green data points represent the 200 genes with the greatest fold change. Yellow and 
green points represent those 200 genes with the highest significance. Green data 
points demonstrate the 93 genes common to both groups.
1 3 2
54,675 genes
22,486 genes
874 genes
107 107
€  =  567
ANOVA at p<0.05
Clustered by K means
Filtered by fraction present
200 most significant 
genes (p<0.0126)
200 most differentially expressed 
genes, (fold change >2.88)
6 27 16 25 11 8
genes genes genes genes genes genes
Figure 3.13: Flow diagram showing selection o f  the most significant and 
differentially expressed genes from the original normalised GeneChip data.
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Figure 3.14: Scatter diagram showing the relationship o f genes between clusters. 
Those 36 genes upregulated in type I colonies were divided into 2 clusters shown as 
blue (25 genes) and purple (11 genes) and those upregulated in type II were divided 
into 4 clusters: red (6 genes), yellow (27 genes), cyan (16 genes and orange (8 
genes).
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Common , Fold „  . .p value , Descriptionname  _______change_______
GENES UPREGULATED IN TYPE II COLONIES
ZNF540 0.006 5.236
DKFZp686
01327 0.006 3.344
ATP6V1C2 0.008 6.369
KRTDAP 0.008 9.901
UPK1A 0.010 5.025
0.012 3.378
C10orf99 0.001 5.348
KLK12 0.001 4.255
ALOX12B 0.002 10.753
ANKRD22 0.002 3.846
GDPD3 0.004 4.115
SDR-O 0.004 8.547
IL1F5 0.004 2.933
HPGD 0.008 4.785
HPGD 0.004 4.926
HPGD 0.004 4.348
BBOX1 0.005 3.012
MUC15 0.005 6.944
MUC15 0.006 5.464
HAL 0.005 4.082
OLAH 0.006 6.098
PIP5K1B 0.006 4.255
ICEBERG 0.006 3.802
ATP13A4 0.007 3.497
LOCI 96264 0.007 2.976
SPINK5 0.009 3.610
CYP4F3 0.010 3.367
RAPGEFL1 0.010 4.049
SLURP1 0.010 3.817
TREM1 0.011 3.745
KLK7 0.012 3.205
GRHL1 0.012 3.311
A2ML1 0.013 3.205
zinc finger protein 540
hypothetical gene supported by BC043549;
BX648102
ATPase H+ transporting, 42kDa, V 1 subunit C2 
keratinocyte differentiation-associated protein 
uroplakin 1A 
Transcribed locus.
chromosome 10 open reading frame 99 
kallikrein-related peptidase 12 
arachidonate 12-lipoxygenase, 12Rtype 
ankyrin repeat domain 22 
glycerophosphodiester phosphodiesterase 3 
orphan short-chain dehydrogenase / reductase 
interleukin 1 family, member 58 
hydroxyprostaglandin dehydrogenase 15-NAD 
hydroxy prostaglandin dehydrogenase 15-NAD 
hydroxyprostaglandin dehydrogenase 15-NAD 
butyrobetaine y, 2-oxoglutarate dioxygenase 1 
mucin 15 
mucin 15
histidine ammonia-lyase 
oleoyl-ACP hydrolase
phosphatidylinositol-4-phosphate 5-kinase, type 1(3 
ICEBERG caspase-1 inhibitor 
ATPase type 13A4 
hypothetical protein LOCI96264 
serine protease inhibitor, Kazal type, 5 
cytochrome P450, family 4F, polypeptide 3 
RAP guanine-nucleotide-exchange factor-like 1 
secreted LY6/PLAUR domain containing 1 
triggering receptor expressed on myeloid cells 1 
kallikrein-related peptidase 7 
grainyhead-like 1 (Drosophila) 
alpha-2-macroglobulin-like 1__________________
KLK12 0.001 4.065 kallikrein-related peptidase 12
KLK12 0.002 4.098 kallikrein-related peptidase 12
RPTN 0.001 5.714 repetin
WFDC12 0.002 4.762 WAP four-disulfide core domain 12
ACPP 0.002 5.988 acid phosphatase, prostate
CLDN17 0.002 4.902 claudin 17
BNIPL 0.003 3.205 Bcl2/adenovirus E1B 19kD interacting protein like
BPIL2 0.003 4.405 bactericidal/permeability-increasing protein-like 2
LOCI 47645 0.003 4.975 hypothetical protein LOCI47645
ATP6V1C2 0.004 3.289 ATPase, H+ transporting, 42kDa, VI subunit C2
MARCH3 0.006 4.000 membrane-associated ring finger (C3HC4) 3
KRT78 0.006 3.378 keratin 78 / keratin 5b
LCE3D 0.009 4.065 late comified envelope 3D
HOP 0.012 3.226 homeodomain-only protein
ELOVL4 0.012 2.882 elongation of very long chain fatty acids-like 4
RASGEF1B 0.012 3.597 RasGEF domain family, member IB
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4 OVOL1 0.001 3.226 ovo-like 1 (Drosophila)
4 NDRG2 0.004 2.899 NDRG family member 2
4 SASP 0.005 4.115 skin aspartic protease
4 AZGP1 0.007 4.405 alpha-2-glycoprotein 1, zinc-binding
4 LCE1B 0.010 3.356 late comified envelope 1B
4 SPRR2B 0.011 3.534 small proline-rich protein 2B
4 SPRR2G 0.001 6.061 small proline-rich protein 2G
4 SPRR3 0.009 5.025 small proline-rich protein 3
GENES UPREGULATED IN TYPE I COLONIES
5 PTGS2 0.006 3.414 prostaglandin-endoperoxide synthase 2
5 KRTAP2-1 0.008 6.502 similar to keratin associated protein 2-4
5 CCND2 0.007 2.953 cyclin D2
5 TGM2 0.013 2.929 transglutaminase 2 (C polypeptide)
5 VIM 0.001 3.374 vimentin
5 NNMT 0.008 3.292 nicotinamide N-methyltransferase
5 PLOD2 0.011 3.293 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2
5 FBN1 0.006 3.604 fibrillin 1 (Marfan syndrome)
5 IL8 0.005 4.508 interleukin 8
5 CXCL1 0.001 3.696 chemokine (C-X-C motif) ligand la
5 L1CAM 0.003 3.372 LI cell adhesion molecule
5 SLC26A2 0.004 3.393 solute carrier family 26 member 2 -sulfate transport
5 FAP 0.004 4.572 fibroblast activation protein, alpha
5 FN1 0.011 4.425 fibronectin 1
5 COL5A1 0.009 3.369 collagen, type V, alpha 1
5 DCBLD2 0.002 5.722 endothelial and SM cell-derived neuropilin-like
5 COL3A1 0.012 4.663 collagen, type III, alpha 1
5 NEFL 0.006 7.547 neurofilament, light polypeptide 68kDa
5 RBM22 0.005 2.887 RNA binding motif protein 22
5 MAP1B 0.008 3.016 microtubule-associated protein 1B
5 REPS2 0.010 2.928 RALBP1 associated Eps domain containing 2
5 CTSB 0.003 4.085 cathepsin B
5 PGM2L1 0.002 3.456 phosphoglucomutase 2-like 1
5 PHLDB2 0.003 3.531 pleckstrin homology-like domain, family B, 2
5 0.008 3.427
6 ZBTB10 0.003 6.146 zinc finger and BTB domain containing 10
6 GLIPR1 0.004 3.312 GLI pathogenesis-related 1 (glioma)
6 GLIPR1 0.007 3.221 GLI pathogenesis-related 1 (glioma)
6 IL6 0.006 5.507 interleukin 6 (interferon, beta 2)
6 PPBP 0.008 8.333 pro-platelet basic protein (chemokine) ligand 7
6 0.010 4.029 Full length insert cDNA clone ZM10C10
6 TGFB2 0.010 3.986
6 LGALS1 0.011 3.582 lectin, galactoside-binding, soluble, 1 (galectin 1)
6 MSI2 0.011 3.261 musashi homolog 2 (Drosophila)
6 NRG1 0.012 2.899 neuregulin 1
6 FNDC3B 0.012 2.985 fibronectin type III domain containing 3B
Table 3.11: The most significant and differentially expressed genes between type I 
and II colonies. Those 57 genes upregulated in type II colonies are shown segregated 
into cluster numbers 1-4, those 36 upregulated in type I colonies in their clusters 
numbered 5 and 6.
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3.8 Identifying the biological significance underlying statistically
significantly differently expressed genes in type I and II colonies.
Oligoarrays are being used extensively in molecular biology. They generate a vast 
amount o f data, which can be manipulated in numerous different ways. This analysis 
attempted to appropriately filter out statistically relevant genes that were 
correspondingly biologically significant. While technical variations were avoided 
wherever possible, biological variation can only be overcome by large numbers o f 
replicates. With the small number o f  replicates here, many genes failed to reach 
statistical significance, and a relatively small final gene list was obtained. In 
addition, this will contain some falsely positive genes, as the data did not allow a 
multiple testing correction step. This also reflects the very similar origin o f  the 
colonies and the subtle difference under investigation. A further note o f caution is 
required as three genes apparently upregulated in type I colonies (in cluster 5), 
vimentin, fibrillin 1 and fibroblast activation protein a  are likely to be derive from 
contaminating murine fibroblasts. For instance, vimentin is used diagnostically as a 
stromal marker and its expression in epithelia is usually seen in the epithelial 
mesenchymal transition o f  increasingly malignant cancers (Fry et al, 2000; 
Ramaekers et al, 1989).
Whole genome oligoarrays are often used somewhat speculatively to identify 
activated genes or biological processes that merit further study. Clustering genes 
assists identification o f  these, as it is likely that genes that are over or 
underexpressed simultaneously are interacting. The clusters generated here, did not 
always segregate genes well. Some o f  the 93 genes, expressed sequence tags or other 
sequences identified had as yet no known function, while others had not been studied 
in epithelia or the prostate and it was impossible to draw biological meaning from 
them. Despite this, some surprising gene expression patterns did emerge.
3.8.1 Genes upregulated in type I colonies
Genes involved in extracellular matrix interactions, cell migration, inflammation and 
proliferation were upregulated in type I colonies, though seemed spread between 
both clusters.
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Prostaglandin-endoperoxide synthase 2 (also known as COX2), galectin 1 and 
transglutaminase 2 are all important in extracellular matrix interactions contributing 
to cell migration. Increased expression o f  COX2 and galectin caused increased cell 
adhesion, with galectin binding laminin and fibronectin (Tsujii and DuBois, 1995; 
Ellerhorst et al, 1999). Transglutaminase 2 plays a central role in regulating ECM 
remodeling and controls dynamic adhesion formation in cell spreading and migration 
(Stephens et al, 2004). Extracellular matrix proteins fibronectin, type III collagen 
and type V collagen are also upregulated. Two microtubule genes (microtubule- 
associated protein IB and pleckstrin homology-like domain B2) are upregulated, 
which may suggest further internal cytoskeletal rearrangements.
Cell motility is also promoted by the LI cell adhesion molecule, which promotes the 
scattering o f  epithelial cells from compact colonies; pro-platelet basic protein, which 
allows neutrophil adhesion and transendothelial migration, and transforming growth 
factor (32 (isoform 2), which enhances prostate cancer cell motility and metastasis 
(Shtutman et al, 2006; Schenk et al, 2002; Aalinkeel et al, 2004). Also cathepsin B is 
found in basal cells o f  the prostate acinus, can degrade extracellular matrix and plays 
a key role in cancer cell migration and invasion (Sinha et al, 1989; Gondi et al, 
2006).
Most notable in the list o f  upregulated type I colony genes was the number o f  pro- 
inflammatory cytokines. Interleukins 6 and 8 are both potent prostate epithelial and 
stromal growth factors and are upregulated in BPH (Giri and Ittmann, 2001; Kramer 
et al, 2007). Neuregulin 1 is also upregulated. This is the ligand o f  ERBB2, a 
transmembrane receptor tyrosine kinase which is a critical component o f  IL6 
signaling through the MAP kinase pathway (Qiu et al, 1998). COX2 enzyme 
converts arachidonic acid to various pro-inflammatory prostaglandins while pro­
platelet basic protein recruits neutrophils to sites o f  inflammation. Conversely 
transforming growth factor (32 is thought to be inhibitory to prostate growth, though 
its levels are high in BPH suggesting it is not entirely able to suppress hyperplastic 
growth (Kramer et al, 2007). An inflammatory process underlying the aetiology o f 
BPH has long been postulated (Kramer et al, 2007). These colonies were derived
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from BPH tissue, and the upregulation o f  inflammation related genes in these 
proliferative cells would support this theory.
3.8.2 Genes upregulated in type II colonies
Clustering was more effective though not perfect for those genes upregulated in type 
II colonies as genes with similar functions were grouped together. In cluster 4 were 
upregulated genes predominately responsible for keratinisation o f stratified epithelia, 
while cluster 3 contained markers o f  differentiated prostate and epithelial cells. 
Concentrated in cluster 2 were genes involved in ensuring the impermeability o f  
epithelia along with some differentiation markers. Cluster 1 contained two genes o f 
known function, which again related to epithelial differentiation.
The epidermal differentiation complex on lq21 contains a large number o f  genes that 
are o f crucial importance for the maturation o f  the human epidermis (Marenholz et 
al, 2001). Six such genes upregulated in type II colonies are small proline-rich 
protein genes 2B, 2G and 3, late comified envelope genes IB and 3D, and repetin 
(Krieg et al, 1997). A further four upregulated genes: elongation o f  very long chain 
fatty acids-like 4, interleukin 1 family, member 55, arachidonate 12-lipoxygenase 
and Kazal type 5 serine protease inhibitor were involved in the generation o f  the 
epidermal permeability barrier which is critical for viable skin function (Li et al, 
2007; Patel et al, 2006; Moran et al, 2007, Hachem et al, 2006).
Other genes expressed in keratinizing epithelium include keratinocyte 
differentiation-associated protein (KRTDAP), which is seen in suprabasal cell layers 
o f  the embryonic epidermis, and kallikrein-7 is known to be involved in 
desquamation o f  comeocytes (Oomizu et al, 2000; Shaw and Diamandis, 2007). 
SLURP 1 and a2-macroglobulin-like 1 are late markers o f epidermal differentiation 
(Favre et al, 2007; Galliano et al, 2006).
Type II colonies also overexpressed a number o f recognised markers o f prostate and 
bladder epithelial differentiation. These were prostate acid phosphatase, kallikrein 12 
which has been localised to the luminal cells o f  the normal prostate, zinc-binding 
alpha-2-glycoprotein 1 which is produced by prostate epithelial cells and represents
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30% o f  seminal plasma proteins and uroplakin 1 A, a marker o f  urothelial 
differentiation (Memari et al, 2007; Lapointe et al, 2004; Southgate et al, 2007).
Some pro-apoptotic and anti-proliferative genes were also found, such as 
BCL2/adenovirus E1B 19kD interacting protein and NDRG family member 2, and 
another, skin aspartic protease helps trigger terminal differentiation (Xie et al, 2005; 
Kovacevic and Richardson, 2006; Rhiemeier et al, 2006).
3.8.3 Apparent biological differences in gene expression between type I and 
type II colonies
Even significant genes may have their expression levels altered within the cell by 
post-translational modifications, so confirmation at the protein expression level 
would be necessary to confirm the patterns identified here. For the purposes o f 
further discussion similar gene and protein expressions were assumed.
The gene expression profile o f  type I colonies suggested that these cells are 
proliferating rather than differentiating, migratory and interacting with the 
extracellular matrix rather than other cells. In contrast, almost all the genes 
upregulated in type II colonies related to epithelial differentiation, and predominately 
keratinocyte differentiation raising the possibility that the epithelial cells are 
undergoing squamous differentiation. Given that the type I colonies were postulated 
to derive from TA cells and the type II from stem cells, the expectation had been that 
these phenotypes would have reversed.
3.9 Discussion
This project aimed to study the small population o f prostate epithelial cells that grow 
in serum and androgen free culture and gain a better understanding o f the differences 
between the two cell populations identified retrospectively by their differing colony 
morphologies.
It was hypothesized that type II colonies derived from stem cells, so in comparison 
with the TA derived colonies would be expected to be more proliferative,
140
demonstrate self-renewal, differentiate into all lineages o f  the prostate and 
demonstrate a gene expression profile consistent with this.
These investigations have demonstrated that type II cells tend to be more 
proliferative in culture than type I, though they proliferate far more in the first 14 
days in culture. There appears to be no difference in the Matrigel-induced 
differentiation potential o f both colony types, but type II colonies do not demonstrate 
any colony self-renewal when replated, and assume a type I phenotype. Monolayer 
immunohistochemistry o f  the two colony types (figure 3.5) confirms the K 14 
expression o f  the more undifferentiated type II colonies and the more differentiated 
luminal K8 staining o f  the type I colonies as reported by Hudson et al (2000). 
However, when the gene expression profiles o f  the two colonies are compared, the 
type I cells are more proliferative and undifferentiated and the type II cells are 
expressing late markers o f  (presumably androgen-independent) squamous 
differentiation.
A reason for this apparent switch in phenotypes may relate to the cell-cell 
interactions within the type II colony, which are lacking in the type I. The cell o f  
origin o f  a type II colony may be a stem cell, which loses its self-renewal abilities in 
culture by commencing differentiation, or an early transit amplifying cell. At the 
time o f  plating, type II generating cells may be expressing genes that promote tight 
cell-cell adhesion to create an intact basal layer. These cells are highly proliferative 
over the first two weeks and generate a tightly packed colony. Eventually, cells in 
the center o f  the colony will be contact-inhibited which predisposes to 
differentiation, which in this case proceeds down an apparently squamous route (Ura 
et al, 2004). Squamous differentiation genes might be expected to stand out when 
colony gene expression is compared, as differences between the undifferentiated 
glandular epithelial type II basal cells and the type I cells may be o f  a much lower 
magnitude than differentiating type II cells that are switching to a different 
histological cell type entirely.
At the time o f  plating, the later TA cells that generate type I colonies may be 
expressing genes to help them migrate within the prostate epithelial layers. They 
form looser colonies and without contact inhibition remain proliferative and more
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migratory as they form a colony. When a type II colony is replated, the cells assume 
a type I phenotype. This may be because their contact inhibition is lifted, or that 
differentiation in monolayer culture is only be possible on a foundation o f  basal 
cells, which is lost with replating, or alternatively that the type II cells have become 
more differentiated over two weeks so are now at the level in the epithelial hierarchy 
that the type I cells were when originally plated.
It is likely, if  stem cells exist in primary cultures, that they are lost with serial 
passage or overgrown by non-stem cells. Gao et al (2001) found that prostatic 
epithelial cell organoids immediately placed in Matrigel and injected into mice, 
exhibited stem cell-like activity by forming acini with basal and luminal cells. 
However if  cells were isolated and grown in primary culture prior to implantation, 
they remained as small basal cell nests. Unlike the organoids, the previously cultured 
cells did not induce infiltration and smooth muscle differentiation o f  mesenchymal 
cells, an event that may be critical for maintenance and function o f stem cells.
This interpretation implies that the morphology o f  the prostate epithelial cells in 
primary culture may be determined by their gene expression patterns a t the time, but 
the environmental cues and cell interactions that they experience in culture has an 
impact. The exact cells o f  origin o f the type I and type II colonies remains unclear 
though their behaviour would suggest that they are differently aged transit 
amplifying cells. What is certain, is that their phenotype is unlikely to remain the 
same after two weeks in monolayer culture.
Squamous differentiation o f  prostate epithelial cells is rarely reported, though 
interestingly some o f  the Matrigel structures obtained in this project from both type I 
(figure 3.4, E) and type II (figure 3.5) colony cells are reminiscent o f  a stratified 
keratinising epithelium. Clinically, squamous differentiation is encountered 
sporadically in prostate cancers and oestrogen will induce squamous metaplasia in 
rodent prostates (Parwani et al, 2004; Cunha et al, 2001). Dalrymple et al (2005) 
observed prostate transit amplifying cells dividing using time-lapse video­
microscopy. The two daughter cells migrated apart to fill the culture surface, ceasing 
proliferation at confluence. However if  grown in high calcium concentration 
medium, cells gathered into small groups and ceased proliferation due to contact
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inhibition. They then underwent squamous differentiation - developing comified 
envelopes before dying.
Though no other authors have studied these colonies individually, more recently the 
phenotype o f  primary cultures o f  prostate epithelium in low calcium, serum free 
medium has been described as representing transit amplifying cells (Uzgare et al, 
2004). These cells progressively mature over time in culture, with later passages 
showing an increasing proportion o f  slower cycling, K8+/ K18+ cells until they lose 
proliferative ability by the 7 -10th passage. Liu and Peehl (2001) also concluded that 
such cells were TA cells on the basis o f  their cluster designation antigen expression. 
One other study has highlighted the heterogeneity o f prostate cells in culture. Tokar 
et al (2005) plated out individual cells from a human papillomavirus-18 
immortalised prostate epithelial cell line, and selected two clones on the basis o f 
different morphology, calling them WPE-stem (as they were potentially stem cells) 
and WPE-int (potentially intermediate TA cells). The former were small cells, which 
expressed high levels o f  p63 and CK5/14 and grew in soft agar while the latter 
expressed K18, had larger polygonal cells and was less clonogenic. However no 
further investigation o f  sternness was undertaken, and as the WPE-stem cells were 
p63+ again these two cell populations are both likely to be TA cells.
3.10 Future directions
When the proliferative heterogeneity o f  the prostate was first reported in 2000, it 
represented the first in vitro evidence for the existence o f  the then unknown prostate 
stem cell (Hudson et al, 2000). Without knowing the marker expression on the stem 
cell, this modified colony-forming assay was invaluable for demonstrating any 
degree o f  enrichment achieved by selecting for speculative markers (Collins et al, 
2001). Colony forming assays are still used but the heterogeneity o f  the colonies has 
not been investigated further other than in this study. Most o f  the impressive 
progress towards identifying the prostate stem cell has used cell sorting o f  primary 
cells, a reflection o f  the change in phenotype that occurs with in vitro culture. 
However the assays required for identification and proof o f  stem cells such as mouse 
xenografts are laborious. With confirmation o f  the prostate stem cell phenotype, it 
will be interesting to see what colonies are grown when a pure stem cell population
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is plated. If  colonies are characteristic, then low-density culture could re-emerge as a 
more convenient way o f  confirming the presence o f  stem cells for the rapid, large 
scale screening o f stem cell killing molecules. I f  type II colonies are derived initially 
from a stem cell, then a drug added to culture medium that consistently yields only 
type I colonies may be selectively destroying stem cells, and would represent a 
candidate for clinical studies.
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CHAPTER 4
ACQUISITION AND ANALYSIS OF EPITHELIAL COLONIES 
FROM RADICAL PROSTATECTOM Y TISSUE.
4.1 Introduction
It was hypothesized that the stem cell model o f  cancer would apply in prostate 
cancer. Thus cultures o f  malignant prostate tissue would, like BPH, demonstrate 
proliferative heterogeneity. As the most undifferentiated and rarest o f the cell 
fractions in low-density culture, type II colonies were o f particular interest.
While many studies have compared benign and malignant tissue, few have 
compared such a small fraction o f  prostate epithelial cells. Identification o f 
expression differences between these colonies had the potential to identify genes 
peculiar to stem cells, which could ultimately be manipulated for clinical 
benefits.
In this study colonies were obtained from parallel cultures o f  benign and 
malignant prostate tissue derived from early prostate cancers. In view o f  the risk 
o f  contaminating benign or malignant cells within each sample, the nature o f 
each colony had to be determined individually. It was hypothesized that LOH 
analysis would be sufficiently discriminatory, allowing accurate comparison o f  
the characteristics and differential gene expression o f  the benign and malignant 
colonies.
4.2 Acquisition o f paired benign and malignant prostate tissue samples 
from radical prostatectomy specimens.
In total, 18 radical prostatectomy specimens were sampled for malignant and 
benign prostate tissue. Typical o f  the radical prostatectomy population, patients 
were relatively young with a median age o f  64 (range 54-70 years old), and had a 
median biopsy and gland Gleason grade o f  3+4 (range 3+3 to 4+5) and a mean 
prostate weight o f 40g (standard deviation 9.7g). Patient characteristics, prostate 
biopsy results and corresponding radical prostatectomy histology are listed in 
table 4.1. Many potential patients undergoing surgery had unsuitable biopsy
146
results, as selection required a high percentage (by length) o f core involvement. 
A biopsy core was between 10 and 16mm long so 70% involvement for example, 
equated to 7-11mm cancer diameter along the line o f  the biopsy.
Patient Age PSA
(ng/
dL)
Biopsy
Gleason
Grade
Biopsy histology RRP
Gleason
grade
Gland weight and cancer 
location
1 69 14.5 3+4 All 8 cores positive, but L 
70-90%, R 10-20%. L 
sided nodule
4+3 58g, multifocal, bilateral 
tumour, largest 28mm on 
L
2 70 5.7 3+3 3/6 positive, all R 80-90%  
involved. L: Atypia & 
HGPIN
3+3 40g, bilateral foci R>L, 
largest 20mm on R
3 67 8.3 3+4 2/6 positive, R apex 55%, 
L <lm m
3+4 52g, 2 foci, R side, 8 & 
11mm
4 64 5.2 3+3 3/6 cores positive, R 10%, 
L 40% apex & 90% base
3+4 48g, multifocal, largest 
tumour 36mm L & centre
5 59 7.4 3+3 2/6 positive: 70% L base, 
15% L midzone. L 
nodule.
3+3 34g, 10mm focus on R 
side
6 58 5.9 4+4 3/6 positive. 60% o f  R 
mid & base cores, <10% 
L apex
3+4 46g, 3 foci & HGPIN. 
Largest 8mm
7 61 5.2 3+3 3/6 cores positive on R 
40-60%
3+4 33g, 20mm focus R
8 68 8.3 3+4 2/6 cores, R central 35% 
5mm, L <lm m
4+4 57g, 2 foci 13 & 20 mm 
on R / midline
9 70 9.7 3+4 2/10 cores positive. 
30&70% on R
4+3 47g, 2 foci R&L, largest 
10mm on L, HGPIN
10 66 6.2 3+4 3/8 cores positive, all L: 
80-90%
3+4 51g, 32mm L focus 
HGPIN
11 54 3.4 3+3 3/6 cores positive, all L 
sided <10-90%
3+4 34g, L side 15mm focus
12 68 8.5 4+3 3/8 biopsies positive, all 
on L
4+3 28g, 2 foci merge 30mm  
anterior & L
13 63 10.0 4+5 All 6 cores positive, 
<20% R, >80% L
4+4 43g, 6 foci. Largest 
16mm on L
14 66 8.0 3+4 80% o f  1/4 R cores, <10%  
o f  1/4 L cores
4+3 50g, bilateral, 2 foci, 
16mm R, 8mm L
15 54 4.0 3+3 2/7 cores positive. R 
apex/midzone 70- 80%
3+4 61g, 2 foci on R, largest 
22mm
16 55 7.2 4+3 2/10 cores positive. 60- 
80% L base. MRI: L 
capsular breach
4+3 38g, T3 on L. 18mm 
focus & HGPIN
17 62 4.9 3+4 3/6 cores positive. 40- 
50% L, <10% R
3+4 56g, bilateral, 5 foci 
largest L, 16mm.
18 63 4.9 3+4 2/6 cores positive L apex . 
10%, L midzone 70%
4+3 40g, L sided 34mm 
tumour
Median 64 6.7 3+4 3+4
HGPIN -  High grade prostatic intra-epithelial neoplasia, MR1 -  Magnetic Resonance Imaging, 
RRP -  radical retropubic prostatectomy.
Table 4.1: Patient characteristics and histopathology o f  prostates sampled for • 
benign and malignant tissue.
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4.3 Outcomes o f culture o f paired benign and malignant radical 
prostatectomy tissue samples.
From each fresh prostate, one benign tissue sample and one or two cancer tissue 
samples were cut by the histopathologist. It was usually easy to distinguish the 
hyperplastic transitional zone from the peripheral zone. Presumed benign tissue 
was taken from the peripheral zone on the side o f  the prostate most negative for 
cancer on biopsies.
To the naked eye, areas o f  prostate cancer were not as easily distinguishable, 
though high-grade (Gleason 4 or 5) cancer looked slightly more yellow in the 
unfixed gland (personal communication, Dr M Constance Parkinson). The 
sampling o f  cancer tissue specimens thus relied on tissue appearance and 
firmness using fingertip palpation, guided by the biopsy and preoperative 
magnetic resonance imaging results and the experience o f  a dedicated Consultant 
Urological Histopathologist.
Even in patients with appropriate biopsy findings, these did not always predict 
the Gleason grade or distribution o f  the prostate cancer in the whole gland, 
though tumours tended to be large (see table 4.1). This made the prospective 
identification o f  prostate cancer tissue in the fresh specimen more difficult, 
especially as histological fixing, embedding, staining and assessment o f  the 
whole gland was not complete until eight days after specimen acquisition. As 
part o f  the histological assessment o f  the whole gland, the sites o f  tissue 
sampling were assessed in terms o f  its location in relation to the cancer foci.
From each prostate, the presumed benign and malignant samples were 
immediately processed into a single cell suspension, plated out and colonies 
assessed at two weeks. The samples acquired and the outcome o f  culture are 
summarised in table 4.2.
The colonies were used for a number o f  purposes.
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Given the difficulty in distinguishing between benign and malignant areas o f 
fresh prostate tissue, the first requirement was to confirm the presumed origin o f 
each colony individually, before further characterisation could be done. It was 
assumed that each colony represented the clonal expansion o f a single prostate 
epithelial cell plated 14 days previously, and thus that all cells within the colony 
would be genetically identical. It was hypothesized that the genotype o f  a benign 
colony would match that o f  benign prostate tissue from the original specimen, 
and that o f  a cancer colony would match that o f  the focus o f  prostate cancer that 
had been sampled.
Loss o f  heterozygosity (LOH) analysis has been used by many authors to identify 
common sites o f  mutation and chromosomal loss in prostate cancer and was also 
used by Bright et al to successfully distinguish between three otherwise 
morphologically identical paired benign and malignant early prostate cancer cell 
lines (Bettendorf et al, 2005; Bostwick et al, 2002, Bott et al, 2006; Bright et al, 
1997; Cheng et al, 1998; Fromont et al, 2003; Ruijter et al, 1999). LOH analysis 
was therefore applied to DNA extracted from lymph nodes (for a germ line 
control), histologically confirmed benign and malignant areas o f the formalin 
fixed prostate (to identify loci o f  interest) and individual presumed benign / 
malignant colonies (to analyse at loci o f  interest).
Though some colonies were scraped up entirely for DNA extraction, others were 
individually ring cloned into a 25cm tissue culture flask and allowed to 
proliferate to semi-confluence. When successful, this provided far greater 
numbers o f  cells for extraction o f  DNA (10% o f  cells) and total RNA (90%). 
RNA was extracted from individual colonies with the intention that after 
confirmation/exclusion o f malignancy their gene expression could be evaluated 
using DNA microarrays.
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Patient Sample Tissue
weight
Cell 
yield x 
106 / g
Cells
plated
xlO3
% flasks 
remaining 
at 2 weeks
Outcome
1 Benign 1 R anterior 0.5 32 10 80% Colony DNA
Benign 2 R 0.3 6 10 80% extracted
Cancer L 0.4 16 40 75%
2 Benign L 0.03 8.7 8 50% Colony DNA
Cancer 1 R posterior 0.07 2.7 24 56% extracted
Cancer 2 midline 0.05 6 16 38%
3 Benign L 0.2 5.6 18 22% 74% flasks infected,
Cancer 1 R 0.2 5.9 18 11% no cancer colonies
Cancer 2 R 0.2 8.1 18 44% grown
4 Benign R 0.05 13 16 0% 76% infected,
Cancer 1 R 0.15 8.9 17 6% including all benign
Cancer 2 L 0.2 4.7 17 6% flasks
5 Benign R 0.5 4.6 25 96% Cancer sample from
Cancer L 0.3 6.4 25 88% benign area o f  gland
6 Benign 0.34 1.7 25 4% 96% infected
Cancer 0.30 1.9 25 0%
7 Benign 0.08 3.2 20 85% Poor colony yield
Cancer 0.10 3.1 20 80% throughout
8 Benign R 0.04 4.7 24 71% N o benign colonies
Cancer 1 R 0.2 0.08 24 92%
Cancer 2 R 0.04 0.003 24 73%
9 Benign R 0.33 5.3 20 100% 100% survived, but
Cancer L 0.31 7.2 20 100% few benign colonies.
Lost at ring cloning
10 Benign R 0.24 10 20 100% Colonies lost during
Cancer L 0.08 6 20 95% ring cloning
11 Benign 0.16 2.8 22 91% Colony DNA
Cancer 0.07 9.7 18 94% extracted
12 Benign R 0.07 4.3 29 100% Colony DNA & RNA
Cancer L anterior 0.07 3 29 100% extracted
13 Benign R anterior 0.6 0.1 18 94% Atypical appearance
Cancer L 0.4 0.07 18 78% o f  cancer colonies
14 Benign L anterior 0.3 3.2 24 100% Colony DNA & RNA
Cancer R posterior 0.2 4.4 24 96% extracted
15 Benign 0.2 0.9 18 94% Colony DNA & RNA
Cancer 0.2 1.9 18 100% extracted
16 Benign R 0.21 1.3 21 100% Colony DNA
Cancer L lateral 0.3 1.1 21 100% extracted -  not used
17 Benign 0.18 0.52 21 86% Cancer sample from
Cancer 0.11 0.95 21 100% benign area o f  gland
18 Benign 0.18 1.1 21 71% Colonies lost to ring
Cancer 0.12 0.7 21 29% cloning
Mean Benign 0.2 (0.2) 5.7 (7.2) 19(5) 72 (34%)
(s.d.) Cancer 0.2 (0.1) 4.5 (4.0) 2 2 (5 ) 65 (34%)
s.d. -  standard deviation
Table 4.2: Outcome o f  culture o f  benign and malignant prostate tissue.
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O f 18 prostates used, only seven prostates yielded colony RNA and DNA or 
DNA alone for further experimentation, o f  which six were used (see table 4.2). 
O f the eleven prostates lost, in three cases this was due to contamination with 
fungal spores, most likely introduced when the pathologist dissected out the 
samples. On two occasions, while colonies grew well, during the histological 
assessment o f  the whole gland (seven days into the tissue culture process), it was 
evident that the tissue sampled from the cancerous side o f the prostate had not 
come from within the focus o f  cancer. The colonies from three prostates were 
dedicated to ring cloning to obtained paired DNA and expanded RNA colony 
samples, but became infected in secondary culture or failed to settle and 
proliferate. For two prostates, colony yield was insufficient; with globally low 
yields in one, and adequate cancer colony numbers, but no matching benign 
colonies in the other. Finally cancer colonies from one prostate were very 
atypical, with thin cells with irregular outlines, which were not used.
Early attempts at prostate tissue culture were remarkable for the extent o f  
infection encountered. Culture flasks were largely contaminated with fungal 
growth, though yeast infection was encountered rarely. Though cultures o f  TURP 
tissue occasionally became contaminated, infection rates were far higher in the 
culture o f  radical prostatectomy tissue obtained from the pathologist. Fungal 
colonies were seen at any time during the two weeks in culture with progressive 
attrition o f  flask numbers.
A number o f  changes were introduced to reduce the infection rate. Antibiotic 
concentrations in the collecting medium were increased to 10%. PrEGM culture 
medium routinely contained 0.1% by volume o f  amphotericin B and gentamicin 
antibiotics, so further antibiotics were added to a concentration o f 1% by volume. 
Careful review o f tissue culture technique was undertaken and cell culture was 
switched from 5cm diameter Petri dishes, to 25cm2 Nunc flasks, which were 
easier to handle. The number o f  flasks set up for each experiment was also 
increased in response to the high attrition rate. Replacing culture medium twice a 
week rather than three times did not appear to reduce contamination rates, 
despite the perception that infection was being introduced during tissue culture 
due to the sporadic timing o f  infections.
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Requiring the pathologist to wear sterile gloves and use sterile instruments (a 
change from the usual laboratory protocol) greatly reduced infection rates and 
this coincided with a change in pathologist. The first pathologist inked the edges 
o f  the freshly sliced prostate before dissecting out the samples, to allow 
identification o f  the surgical margins. Though this ink did not come into contact 
with the tissue taken, it is almost always contaminated with fungal spores 
(personal communication, Dr C Corbishley). These changes were instituted 
between prostates number six and seven. Infections were reduced but not 
eradicated by these interventions, and continued vigilance was required at all 
stages, especially during sample acquisition.
4.4 M orphological characteristics o f primary prostate epithelial colonies 
derived from presumed benign and malignant colonies.
Surviving flasks o f  presumed benign and malignant cells were scored after two 
weeks monolayer culture. Visually, and under low and high power microscopy 
there were no distinguishing morphological differences between the colonies (see 
figure 4.1).
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Figure 4.1: A&B Representative dishes after 14 days o f  low density culture o f 
1000 primary prostate epithelial cells from presumed benign or malignant radical 
prostatectomy tissue; stained for cytokeratins 5,6 and 18. Type I colonies from 
benign (C) and malignant (D) cells, and type II colonies from benign (E) and 
malignant (F) cells looked similar.
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Both type I and II colonies were present based on their characteristic appearance 
under direct vision. Within and between patients there was great variation in 
flask colony yields and the ratio o f  colony types, though invariably there were 
more type I colonies than type II. Table 4.3 shows the colony forming efficiency 
for the 9 prostates out o f  18, for which characteristic colonies were obtained from 
both the benign and cancer samples, and <25% o f  cells plated for each sample 
became infected.
Presumed benign Presumed malignant
Prostate
No. o f  
dishes 
scored
Mean 
total % 
CFE 
(>32 
cells)
Mean % 
type II 
CFE
% total 
colonies 
type II
No. o f  
dishes 
scored
Mean 
total % 
CFE 
(>32 
cells)
Mean % 
type II 
CFE
% total 
colonies 
type II
1 8* 0.74 0.00 0.0 30* 0.48 0.02 3.5
8* 0.56 0.00 0.0
7 17* 0.02 0.01 25.0 16* 0.04 0.01 28.6
9 20 0.01 0.00 0.0 20 0.42 0.11 26.2
10 20 0.09 0.03 27.8 19* 0.79 0.19 23.8
11 20* 0.49 0.20 39.8 17* 0.17 0.08 44.8
12 29 0.53 0.05 9.8 29 0.36 0.02 5.8
14 24 0.34 0.09 25.6 23* 0.04 0.00 11.1
15 17* 0.26 0.04 13.6 18 0.36 0.07 18.5
16 21 0.12 0.00 4.0 21 0.38 0.00 1.3
Mean 18 0.32 0.04 15.0 21 0.34 0.56 18.0
s.e.m. 2.2 0.09 0.10 0.05 1.7 0.08 0.21 0.05
CFE = colony forming efficiency, s.e.m. = standard error o f  the mean, * excludes dishes lost to 
infection that were not scored.
Table 4.3: CFEs o f  presumed primary benign / malignant prostate epithelial cell 
cultures. CFE and proportion o f  type II colonies was not significantly different 
between the presumed benign and malignant samples (student’s t-test, p= 0.84 & 
0.59 respectively).
As with the TUR derived prostate tissue, colonies were typed on their 
morphology and overall appearance under direct vision and their diameter, cell 
density, number o f  cell doublings and total colony cell number. Proliferative 
heterogeneity was apparent for the two colony types in both presumed benign 
and presumed malignant tissue. The distribution o f  colony cell numbers for each
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type is shown in figure 4.2. Though cell number, diameter and the cell density 
was significantly different between the populations o f type I and type II cells 
(student’s t-test, pO.OOOl for all) in practice the cell density across 1mm for 
each colony was the most useful objective discriminator. Though no one 
parameter demonstrated precise partitioning o f the two colony types, this would 
be expected due to the normal biological variation present in two normally 
distributed cell populations whose extremes overlap. The distribution o f cell 
densities across colony type for each tissue source is shown in figure 4.3.
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Figure 4.2: Distribution o f  presumed benign and malignant prostate epithelial 
cell colonies by total colony cell number (binned by potential cell doublings) and 
type. Error bars show the standard error o f the mean for the first 10 dishes from 3 
experiments (prostates 1, 7 and 11).
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Figure 4.3: Distribution o f presumed benign and malignant prostate epithelial 
cell colonies by cell density per millimetre. Error bars show the standard error o f 
the mean for the first 10 dishes from 3 experiments (prostates 1, 7 and 11).
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Table 4.4 (extended from table 3.2) shows how the colonies derived from 
presumed benign or malignant peripheral zone radical prostatectomy tissue 
compares.to colonies derived from transitional zone prostate tissue harvested at 
TURP in this study and as reported by Hudson et al, (2000).
Hudson et al, 2000 Present study
T issue source 
T issue Type
TURP
Transitional zone  
BPH
TURP
Transitional zone  
BPH
Radical prostatectomy 
Peripheral zone
Presumed benign Presumed cancer
Colony type I II I II I II I 11
Diameter 
(m m , mean)
<4 >3 0 .5 -1 7
(4)
9 -2 0
(11)
0 .5 -1 8
(4)
5-27
(14)
0 .5 -1 0
(2)
5 -3 2
(13)
Cell number 
xlO 3 (m ean)
< 8 .5 8 -4 0 0.04—48
(8.3)
2 8 -6 0 7
(169)
0 .03-
176
(13)
2 2 -
1,456
(309)
0 .07-80
(5 .3)
2 6 -
1,736
(380)
Num ber o f
doublings
(m ean)
5 -1 2 12-14 5 -1 6
(11)
15-19
(17)
5 -1 7
(11)
14-20
(17)
6 -1 6
(10)
1 4 -2 0
(17)
Density
(cells/m m ,
mean)
<30 3 0 -5 0 7 -3 2
(19)
3 3 -5 9
(40)
4 -3 9
(21)
3 0 -5 6
(40)
6 -3 8
(22)
3 0 -5 6
(40)
Outline irreg reg irreg reg irreg reg irreg reg
Frequency 
o f  colon ies
90% 10% 83% 17% 85% 15% 82% 18%
Mean % CFE 5.26 0.54 0.22 0.05 0.28 0.04 0.28 0 .06
Incidence o f  
colony  
forming cells
1/17 1/185 1/377 1/1961 1/419 1/2091 1/335 1/1950
CFE -  colony forming efficiency, reg -  regular, irreg - irregular
Table 4.4: Characteristics o f the two colony types obtained from primary 
prostate epithelial cell culture by Hudson et al, (2000) and in the present study 
from peripheral benign and malignant and transitional zone tissue.
The characteristics o f the colonies grown from transitional zone BPH, and 
presumed malignant and benign peripheral zone tissue are remarkably similar 
(discussed below). Type I colonies are commoner than type II which were grown 
in seven out o f nine o f the scored experiments. As discussed in section 3.2,
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overall colony yield is reduced compared to the findings o f Hudson et al (2000) 
and the likely reasons behind this stand, as tissue was processed in the same way.
These colonies were derived from different zones o f the prostate. The transitional 
zone is traditionally the site o f benign prostatic hyperplasia, while cancers 
predominately arise within the peripheral zone (McNeal 1968; McNeal et al, 
1988). No difference in clonogenicity was encountered between the two zones, 
which concurs with the findings o f Laczko et al (2005) who reported no 
difference in Ki-67 staining between the transition zone and peripheral zone o f 
cadaveric donor prostates.
The malignant and benign colonies demonstrated no distinguishing features 
between them. Confirmation o f  each colony’s benign/ cancer status was required 
before any formal conclusions could be drawn about them, and prior to any 
comparisons o f differential gene expression or in vitro / in vivo characteristics. .
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4.5 Differentiating between benign and malignant colonies using LOH  
analysis.
The method o f tissue acquisition and the multifocal nature o f prostate cancer 
made it possible that within each sample were contaminating benign or 
malignant cells that might have resulted in colonies derived from a single cancer 
cell amongst benign colonies and vice versa. It is common to identify a number 
o f different foci o f prostate cancer within a radical prostatectomy specimen. 
These foci may be very small, may merge to create an apparently larger focus 
which in reality is derived from two different clones, and can have irregular 
borders so that benign tissue may interdigitate with malignant tissue (Ruijter et 
al, 1999). In addition, other histological entities such as proliferative 
inflammatory atrophy, atypical adenomatous hyperplasia and high grade 
prostatic intraepithelial neoplasia (HGPIN) may also be sampled within a 
macroscopically benign or malignant area o f prostate, each o f which may differ 
in its genetic changes, including LOH.
4.5.1 Establishing LOH control samples using early prostate cancer cell 
lines with LOH at known loci.
Bright and colleagues (1997) developed seven paired benign and malignant 
immortalised prostate epithelial cell lines from six successive patients. Using 
fresh prostate specimens, pure tumour or benign samples were microdissected 
out by an experienced pathologist. Despite this, even the smallest samples 
contained a diverse mixture o f cell types including stroma, normal epithelium, 
PIN, and invasive tumour. Primary prostate cell cultures were established and 
then immortalized using the E6 and E7 transforming proteins o f human 
papilloma virus serotype 16. Extensive cloning and passaging resulted in stably 
transfected cell lines.
Out o f a number o f techniques tried, all but LOH analysis failed to demonstrate a 
difference between the cell line pairs. Both cancer and benign cells had similar 
karyotypes (usually normal male in localised prostate cancer), similar 
phenotypes, similar growth rates in culture and in nude mice and similar PSA
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expression. However, LOH analysis o f 8p 12-21, a region especially implicated 
in prostate adenocarcinoma, demonstrated allele loss in the cancer cell lines 
which corresponded to one or more o f the foci microdissected from the original 
cancer, which was absent in the corresponding benign cell lines. Not all cancers 
had LOH on 8p 12-21 and one patient showed LOH in multiple benign glands as 
well as his cancer.
To establish positive controls for the colony LOH analysis, the LOH analysis o f 
three o f these paired cell lines was repeated, for four o f the eight loci reported by 
Bright et al (1997) and for 25 other microsatellite loci also reported as lost in 
prostate cancer on other chromosomes. The results and a comparison with those 
o f Bright et al (1997) are shown in table 4.5.
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Paired cell lines 
(benign / cancer) 
Micro-satellite 
marker
1532NPT/ 
1532CPT 
Bright 
et al
Present
1535NPT/ 
1535CPT 
Bright 
et al
Present
1542NPT/ 
1542CPT 
Bright
et al
Present
D1S158 hom 0.85 0.97
D1S414 0.93 0.99 0.97
D3S1263 0.84 Hom 0.97
D5S656 0.99 0.95
D6S314 0.88 0.97 0.96
D6S501 0.34 Hom 0.94
D7S523 0.98 0.98 0.75
SFTP2 hom hom LOH 0.93 0.93
D8S133 LOH LOH LOH 0.00
D8S136 LOH 0.05 LOH 0.99 LOH 0.11
NEFL LOH 0.02 LOH 0.99 0.32
D8S137 hom LOH
D8S131 hom LOH LOH
D8S339 het het
ANK hom
D8S1991 0.10 0.94 0.06
D8S255 0.08 0.97 0.14
D8S549 hom hom
D9S1748 0.78 0.95 0.94
D9S1679 0.92 0.64 0.98
D10S541 0.82 0.98 0.98
D10S587 0.83 Hom 0.93
D11S902 hom 0.96 0.79
D11S990 1.00 0.95 hom
D12S89 0.98 1.00 0.95
D12S1697 hom 0.98 hom
D13S171 0.99 0.99 0.06
D13S284 0.97 0.99 0.97
D16S505 0.97 0.95 0.94
D16S422 hom 0.94
D16S413 0.90 1.00 1.00
D16S515 0.89 0.90 0.98
D18S363 0.92 0.91 0.98
LOH - LOH seen in cancer sample compared to benign sample.
Table 4.5: LOH analysis o f three 
paired cell lines for the eight loci 
assessed by Bright et al and for 29 loci 
assessed in the present study.
Absent data occurred where the locus
hom Homozygous / uninformative 
Heterozygous = 0.71-1.00 
30-49% loss: 0.51-0.70 
50-74% loss: 0.25-0.50 
75-100% loss: <0.25 
blank = unknown
was not examined or electropherograms were uninterpretable, usually because 
concentrations o f  PCR product were too high.
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When performing their LOH analysis, Bright and colleagues used 
autoradiography o f radiolabelled DNA bands on a high-density gel. LOH was 
called if there was at least 75% loss o f one allele as visualised by three 
independent observers. The AB1 Prism 3700 DNA analyser is more quantitative 
and requires the imposition o f a somewhat arbitrary cut-off value to determine 
whether LOH is present, in the face o f occasionally equivocal results. Extending 
the LOH analysis to 29 microsatellite markers with a cut-off o f 75% identified 
two further loci with LOH in 1532CPT and three in 1542CPT. For the four loci 
published by Bright et al (1997) that were checked, there was complete 
agreement for 1542CPT and 1532CPT cell lines and complete disagreement for 
1535CPT. The cell lines analysed as 1535NPT and 1535CPT were a match as 
their alleles reliably agreed in length and were often different lengths to the other 
two cell line pairs. However it seems most likely that the two flasks o f cells 
harvested for DNA had been previously mislabelled and both contained the 
benign cells 1535NPT, and that 1535CPT was never analysed. This accounts for 
the heterogeneous product lengths found at the three loci used for comparison as 
if both samples had been 1535CPT then all three would have been homozygous.
When comparing two clonally expanded cell lines, one would expect either 
complete presence o f two alleles or complete loss o f one allele. However this 
does not occur, and it demonstrates the degree o f noise associated with this 
analysis. The LOH detected here had percentage allele losses o f 86-100% and 
interestingly, even when two identical cell lines were compared, as was 
inadvertently done with 1535NPT cells, allele losses o f 0-15% were 
demonstrated with one outlying result o f 36% allele loss. Noise will derive from 
perturbations in the PCR process and the resolution o f the bioanalyser. The 
finding o f 36% LOH at locus D9S1679 for this ‘pair’ o f cell lines requires 
explanation as there should be no LOH or any approach to it. The presence o f a 
subclone with a mutation at this locus in one o f the cell lines, acquired in culture 
could account for this, though an artefact o f the technique seems more likely.
Understanding the significance o f equivocal results such as the 66% and 68% 
LOH found by the assay system at use in this project is difficult. In some 
cancers, duplication o f chromosomes can occur, such that there are three or four
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copies o f a locus. If  a cancer has two copies o f  one allele length and one o f 
another, with each gene amplified equally, a 50% allele loss would be reported 
(even though no sequences have been lost). Because o f this, some authors have 
adopted the term ‘allelic imbalance’ to better acknowledge such possibilities.
The variability inherent in this system can be accommodated if the cut-off point 
is relaxed, and 75-80% loss appears appropriate. However in the analysis o f 
primary tissue, the presence o f  uncertain levels o f  contaminating normal cells 
will further obscure the true presence o f  LOH so thresholds must be lowered.
Bright et al (1997) repeated their LOH analysis twice if DNA allowed. Here 
LOH analysis was performed only once for these cell lines, though loci used as 
positive controls were confirmed many times in later analyses. Cell line pairs 
1532NPT/1532CPT and 1542NPT/1542CPT were used as positive controls at 
loci D6S501, D8S133, D8S136, D8S255, D8S1991, NEFL and D13S171.
4.5.2 LOH analysis o f original tumour / benign prostate tissue sampled for 
culture o f colonies
In order to identify those loci o f  interest for each sampled prostate cancer, LOH 
analysis was performed on DNA derived from the paraffin embedded prostate at 
sampled sites that had been histologically confirmed as malignant or benign. 
Those loci demonstrating LOH were then analysed in DNA from corresponding 
benign and malignant colonies. Six patients’ prostate tissue was assessed for up 
to 55 loci in total. Table 4.6 shows the LOH analysis findings.
As the prostate tissue was not a pure sample o f  prostate epithelial cells, but was 
contaminated with stromal cells, blood cells, nerves and vessels any LOH within 
the malignant epithelium would be diluted by the other cells’ normal genotypes. 
Two threshold levels for assigning LOH were considered, and these were relaxed 
to 50% loss (calculated as <0.5 if loss o f  the shorter allele or >2.00 if loss o f  the 
longer allele) and 30% loss (calculated as <0.7 if loss o f the shorter allele or 
>1.43 if loss o f the longer allele). A wide variety o f allele loss was encountered 
each side o f this value.
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Patient #1 #2 #11 #12 #14 #15
Marker B el Be2 Ca Be C al Ca2 Be Ca Be Ca Be Ca Be Ca
D1S158 0.89 0.93 0.93 0.98 0.89 0.99 0.90 0.93 1.05 1.06 Hom Hom 0.95 1.08
D 1S305 ' 0.54 0.93 0.99 1.05 1.03 Hom Hom Hom Hom
D 1S414 1.00 1.01 1.06 0.95 0.93 1.00 Hom Hom 0.94 0.87 Hom Hom
D 1S422 1.05 1.06 1.05 0.96 0.98 1.00 Hom Hom 1.15 0.98 0.95 1.06 1.15 1.08
D2S222 Hom Hom Hom Hom Hom Hom 0.95 0.90 1.00 0.95 Hom Hom 0.84 0.89
D3S1263 1.06 1.01 1.00 0.92 0.95 0.94 0.91 0.98 1.12 Hom Hom
D5S500 1.02 1.04 0.95 0.99 1.09 1.04 1.00 0.97 0.95 0.93 0.93
D 5S656 1.05 1.08 1.06 0.86 0.93 1.05 1.03 0.97 Hom Hom 1.17 0.98 0.83 0.86
D6S251 0.89 0.93 0.97 1.03
D 6S314 1.03 1.07 1.01 Hom Hom Hom Hom Hom 1.00 0.98 0.99 0.97 0.97 0.96
D6S501 0.97 1.08 0.99 1.01 1.01 0.97 1.08 1.00 1.06 1.07 0.97 1.00
D 7S480 0.97 0.95 0.96 0.95 1.06 1.05 1.03 1.00 1.00 0.96 1.01 1.00 0.95 0.95
D7S523 1.07 0.99 1.04 1.02 0.95 1.17 1.06 1.06 Hom Hom Hom Hom 0.98 0.97
D8S133 Hom Hom Hom 0.93 0.99 1.08 1.02 0.99 0.94 1.25 0.99
D8S136 0.93 0.89 0.49 |o.98 1.01 0.99 0.97 1.48 1.07 0.97 0.92 1.18 0.95 1.03
D 8S137 0.97 0.97 0.99 0.99 0.99 1.02 Hom Hom 1.13 1.02 Hom Hom Hom Hom
D 8S255 0.96 1.04 1.03 0.99 0.95 0.95 1.02 1.14 Hom Hom 0.99 0.95 0.94 1.12
D 8S549 0.95 1.01 0.94 0.98 0.86 0.93 1.06 1.01 1.05 0.93 0.99 1.01 Hom Hom
D8S1991 0.97 0.53 0.44 1.08 1.05 1.06 Hom Hom 1.06 0.88 0.94 0.99 Hom Hom
NEFL 0.99 1.04 0.51 0.92 0.59 0.58 0.89 0.88 1.06 1.01 0.96 1.04 Hom Hom
SFTP2 1.01 0.98 0.86 1.01 1.14 0.99 0.96 0.90 1.05 0.93 1.13
D9S1679 0.94 0.92 1.02 0.99 Hom Hom 0.98 1.01
D9S1748 1.01 1.03 1.06 0.99 1.11 0.97 1.00
D10S211 1.00 0.87 1.01 1.03 1.04 1.07 1.05 1.10 1.10 1.09
D10S541 1.10 0.93 1.02 2.17 0.22 1.12 1.03 1.07 1.02 1.06 0.89
D10S587 1.05 1.04 0.95 0.99 1.00 1.00 1.12 0.99 1.10 0.96 1.03 0.94 0.94
DIO S1246 1.08 1.10 0.55 0.91 0.88 1.00 0.97 1.01 Hom Hom Hom Hom 1.02 0.98
DIO S1765 0.99 1.04 1.00 0.95 0.95 1.00 0.81 1.13 1.00 0.95
D10S2491 0.98 1.11 0.99 1.01 0.94 0.97 1.08 0.90 1.06 0.97 0.90
Table 4.6: DNA derived from 
histologically confirmed benign / 
malignant areas o f six paraffin 
embedded prostates that had been 
sampled for colonies was analysed at 55 loci for LOH. The proportion o f LOH is 
given compared to lymph node DNA.
Horn Homozygous / uninformative 
Heterozygous = 0.71-1.42 
30-49% loss: 0.51-0.70 or 1.43-1.99■=50-100% loss: <0.50 or >2.00r | blank = unknown
1 6 4
#1 #2 #11 # 1 2 # 1 4Patient 
(co n t...)
Marker B el B e2  Ca Be C al Ca2 Be Ca Be Ca Be Ca
# 1 5
Be Ca
D11S902
D 11S903
D 11S916
D 11S990
D 11S2000
D 12S89
D 12S1697
D13S165
D13S171
D13S263
D13S269
D13S284
D15S1232
D16S413
D16S422
D16S505
D17S515
D17S786
D17S855
D17S938
D18S363
D18S364
D 18S470
D18S541
D 19S223
D 21S156
1.19 0.88 1.19 1.09 0.91 0.97 1.15 1.06
Hom Hom Hom 0.98 0.87 Hom Hom
0.89 1.13 1.04 0.91 1.00 1.00 1.01 1.02 0.91 0.97 1.00 1.01
0.99 1.06 0.96 Hom Hom Hom 0.99 1.03 1.29 1.05 Hom Hom
1.09 0.57 1.02 1.06 1.04 1.02 0.82 0.98 1.03 Hom Hom
1.02 1.00 1.05 1.18 1.01 1.00 0 .96 0.93 1.07 1.00 Hom Hom
1.04 0.55 1.10 1.06 0 .97 1.09 0.95 0.90
1.00 0.95
0.99 0.99 0.91 1.01 1.02
0.99 1.03 1.00 1.00 1.12 1.07 1.05 0 .66  0.95 0.98 0.99 0.99
0.86 0.93 0.97 0.94 0.59
1.42 0 .99
Hom Hom Hom 1.02 1.01 0.54 1.00 0.88
Hom Hom Hom
0.95 1.11
Hom
1.14 1.05 0.21
1.07 0 .99  Hom 
1.02 1.02
1.02 1.01 1.03 1.05 
0.85 0.95
0.95 0.90 1.09 1.00 0.99 0.99 0.91 1.03
Hom Hom Hom 0.92 0.57 0.95
1.04 0 .99  
1.01
1.09 1.07 1.99 1.00 0.90 1.01 0.95 1.08
1.12
1.01 1.21 0.54 0.91 0.92 0.91 Hom Hom
1.11 0.53 1.08 0.98 1.05 1.05
0.95 0 .97  0.98  
0.87  
0.99
1.13 0 .99  0.96  
0.93
Hom
1.01
0.70
0.49
0.97 0.99  
1.07 0.92
1.01 1.04 
0.93 0.98  
Hom Hom
1.02 0.94  
0.92 0.96  
Hom Hom 
0.96 0.97  
0.99 1.01 
1.01 1.07 
Hom Hom  
1.35 1.22 
Hom Hom 
1.00 0.85  
Hom Hom
0.92 0.95 
1.24 0.25
0.85
0.98
0.95
Hom
0.61 0.67
0.94 0.97  
0.96 0.90  
0.90 1.03 
1.00 1.07 
1.06 1.17
0.98 1.03 0.99 0.94 0.94 0.93 1.0) 2.84 0.96 0.93 1.00 0 .67 0.96 0.45
FALI at 50% 0.00 0.00 0.11 0.00 0.00 0.00 0.03 0.05 0 .00  0 .00 0.00 0.03 0.00 0.05
FALI at 30% 0.03 0.11 0.23 0.00 0.06 0.06 0.03 0.14 0 .00  0.00 0.00 0.09 0.02 0.07
FALI - fractional allelic-loss index (proportion o f  informative loci showing LOH)
Table 4.6: continued. Hom Homozygous / uninformative 
Heterozygous = 0.71 -1.42 
30-49% loss: 0.51-0.70 or 1.43-1.99 
50-100% loss: <0.50 or >2.00 
blank = unknown
1 6 5
For the six prostates analysed, Seventeen percent o f all loci were homozygous. 
Using a cut-off o f 50%, seven loci demonstrated LOH for one or more prostates and 
four prostates (67%) demonstrated one or more foci o f LOH. Using a cut-off o f 
30%, 21 loci demonstrated LOH for one or more prostates and five prostates (83%) 
demonstrated one or more foci o f LOH. The incidence o f LOH is often given in 
terms o f the fractional allelic-loss index (FALI), which is the proportion o f 
informative loci showing LOH. The FALI for each sample is given at the bottom o f 
table 4.6 and ranges from 0.0-0.11 for 50% cut-off, and 0.0-0.23 for 30%.
The presence o f LOH is entirely dependent on the cut-off selected. The most 
convincing LOH demonstrated here showed an 82% loss o f one allele. This 
suggests that in this tissue sample at least contamination with normal tissue 
might be in the region o f 20%, so a relaxing o f  the threshold to 50% is 
reasonable. A plot o f the distribution o f all 493 LOH analysis outcomes (data not 
shown) showed a large clustering o f values centred around 1.0 as would be 
expected and a much smaller cluster centred around 55-60% which could 
represent the population o f loci with LOH. A cut-off o f 30% would include 
these. As the threshold for designating LOH is lowered, the chance o f incorrectly 
calling LOH increases. It was therefore decided to analyse the colonies at the loci 
demonstrating >50% loss first, as a proof o f principle that the colonies will share 
LOH at these loci, with the option o f returning to further loci as required.
The incidence o f LOH identified in these six prostates is low, which limited the 
choice o f loci to analyse in the colonies, and rendered at least one prostate 
unevaluable. This was despite exhaustively screening at 55 microsatellite loci. 
Others have reported higher rates o f LOH in larger series o f radical 
prostatectomy specimens. Bott et al (2006) studied 30 microsatellite loci in 62 
men and identified LOH in 92% o f cases, while Fromont et al (2003) studied 
only 12 loci in 48 men and found 94% had at least one missing locus. LOH rates 
may be lower in this study for a number o f reasons. Firstly numbers are very 
small, so had more prostates been assessed the yield might have approached that 
experienced by others. The prostates harvested contain early prostate cancer that 
will not have accrued a great number o f mutations yet though losses o f DNA are 
five times more common than gains in primary prostate cancer (Visakorpi et al,
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1995). Yield can also be increased by using several overlapping or adjacent 
markers for candidate loci, which was not done here for most chromosomes 
(Leube et al, 2002). Finally contamination o f the tumour sample with normal 
cells or a mix o f different cancer foci may be too great (MUller et al, 2004).
There is also the possibility that early PCR cycles randomly favour benign alleles 
leading to over-representation o f them in the final PCR product (Seiben et al, 
2000).
4.5.3 LOH analysis o f presumed benign and malignant colonies at loci 
demonstrating LOH in the primary tumour
Altogether seven loci demonstrated allele loss o f >50% in four o f the original 
cancer samples. For these seven loci, DNA derived from between 14 and 17 
presumed benign and between 12 and 20 presumed malignant colonies was 
analysed. Figure 4.4 shows the electropherograms obtained from benign and 
malignant tissue from the original fixed tissue for prostate #1 and corresponding 
electropherograms for some colonies derived from tissue from the same area for 
locus D10S587. The LOH analysis for all such colonies from all four prostates 
are given in table 4.7. A threshold o f 70% was used as a cut-off for LOH in these 
tissues, as the colonally derived colonies would be expected to contain a pure 
population o f genotypically identical cells.
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Figure 4.4: LOH analysis o f original benign/malignant tissue from prostate #1 
and corresponding colonies. The vertical dotted lines denote the lengths o f the 
two alleles o f microsatellite marker D 10S587 in this patient (177 and 187 bp). 
Colonies showed various LOH patterns and allele lengths suggesting MSI.
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Prostate #1 #11 #14 #15
Locus DIO D16 D10 D21 D17 D17 D21
S587 S413 S541 SI 56 S855 S855 SI 56
Original Benign 1.05 1.14 2.17 1.01 0.87 1.24 0.96
1.04 1.05
B1 7.52 9.89 2.69 0.98 0.79 0.94 0.89
B2 16.0 MSI 0.90 1.05 0.99 0.99 1.23
B3 0.02 0.78 | 13.3 1.12 1.00 1.08 -
B4 0.98 0.99 - 0.89 MSI - 1.10
B5 - - 0.96 1.07 1.01 1.32 1.12
B6 1.10 - - - 0.90 0.62 0.96
B7 0.94 0.91 0.01 1.12 1.20 0.05 |  1.10
B8 MSI 1.48 0.87 0.88 0.99 1.04 1.22
B9 0.01 12.2 16.8 1.44 - 0.96 0.93
BIO 0.02 1.24 - - o .qB 1.02 0.81
B 11 0.87 0.94 0.99 1.02 0.89 0.90 1.14
B12 15.6 1.37 - 1.13 - 1.01 1.28
B13 1.08 1.00 - - - 0.99 1.00
B14 - 0.99 1.01 0.83 0.53 0.06 2.29
B15 1.01 26.43 0.83 15.2 0.91
B16 0.93 1.12 0.90
B17 1.11
Original Cancer 0.18 0.21 0.22 2.84 0.49 0.25 0.45
Cl 0.02 MSI 0.78 1.13 1.00 1.09 1.27
C2 0.08 0.01 1.00 1.08 0.98 20.7 |  0.70
C3 MSI 0.01 0.04 0.90 0.78 - 1.03
C4 MSI 0.01 0.02 0.99 - - 1.55
C5 12.1 1.11 - - 0.98 1.00 0.61
C6 0.97 1.03 1.23 0 .6 4 MSI 0.02 1 1.08
C7 - - - 2.50 1.02 0.88 1.33
C8 0.01 0.03 - 0.84 1.01 0.96 0.95
C9 - - 0.76 1.01 0.96 - 1.27
CIO 0.02 0.94 - - 1.25 0.03 |  1.38
C ll 1.00 1.07 0.03 1.11 - 0.79 1.44
C12 - - 0.01 12.1 1.04 MSI 4.83
C13 - - - 0.95 1.13
C14 MSI 0.65 0.90 - -
C15 0.02 0.01 - 1.03 1.01
C16 1.10 0.80 -
Cl 7 -
Cl 8 0.10
C19 1.11
C20 1.06
Table 4.7: Outcome o f LOH 
analysis o f presumed benign 
and malignant colony DNA 
at loci identified as missing 
in the original prostate.
Heterozygous: 0.71-1.42
30-49% loss: Lower al lele 0.51 -0.70
Upper allele 1.43-1.99
50-69% loss: Lower allele 0.31 -0.50
Upper allele 2.00-3.32
70-100% loss: Lower allele <0.30
Upper allele >3.33
Microsatellite instability MSI
Uninterpretable -
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Prostate #1 #11 #14 #15
Locus DIO
S587
D16
S413
DIO
S541
D21
S156
D17
S855
D17
S855
D21
S156
‘BENIGN' COLONIES
Number assessed 14 14 10 12 14 13 13
% (no.) with expected 
normal alleles 
% (no.) colonies with 
LOH
50(7)
43(6)
71(10)
21(3)
70(7)
30(3)
92(11) 
8(1)
86(12)
7(1)
85(11)
15(2)
100(13)
0
% (no.) with MSI 7(1) 7(1) 0 0 7(1) 0 0
‘CANCER’ COLONIES
Number assessed 12 12 8 10 14 11 14
% (no.) normal germ 
line alleles 25(3) 42(5)
50(4) 70(7) 86(12) 64(7) 64(9)
% (no.) colonies with 
expected LOH 
% (no.) with other 
LOH
42(5)
8(1)
42(5)
8(1)
50(4)
0
20(2)
10(1)
7(1)
0
18(2)
9(1)
0
36(5)
% (no.) with MSI 25(3) 8(1) 0 0 7(1) 9(1) 0
MSI -  Microsatellite instability
Table 4.8: Summary o f findings o f  colony LOH analysis, using a cut o ff o f 70%.
The hypothesis was that the LOH identified in DNA from the original benign and 
malignant tissue from each prostate would be present in the colonies grown from 
adjacent tissue, thus distinguishing those benign colonies contaminating the 
population o f cancer colonies. Figure 4.4 and table 4.7 demonstrate that this is 
not the case. A far greater variety o f allele lengths and loss was seen in both the 
presumed benign and presumed cancer colonies than seen in the original prostate 
tissue.
LOH was present frequently in the colonies. As expected, because the source o f 
the DNA was from a purer, clonally derived population o f cells, the signal from 
the lost allele was very weak if not absent compared to the signal from the 
retained allele, giving definitive LOH appearances and very high percentage 
losses. However, LOH was seen not only in the presumed malignant colonies,
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but also in the benign ones. Furthermore, even where a colony demonstrated 
LOH, this was sometimes due to loss o f  the other allele than the one lost by the 
original cancer. A summary o f  the frequency o f each o f these outcomes is given 
in table 4.8. For individual benign colonies, between 50 and 100% o f them had a 
normal genotype to match the original sample, but from 0 - 43% had LOH. For 
the cancer colonies, 0-50% had the same LOH pattern as the wholemount 
tumour, but 25-86% had a normal genotype and 0-36% showed another LOH 
pattern again. There was a higher number o f  cancer colonies with a normal 
phenotype at those loci where LOH in the original block was close to the cut o ff 
e.g. D17S855 had 51% allele loss and 86% ‘normal’ cancer colonies. Thus these 
loci may not in fact have been mutated in the original cancer, and benign 
colonies would be expected.
MSI was also seen in the colony DNA. Here both alleles were present, but one 
differed in length by up to 14 extra base pairs or by a loss o f up to 4 base pairs 
compared to the original DNA. There was also evidence o f duplication o f  some 
alleles with a third allele with a different length being present alongside both 
expected alleles. The electropherogram for the cancer colony C4 in figure 4.4 
demonstrates this phenomenon with three peaks suggesting three alleles 177, 183 
and 187 base pairs in length.
There was little internal consistency for colonies analysed at even only two loci, 
with a presumed benign or cancer colony demonstrating a normal genotype at 
one locus and LOH at the other. Only a minority o f  colonies matched the 
genotype o f the original tissue for the two loci screened making them candidate 
confirmed benign and malignant colonies. Nor did the incidence o f abnormality 
seem greater in the cancer colonies than the benign as might have been expected 
given that the real concern was that benign cells would contaminate cancer 
tissue, while truly benign tissue is easier to select. Given the large numbers o f 
benign colonies that apparently harbour genetic alterations, and o f cancer 
colonies that lack them, it would be necessary to screen these candidate colonies 
at a number o f other loci before being confident o f  their pedigree. O f course, 
with the low rate o f LOH in the original cancer, there are limited numbers o f  loci 
to use.
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Such extreme apparent variation in the genotype o f these colonies compared to 
the original prostate tissue sample rendered LOH analysis unusable as a means o f 
classifying colonies. This may be the result o f  a number o f factors. Inevitably, 
the tissue used to grow colonies, cannot be submitted for LOH analysis and vice 
versa. Though both were adjacent in the original prostate, the cultured tissue may 
have differed from the analysed tissue. Thus a different cancer with a different 
genotype could have been grown to that analysed for LOH. Equally two colonies 
with different genotypes could have grown on top o f each other, appearing 
macroscopically as one colony, while its DNA was a mixture. This might 
account for the presence o f  two alleles in a cancer colony, but not for some o f  the 
other genotypes encountered.
Obtaining these results due to culture artefacts also seems unlikely. This extent 
o f genetic variation might imply a high degree o f genetic instability and 
acquisition o f  mutations as each cell rapidly clonally expanded during the weeks 
in culture before and after ring cloning. The development o f LOH and MSI in the 
benign colonies would alter their two allele appearance, while development o f 
MSI in cancer colonies, would cause the remaining allele to show heterogeneous 
allele lengths again. In reality, even if these cells were this unstable, the 
likelihood o f so many colonies mutating at these specific loci is minimal. Indeed, 
the entire basis o f  tissue culture and the use o f cell lines relies on their genetic 
stability in long term culture. Despite multiple passages, the cell lines established 
by Bright et al have retained their distinctive LOH pattern. One study evaluated 
changes in the restriction fragment length polymorphism patterns o f four 
leukemic cell lines in culture at monthly intervals for a year (Parson et al, 2005). 
Two developed changes between the second and third month due to the 
emergence o f  heterogeneous subclones. However this is still far longer in culture 
than the few weeks spent by the colonies, and these cancer cell lines, with known 
mutations in mismatch repair genes would be expected to be more unstable than 
some benign prostate epithelium.
Although it is probable that the colony DNA is minutely contaminated with 
mouse DNA from their necessary growth on a feeder layer, the surviving feeder
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cells were rinsed o ff  prior to colony harvesting and all LOH analysis primers 
were blasted to confirm their specificity for human DNA. Also the mouse alleles 
for any locus would have to correlate closely in length.
Two plausible explanations remain to account for these findings: DNA artefact, 
and the selection by culture o f  individual mutation bearing cells not identified 
when the tissue as a whole is analysed for LOH or histologically.
The impact o f  experimental artefact on these results cannot be quantified, but 
could potentially be significant. Throughout these experiments the total amount 
o f DNA available for analysis amounted to a few micrograms only. Original 
prostate DNA was paraffin embedded and stained, and some colonies were 
scraped o ff  the culture flask so DNA quality might have been affected. Longer 
nucleotide products were harder to obtain results from and required a number o f  
repeated reactions. The majority o f  experiments were performed once if  a result 
was obtained first time. However, often an electropherogram was too weak to be 
interpreted so the concentration o f  PCR product was increased and the sample 
run again. If  this did not yield a meaningful result, the PCR was repeated. For 
both the original and colony DNA confirmatory repeat LOH analysis would have 
been desirable, though DNA quantities would limit the number o f  loci re­
screened.
Work by Seiben et al (2000) suggests that the amount o f  DNA used in the initial 
PCR reaction is critically related to the incidence o f  artefactual LOH or MSI. 
Mispriming during the PCR reaction especially in an early amplification cycle 
can result in incomplete, additional or entire non-amplification o f  alleles.
Fixation and staining causes DNA fragmentation, which reduces the efficiency o f  
the PCR. In addition, microsatellite DNA regions are already prone to erroneous 
transcription due to polymerase slippage on the repeat regions and misannealing 
and hairpin formation especially in CG rich sequences (Diaz-Cano, 2001). 
Plentiful DNA minimises the impact o f  these errors on the final outcome.
Seiben et al (2000) found that the incidence o f  artefactual LOH in 12pl PCR 
reactions containing 0.05ng o f  tem plate DNA was 17.5% while this dropped to
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3.2% for 5ng and 0.7% for lOng. Artefactual MSI was seen in 16.5% o f 0.05ng 
DNA reactions, but was absent when 5ng or lOng was used. They found that 
LOH artefact rates were higher in fixed tissue, and MSI rates higher when longer 
fragments were being amplified (3.2% if <120 base pairs, 7.7% if >190 base 
pairs). A specific artefact was never reproduced in a second PCR reaction, 
though on occasion a different LOH artefact was seen. The authors 
recommended a minimum amount o f  5ng o f fresh tissue DNA or lOng o f 
archival tissue DNA be used in PCR reactions when investigating LOH. They 
commented that as quantification o f  DNA prior to LOH analysis is not routinely 
performed, so PCR artefact may be responsible for a proportion o f  the LOH and 
MSI reported in the literature, and may explain conflicting studies.
In this project, the colonies from the first two prostates were fixed and stained 
before being scraped o ff the plastic dish with a scalpel for DNA. Subsequent 
colonies were harvested fresh and also ring cloned with DNA obtained at first 
passage. The DNA from the first two prostates was extracted using the small cell 
sample method (see Methods, section 2.9), which yielded 50pl o f  template DNA 
solution. Subsequent samples were processed through a column with a final 
volume o f  160pl. Because o f  limited DNA samples, early PCRs used 1.5pl o f 
template, and later ones 2.5pl. DNA concentrations were not measured at the 
time o f analysis, as their dilution meant that an optical density could not be 
obtained without committing large volumes o f  DNA solution to the analysis. 
Retrospective analysis o f  DNA quantities showed that colony DNA extracted 
from a single fresh type II colony had a mean concentration o f 226ng/pl 
(standard deviation 39ng/pl) while ring cloned colony DNA had a mean DNA 
concentration o f 223ng/pl (standard deviation 51ng/pl), which would have 
resulted in template quantities in the PCR well above the lOng recommended by 
Seiben et al. However for prostates #1 and #2, insufficient volumes o f DNA 
solution remained to permit analysis. It may be relevant that greater variations in 
results were seen in these early prostates than later ones.
DNA artefact may then underlie some o f the results, but perhaps not all. An 
alternative explanation, assuming they withstood confirmatory repeat analyses is 
that the genetic make up o f the individual cells that emerged in culture is far
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more varied than that demonstrated by the tissue as a whole. The histological 
classification o f the formalin fixed prostate specimen is based on its low power 
architecture (Gleason and Mellinger, 1974). Thus the histological diagnosis o f  an 
area o f prostate tissue is based on its overall appearance, just as its genotype (as 
established by LOH analysis) is based on the overall LOH patterns within the 
cells contributing DNA. A small area o f cancer though present, would be 
obscured by more predominant benign tissue. In contrast, the colony DNA 
submitted to LOH analysis reflects the genotype o f  a single cell within the 
prostate. A single malignant cell will not be recognised histologically, but might 
grow into a colony. This also applies to cells with proliferative inflammatory 
atrophy, atypical adenomatous hyperplasia or HGPIN. It is possible that the 
variety o f colony genotypes encountered in this prostate tissue from a man in his 
sixties reflects the variety o f cell genotypes within it.
It would be expected that as these genotypes should be present in the same 
proportions as in the original tissue, the majority o f  colonies from a grossly 
benign looking area o f  prostate tissue should have predominately matching 
benign genotypes. The fact that they seem not to may suggest that the culture 
conditions are selecting for this population o f more genetically variable cells, 
which perhaps possess growth advantages conferred by these very mutations. 
That a mutation at this particular microsatellite locus carries with it a growth 
advantage is not implausible as the loci screened for were initially identified as 
lost in prostate cancer. These type II colonies arise once in approximately every 
2000 cells plated (see table 4.4) so while the genetic instability they apparently 
possess may be rare in a largely benign area o f prostate tissue, so are they.
In fact, the genotype o f primary colonies derived from both benign and 
malignant prostate epithelium has not been previously reported. A similar study 
in breast tissue, another hormonally responsive, glandular tissue prone to 
malignancy has though. Lakhani et al studied colonies o f 1000-5000 cells 
derived from ‘normal’ breast tissue adjacent to breast cancers and from non- 
cancerous breasts, performing LOH analysis at seven microsatellite markers 
(Lakhani et al, 1999). Normal cells showed allelic imbalance in five out o f ten 
breast cancer cases and one o f  three breast reduction specimens free o f cancer.
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They argued against a culture artefact, as the LOH patterns seen were plausible, 
as they were also present in the cancers and concluded that the extent o f genetic 
alteration in ‘normal’ tissue was likely to be underestimated.
Cancer arises through a series o f  mutations, and losses o f DNA are five times 
more common than gains in primary prostate cancer, so microscopically benign 
areas may harbour LOH, especially in cancer prone peripheral zone tissue 
(Hanahan and Weinberg, 2000; Visakorpi et al, 1995). Bright et al (1997) also 
identified LOH in the benign cell lines from one patient. Numerous studies attest 
to the presence o f a far greater degree o f  genetic variation in the prostate than 
currently envisaged. Though none have focused on the progeny o f a single cell, 
the majority o f investigators used laser capture microdissection to study small 
areas o f HGPIN, other histological prostate entities and cancer. Regrettably few 
have similarly analysed adjacent benign tissue or BPH and indeed this tissue is 
sometimes used as a control.
A group under Schalken assessed allelic imbalance at 33 loci in laser 
microdissected HGPIN, and paraffin sections o f  different cancers and different 
areas within the same cancer o f 17 radical prostatectomy specimens (Ruijter et 
al, 1999). Using a benign area o f tissue as a control, they identified common 
patterns o f allele loss in some distinct tumours, but also as much disagreement 
between different loci and within different areas o f  ostensibly the same tumour. 
Also small or low grade tumours and HGPIN showed considerable allelic 
imbalance. The overall picture was complex with evidence for clonal tumour 
spread in some areas that was lacking in other areas within even the same cancer. 
Their conclusion that further study o f  numerous samples at numerous loci was 
required appears correct. Had they assessed benign tissue against a germ line 
control such as peripheral blood lymphocytes, they might have identified an even 
more complex picture.
Other authors have studied the relative allelic imbalance in cancer, HGPIN, 
atypical adenomatous hyperplasia and occasionally benign tissue. Bostwick and 
colleagues (1998) found similar incidences o f allelic imbalance in microdissected 
samples o f HGPIN and cancer (65% and 82% respectively) at six microsatellite
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loci, with evidence o f  clonal progression from one to the other. The same group 
studied atypical adenomatous hyperplasia and found allelic imbalance in 47% o f 
15 lesions, at five loci implicated in prostate carcinogenesis (Cheng et al, 1998). 
Another study also included this in their panel o f  samples, and notably evaluated 
adjacent benign prostate tissue as well (Bettendorf et al, 2005). Allelic imbalance 
at ten loci was identified in 64% o f  14 cancer samples, and 55% o f nine HGPIN 
^samples. Only two o f  ten atypical adenomatous hyperplasia samples showed 
allelic imbalance, but interestingly 50% o f  14 samples o f non-neoplastic tissue 
adjacent to cancer foci showed allelic imbalance.
So at the individual cellular level, there may be more genotypic variation than 
previously thought, especially in a prostate that already contains some cancer. 
Though the extreme variations seen in the colonies are surprising, if all the 
different traces were taken together, both alleles would be well represented and 
the overall appearance would be one o f  heterozygosity as was encountered in the 
original prostate tissue.
There is no doubt that the possibilities raised by this small sample o f colonies 
and prostates needs confirmation by a sim ilar study repeated in duplicate at least, 
and on a larger scale. Parallel analysis o f  cancerous, benign and hyperplastic 
tissue derived prostate epithelial cell colonies alongside laser capture 
microdissected areas o f  the source prostate would allow mapping o f  the genotype 
o f the prostate, and possibly matching o f  colony genotype to histologically 
defined lesions. It would be interesting to know whether the variety o f  genotypes 
in colonies derived from BPH or from younger men (usually cadaveric donors) 
conformed better to the ‘norm al’.
Such wholesale LOH analysis o f  so many samples was extremely laborious. 
However, high-throughput autom ated techniques have recently emerged in this 
arena. The Affymetrix Chrom osom e Copy Number Analysis software can 
analyse high-density single nuclear polymorphism oligonucleotide arrays to 
identify loss o f heterozygosity and chromosomal gains and losses at loci across 
the whole genome in a m atter o f  hours (Affymetrix UK Ltd, High Wycombe,
UK; Zhao et al, 2004; Torring et al, 2007). Such techniques would provide an
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unequalled view o f  the genotypes o f  these colonies and where they stand against 
the genotypes found in the prostate itself.
4.6 Differentiating between benign and malignant colonies using 
expression levels o f genes upregulated in prostate cancer.
Colonies were also assessed for phenotypic differences. The mRNA levels o f 
four genes that have been reported as being over-expressed in prostate cancer 
were assessed using semi-quantitative RT-PCR o f colony total RNA. The four 
genes used were hepsin, AM ACR, EZH2 and PIM1 with GAPDH as a control 
(see appendix 2 for PCR primer sequences).
Hepsin is a cell-surface serine protease that was found to be upregulated 4.3-fold 
in prostate cancer by microarray, 11.3-fold by northern analysis, and which was 
predominately expressed in HGPIN and hormone sensitive prostate cancer on 
tissue microarrays (Dhanasekaran et a l, 2001). Pim-1 is a proto-oncogene which 
expresses a serine/threonine kinase. On tissue microarrays, it is absent or weakly 
staining in 97% o f benign prostate samples, while being moderately or strongly 
present in about half o f  the prostate cancer samples (Dhanasekaran et al, 2001). 
The polycomb group protein enhancer o f  zeste homolog 2 (EZH2) appears to 
have a role in mediating cell proliferation and transcriptional repression in 
prostate cells (Varambally et al, 2002). It is significantly over-expressed in 
prostate cancer compared to benign prostate both on DNA microarrays, RT-PCR 
and tissue microarrays, where respective median staining intensity is 1.5 (95% 
confidence interval (Cl) 1.4-1.6) for benign tissue, and 2.6 (Cl 2.5-2.7) for 
localised cancer. AM ACR has also been shown to be significantly upregulated in 
prostate cancer on DNA microarrays, RT-PCR, western blotting and tissue 
microarrays, where mean protein staining in benign tissue was 1.31 (Cl 1.23- 
1.40) and in malignant samples was 3.20 (Cl 3.10-3.28) (Rubin et al, 2002).
Used diagnostically in prostate biopsy needle samples, it is 97% sensitive and 
100% specific for detecting prostate cancer (Rubin et al, 2002).
Three prostates yielded colonies from which RNA was isolated: three colonies 
were analysed from prostate 12, 37 colonies from prostate 14 and 29 from
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prostate 15. The RT-PCR products were visualised using gel electrophoresis and 
the relative measured intensities (in terms o f  highest intensity and total amount o f 
fluorescence normalised for GAPDH intensity) o f the benign colony bands were 
compared to the malignant colony bands using the Student’s t test (see figure 
4.5). Hepsin PCR yielded minimal product across all samples so was not 
analysed further.
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Prostate Gene Colony 
(available source
colonies)_______________________
Mean peak
intensity,
(significance)
#12 AMACR Benign
(1 benign, Cancer
2 cancer) EZH2 Benign
Cancer
P1M1 Benign
Cancer
GAPDH Benign
Cancer
#14 AMACR Benign
(17 benign, Cancer
20 cancer) EZH2 Benign
Cancer
PIM1 Benign
Cancer
GAPDH Benign
Cancer
#15 AMACR Benign
(14 benign, Cancer
15 cancer) EZH2 Benign
Cancer
PIM1 Benign
Cancer
GAPDH Benign
Cancer
95.2
94.0 (p=0.96)
44.4
76.2 (p=0.01)
10.0
12.6 (p=0.57)
45.5
47.9 (p=0.27)
57.0
50.7 (p-0.49)
61.5
43.1 (p=0.12)
18.1
14.5 (p=0.45)
58.9
52.0 (p=0.94)
Figure 4.5: RT-PCR of total RNA from presumed benign and malignant colonies from three prostates was performed for 3 genes AMACR, 
EZH2 and PIM1 reported as being upregulated in prostate cancer, and for GAPDH. Significance assessed by student’s t-test.
Both visually and statistically there was no difference in intensities between the 
RT-PCR products o f  the presumed benign/cancer colony types for the three 
prostates, with the exception o f  EZH2 for prostate #14. In prostate #15, while 
EZH2 appears to be approaching significance, in fact average expression in the 
benign colonies is greater than in the cancer colonies, thus the change in 
expression levels is contrary to that expected.
The studies that highlighted these genes as molecular discriminators between 
benign and malignant tissue used prostate cancer cell lines D U -145, LN-CAP 
and PC3 as well as fresh and archival tissue (Dhanasekaran et al, 2001; 
Varambally et al, 2002). All three markers are expressed in cell lines, and there 
is evidence that AM ACR is expressed in primary prostate epithelial cell cultures 
(Maria McCrohan et al, 2006; Varambally et al, 2002; Kim O et al, 2004).
The lack o f difference between the presumed benign and presumed cancer 
colonies would suggest that both ‘benign’ and ‘cancer’ tissue samples that were 
cultured may have contained a mixture o f  colonies. Alternatively, these markers 
were defined by their upregulation in ‘w hole’ cancers, and their normal 
expression in these early epithelial cells in culture is unreported and may be 
heterogeneous in its own right. RT-PCR and immunohistochemistry o f  TURP 
tissue derived colonies as a representative source o f benign DNA would be 
interesting. For instances where signal is similar between colonies, it may be that 
the RTPCR reaction for one sample reached its plateau phase and amplification 
ceased sooner that in another less abundant sample, which then ‘caught up’ with 
it. Real-time RTPCR allows quantification o f  PCR product during the 
exponential amplification phase o f  the reaction and is more accurate, though still 
may not have altered the conclusion here (Gilliland et al, 1990).
While care was taken to select those markers well established as differentially 
expressed in prostate cancer compared to benign tissue, no marker exists that 
demonstrates a true on/off expression in the benign/malignant state. Accordingly, 
it is possible that the cancers grown here were o f  the 50% that do not express 
PIM-1. However this would apply to all the cancer colonies grown from the same 
cancer, so homogeneity o f  expression (be it absent or present) would be
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expected. Such a debate could be answered by immunohistochemistry o f the 
paraffin embedded prostate for this marker, but would not assist in the 
interpretation o f the RT-PCR here. Other markers also exist. p63 has been 
described as being absent in prostate cancer by immunohistochemistry, and in 
vitro it is not expressed by the prostate cancer cell lines LNCaP, DU145 and PC3 
but is present in 80% o f  cells from the normal basal prostate epithelial cell line 
PrEC (Signoretti et al, 2000). Claudin-1, a tight junction protein, and annexin II, 
a calcium and phospholipid binding protein also predominately stain benign but 
not malignant glands in immunohistochemistry studies (Krajewska et al, 2007; 
Stewart et al, 2007).
4.7 Discussion
This study has demonstrated that when benign and malignant areas o f peripheral 
zone prostate tissue are sampled, processed into a single cell suspension and 
cultured for two weeks, both yield distinguishable type I and type II colonies. 
Comparisons o f colony incidence and morphology identified no differences 
between colonies from benign and malignant tissue, nor between these and those 
derived from BPH tissue.
It proved impossible in this project to confidently identify benign and malignant 
colonies using differences in genotype detected using LOH analysis, or in 
phenotype using semi-quantitative RT-PCR. Therefore, the characteristics o f 
malignant and benign peripheral zone type I and type II colonies remain 
unknown. Indeed, while it is likely that benign colonies were grown, it is not 
proven that any malignant colonies were grown.
Culture o f primary prostate epithelial cells is difficult; both due to the inherent 
risk o f contamination during tissue selection, and in this project the need for 
reasonable quantities o f corresponding benign and malignant colonies for 
downstream applications. Even for those prostates that were successfully 
cultured, there was a low incidence o f  LOH identified, despite extensive 
screening o f relevant loci. Small DNA amounts and an unexpected variability in 
the genotypes o f  those colonies grown further confounded matters. The
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hypothesis that LOH analysis would cleanly segregate cancer colonies from 
benign ones by matching the genotype o f  the parent cancer was disproved.
Semi-quantitative RT-PCR o f  early prostate cancer markers also failed to 
discriminate benign from malignant prostates, possibly due to baseline variability 
o f expression, mixed benign/malignant colonies or insufficiently discriminatory 
markers.
The inherent difficulty o f distinguishing benign from malignant prostate tissue 
both in the freshly cut specimen and in culture has been noted by others. Rose et 
al (2005) compared primary cultures (in serum free, low calcium medium) o f  six 
benign and six >90% malignant prostate samples using DNA microarray, real­
time RTPCR and immunoblot techniques and found no gene or protein that was 
consistently over-expressed in all the cancer versus BPH cell cultures. In the 
absence o f a specific biochemical or cell surface marker, in vitro behavioral 
properties have traditionally been evaluated. Cultured tumour cells may differ 
from their benign counterparts in a num ber o f ways. These are listed by R Ian 
Freshney (2002b):
1. Aneuploidy revealed by conventional karyotyping or specific molecular 
probes.
2. Heteroploidy with different karyotypes found within the cell population.
3. Loss o f contact inhibition at confluence with disorderly cell migration.
4. Loss o f  density limitation at confluence with continued proliferation.
5. Anchorage independence with greater colony formation in soft agar 
suspension.
6. Higher proteolytic activity.
7. Promotion o f angiogenesis.
8. Invasiveness
9. Tumourigenesis in experimental hosts.
He does however note that freshly explanted tumour cells at early-passage need 
not express all these characteristics, and that as few are diagnostic alone several 
must be demonstrated before declaring malignancy. In fact, transplantation o f
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primary prostate cancer tissue into nude mice results in very infrequent tumour 
formation and prostate cancer does not differ from benign tissue in its response 
to stimulatory and inhibitory factors (Schroeder et al, 1976; Peehl et al, 1989). 
For prostate cell culture in general, and this study in particular, many o f these 
characteristics are untestable. In this study, the difficulties encountered in 
primary cell culture and the number o f  individual colonies requiring assessment 
also precluded comparison o f  some o f  the above characteristics.
Cytology is often used to diagnose cancer, however microscopy o f the colony 
cells after ring cloning did not demonstrate sufficient differences in cell size or 
nuclear-cytoplasmic ratio to allow distinction. Indeed, the ‘virtually normal 
appearance o f the individual cells’ in cytological preparations o f  cancers derived 
from prostatectomy samples has long been noted (Mason, 1964).
In practice, a number o f  assays have emerged as useful discriminators. In a 
recent study with far reaching implications, Dalyrymple et al (2005) 
demonstrated that culturing primary malignant prostate tissue in low-calcium 
medium (defined as <260 pmol/L) selected for benign cells. Serum-free culture 
media are favoured for prostate tissue as serum contains undefined factors that 
are difficult to standardize for, and promotes the growth o f stromal cells. Both 
PrEGM and keratinocyte serum-free medium (K-SFM) complete medium 
(Invitrogen, Carlsbad, CA, USA) are commonly used in studies on benign and 
malignant tissue, and contain low total calcium levels o f  260 ± 14 pmol/L and 75 
± 2 pmol/L respectively. In contrast, all currently available prostate cancer cell 
lines, whether established from early cancers or bone metastases require 10% 
foetal calf serum supplemented media with calcium levels between 650 and 
1,860 pmoI/L. These cell lines demonstrate karyotypic abnormalities, are 
spontaneously immortal and able to undergo numerous serial passages, and form 
tumours when inoculated into mice. Tumours are also expected to demonstrate 
similar marker expression and LOH patterns to the cancer o f origin.
Dalyrymple et al (2005) examined these attributes in cell cultures derived from 
prostate cancer specimens in PrEGM and compared them to cancer cell lines and 
commercially available PrEC benign cells (see section 1.6). Their markers
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matched those o f  the benign cells, for instance, they were AMACR- like PrEC 
cells while all cancer cell lines are AM ACR+. Nor did these cultures progress in 
culture past 8 - 1 0  passages, or form tumours in mice over 6 months. 
Interestingly, when stromal cells and all the cancer cell lines are grown in 
supplemented but low-calcium medium they die within 3 passages. Conversely, 
PrEC cells undergo growth arrest when the calcium concentration in their 
medium is increased to 650 pmol/L.
This raises uncertainty about studies performed on putative cancer cells 
maintained in low-calcium medium. The comparison study by Rose et al (2005) 
described above used this, and could detect no reliable differences. A study o f 
karyotype analysis in two to seven day cultures o f  102 primary prostate cancers 
was performed by Konig and colleagues (1998). They assayed three different 
culture conditions for their cells, concluding that the one that excluded serum 
generated the most cultures. However analysis o f  the metaphase spreads showed 
that most cells had normal karyotypes and it was concluded that the culture 
conditions favoured diploid cells. The authors felt that karyotype analyses such 
as comparative genomic hybridisation that did not require a period in cell culture 
would have more relevance to the study o f  cancer genotypes.
In most studies, the malignant nature o f  the cells obtained is assumed, or at best 
compared to established prostate cancer cell lines (Hall et al, 2002; Bright RK et 
al, 1997; Maria McCrohan et al, 2006; Peehl DM et al, 1989; Rose et al, 2005; 
Collins et al, 2005). In most studies, pathologists dissect out fresh prostate cancer 
tissue as described by W heeler and Lebovitz (1994), with histology o f adjacent 
tissue on all sides confirming 70-90% cancer tissue and by definition 10-30% 
other types o f cells. Improved accuracy has been reported using an operating 
microscope and staining the cut prostate surface with 0.5% aqueous toluidine 
blue (Fischer et al, 2001).
Collins et al (2005) did attempt to confirm the malignant pedigree o f cells 
derived from radical prostatectomy specimens using growth in semisolid media, 
and invasion assay and LOH analysis. Demonstration o f anchorage independent 
growth has long been used to discriminate between benign and malignant cells
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(Sanders and Burford, 1964). Whereas most freshly isolated normal cells grow 
poorly in semisolid agar gel suspension, malignant cells are able to proliferate. 
Benign prostate cells do not form colonies in soft agar (Sinisi et al, 2002). 
Similarly, differences in growth and invasion were identified between primary 
benign and malignant prostate cells co-cultured with primary benign prostate 
stromal cells in a three-dimensional collagen gel (Hall et al, 2002). Collins and 
colleagues’ (2005) cancer derived cells migrated through Matrigel coated filters 
towards a chemoattractant medium, and grew in semisolid methylcellulose and 
while prostate cancer cell lines were used as a positive control, but there were no 
benign negative controls. These cells achieved longevity in culture, which was 
on-going at the time o f publication. Their LOH analysis was unable to 
unequivocally confirm the tumor cell origin o f  the cultured cells. Thus using the 
criteria o f Dalyrymple et al (2005) only the increased proliferative ability o f  the 
‘cancer’ cells (greater than a benign control) would concur with a malignant 
phenotype. Collins et al (2005) stopped short o f in vivo tumourigenic assays, and 
might also have screened for cancer markers such as AM ACR or p63. Litvinov et 
al, (2006) described their findings as ‘intriguing’ but demanded these assays to 
exclude selection o f benign cells.
Finally at least one report exists o f the development o f  a pair o f hTERT- 
immortalized primary non-malignant and malignant human prostate epithelial 
cell lines from primary cultures that demonstrate appropriate malignant 
characteristics, despite being raised in low-calcium medium (Gu et al, 2006). 
Transformed cell lines may therefore differ from cancers that arise 
spontaneously. Certainly it is now mandatory that researchers confirm the 
malignant behaviour o f the cells that emerge from cancer tissue culture.
The colonies in this project were cultured in low-calcium medium. While it is 
likely that cancer cells were present in the epithelial cell suspension plated, the 
malignant nature o f the colonies obtained was not demonstrated using criteria 
suggested by Dalyrymple et al (2005). It was assumed that cancerous cells would 
grow well in the same culture conditions established for benign epithelial cells by 
Peehl and Stamey (1986) and demonstrated to successfully yield benign 
epithelial colonies by Hudson et al (2000). It was also assumed that these
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colonies would look similar, and recognisable as prostate epithelium. Neither 
assumption is unreasonable as Bright et al (1997) reported no difference in 
morphology o f their paired cell lines confirmed using LOH analysis and Peehl 
(2002) reports that ‘no special techniques are required to culture tumor cells. 
Normal, BPH, and malignant tissues all yield finite cell lines with similar 
efficiencies (approaching 90% in our laboratory with tissues derived from radical 
prostatectomies)’. However these cells have a finite lifespan in vitro and she does 
acknowledge that as chromosomal abnormalities in primary cancer cultures are 
difficult to detect it is quite possible that current culture conditions do not 
support the survival o f the most genetically aberrant cancer cells in vitro (Peehl, 
2005).
It is notable that in this study there was no difference in the colony characteristics 
derived from benign and cancer tissues (see table 4.4), which could be 
interpreted as implying that all the colonies were benign. When Liu and Peehl 
(2001) compared the expression profiles o f  over 110 cluster designation cell 
markers between primary and malignant cells cultured in low-calcium medium 
they also found that these were ‘notably sim ilar’.
4.8 Future directions
The effect o f calcium on the selective culture o f  benign or malignant prostate 
cells opens up some intriguing possibilities. Comparing cells in different culture 
media becomes difficult, as too many variables are present. However, the 
outcomes o f benign and cancer tissue culture in terms o f colony morphology and 
yield in the presence o f high calcium medium would be o f great interest. 
However, it would be important to exclude as many stromal cells as possible 
during processing to prevent overgrowth in culture. Any colonies obtained would 
have to be assessed for malignant features, and alongside LOH and real-time 
PCR, some colony cells could be dedicated to invasion, soft agar and in vivo 
tumourigenesis assays. With confirmed malignant and benign colonies, their 
interrogation for clinically relevant genes could commence.
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CHAPTER 5: CONCLUSIONS
Though recent advances in the detection and management o f prostate cancer have 
brought about a downward stage migration in the incidence o f the disease, prostate 
cancer remains the fourth commonest cancer in the UK, representing 12% o f  cancer 
diagnoses and 7% o f  cancer deaths in 2004 (Tarone et al, 2000; 
http://info.cancerresearchuk.org/cancerstats). Despite advances in systemic therapies, 
once prostate cancer has spread beyond the prostate it is incurable (Kipp and 
McNeel, 2007; Arianayagam et al, 2007).
Research into effective therapies continues apace, and the study o f prostate stem 
cells is still in its infancy. The theoretical basis behind the stem cell theory o f cancer 
is robust and represents a novel approach to treating cancer, which might succeed 
where others have failed. Stem cell biology is a major focus o f  research in many 
fields and a remarkable similarity in stem cell markers is emerging across different 
tissues. Other recurring themes include the stem cell niche, common signal 
transduction pathways and the inherent drug resistance conferred by drug efflux 
transporter pumps and anti-apoptotic proteins (Pan et al, 2006; Massard et al, 2006). 
Thus a treatment that proves its effectiveness in one cancer may have a broader 
applicability to many others. Though no anti-stem cell treatment exists as yet, the 
full potential o f stem cell targeted therapies remains unrealised.
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A p p e n d ix  A : Consent forms and Patient Inform ation Sheets
CONFIDENTIAL
Patient Information Sheet
Prostate Cancer Stem Cell Project
Prostate Cancer Research Unit, 
 
Institute of Urology & Nephrology, 
University College London,
Investigators:
Prof J R W Masters BSc PhD FRCPath 
Professor of Experimental Pathology
Miss C L Foley BM BCh MA MRCS 
Clinical Research Fellow
Dear Sir
Please could you help us with a research project. It will not affect your treatment in any way 
and we do not need you to do anything other than give us permission. We would like to have 
some of the prostate tissue that is taken at your operation.
We are studying the cells we think are responsible for prostate cancer. We call them cancer 
stem cells and we believe that they are derived from normal prostate stem cells. We want to 
select a small amount of the prostate tissue taken at your operation and grow the cells in the 
laboratory. Growing and investigating stem cells will help us understand how and why 
prostate cancer develops. We hope that eventually this will lead to new and better 
treatments for prostate cancer.
If you are willing, after your operation we will take the tissue that has been removed from 
your body and select a small amount to take to the laboratory. This will not affect your 
operation in any way, or your treatment. In order to protect confidentiality, no record will be 
kept of your name or other clinical details.
It is possible that some of your cells will be stored for future research beyond the confines of 
this project (if you agree to this). This future research may be carried out by different 
scientists or involve genetic analysis. This will have no repercussions to yourself.
You do not have to take part in this study if you do not want to. If you decide to take part you 
may withdraw at any time without having to give a reason. Your decision whether to take 
part or not will not affect your care and management in any way.
All proposals for research using human subjects are reviewed by an ethics committee before 
they can proceed. This proposal was reviewed by the Joint UCL/UCLH Committees on the 
Ethics of Human Research and the London Clinic Ethical Committee.
Please keep this information sheet. A consent form is attached for you to sign if you are 
willing to help us in this research. I (Charlotte Foley or John Masters) will be coming to see 
you and you can ask us any questions you want.
Charlotte L Foley , John R Masters.........................................................................................
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CONFIDENTIAL
Patient Consent Form
Prostate Cancer Stem Cell Project
Prostate Cancer Research Unit,
Institute of Urology & Nephrology, University 
College London,
Investigators:
Prof J.R W Masters BSc PhD FRCPath 
Professor of Experimental Pathology
Miss C L Foley BM BCh MA MRCS 
Clinical Research Fellow
Dear Sir
Thank you for reading the information about our research project. If you would like to take 
part, please read, place your initials in the boxes and sign this form.
□
□
□
□
□
□
□
1. I have read the attached information sheet on this project (dated 5th February 2002, version 3) 
and have been given a copy to keep. I have been able to ask questions about the project and I 
understand why this research is being done and any risks involved.
2. I agree to give a sample of prostate tissue for research in this project. I understand that giving a 
sample for this research is voluntary and that I am free to withdraw my approval for use of the 
sample at any time without giving a reason and without my medical treatment or legal rights 
being affected.
3. I give permission for someone from the research team to look at my medical records to get 
information on the histopathological findings following examination of the whole prostate 
specimen. I understand that this information will be kept confidential.
4. I understand that I will not benefit financially if this research leads to the development of a new 
treatment or medical test.
5. I know how to contact the research team if I need to.
6. I agree that the sample I have given and the information gathered about me can be stored 
by the Prostate Cancer Research Unit at the Institute of Urology & Nephrology, University 
College London, for possible use in future projects. I understand that some of these projects 
may be carried out by researches other than those who ran the first project.
7. I understand that the project using the sample that I give may include genetic research 
aimed at understanding the genetic influences on prostate cancer, but that the results of 
these investigations are unlikely to have any implications for me personally.
Name (Block capitals) Date Signature
Date of Birth Hospital number
Name of researcher Date Signature
Thank you for agreeing to take part in this research 5thFeb2002: Version 3
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CONFIDENTIAL
Patient Information Sheet
Prostate Stem Cell Project
Investigators:
Prostate Research Unit,
 
Institute of Urology & Nephrology, 
University College London,
Prof J R W Masters BSc PhD FRCPath 
Professor of Experimental Pathology
Miss C L Foley BM BCh MA MRCS 
Clinical Research Fellow
Dr. I. N. Bisson PhD
Post-doctoral Researcher
Dear Sir
Please could you help us with a research project? It will not affect your treatment in any way 
and we do not need you to do anything other than give us permission. We would like to have 
some of the prostate tissue that is taken at your operation.
We are studying the cells we think are responsible for growth within the prostate which we 
call prostate stem cells. We want to select a small amount of the prostate tissue taken at 
your operation and grow the cells in the laboratory. Growing and investigating stem cells will 
help us understand how and why the prostate grows. We hope that eventually this will lead 
to new and better treatments for diseases of the prostate.
If you are willing, after your operation we will take the tissue that has been removed from 
your body and select a small amount to take to the laboratory. This will not affect your 
operation in any way, or your treatment. In order to protect confidentiality, no record will be 
kept of your name or other clinical details.
It is possible that some of your cells will be stored for future research beyond the confines of 
this project (if you agree to this). This future research may be carried out by different 
scientists or involve genetic analysis. This will have no repercussions to yourself.
You do not have to take part in this study if you do not want to. If you decide to take part you 
may withdraw at any time without having to give a reason. Your decision whether to take 
part or not will not affect your care and management in any way.
All proposals for research using human subjects are reviewed by an ethics committee before 
they can proceed. This proposal was reviewed by the Joint UCL/UCLH Committees on the 
Ethics of Human Research.
Please keep this information sheet. A consent form is attached for you to sign if you are 
willing to help us in this research. I (Charlotte Foley or John Masters) will be coming to see 
you and you can ask us any questions you want.
Charlotte L Foley, Isabelle Bisson, John R Masters..............................................................
219
CONFIDENTIAL
Patient Consent Form
Prostate Stem Cell Project
Prostate Research Unit,
Institute of Urology & Nephrology, University 
College London,
Investigators:
Prof J.R W Masters BSc PhD FRCPath 
Professor of Experimental Pathology 
Miss C L Foley BMBCh MA MRCS 
Clinical Research Fellow 
Dr. I. N. Bisson PhD
Post-doctoral Researcher
Dear Sir
Thank you for reading the information about our research project. If you would like to take part, please 
read, place your initials in the boxes and sign this form.
□
□
□
□
□
□
□
I have read the attached information sheet on this project (dated 20th October 2001, version 2) and 
have been given a copy to keep. I have been able to ask questions about the project and I 
understand why this research is being done and any risks involved.
I agree to give a sample of prostate tissue for research in this project. I understand that giving a 
sample for this research is voluntary and that I am free to withdraw my approval for use of the 
sample at any time without giving a reason and without my medical treatment or legal rights being 
affected.
I give permission for someone from the research team to look at my medical records to get 
information on the histopathological findings following examination of the rest of the prostate 
specimen. I understand that this information will be kept confidential.
I understand that I will not benefit financially if this research leads to the development of an new 
treatment or medical test.
I know how to contact the research team if I need to.
I agree that the sample I have given and the related histopathological information can be stored 
by the Prostate Research Unit at the Institute of Urology & Nephrology, University College 
London, for possible use in future projects. I understand that some of these projects may be 
carried out by researchers other than those who ran the first project.
I understand that the project using the sample that I give may include genetic research aimed at 
understanding the genetic influences on the prostate, but that the results of these investigations 
are unlikely to have any implications for me personally.
Name (Block capitals) Date Signature
Date of Birth Hospital number
Name of researcher Date Signature
Thank you for agreeing to take part in this research 20th0ct2001: Version 2
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A ppendix B: Sequences o f  primers for PCR for LOH and reverse-transcription PCR.
f ~  0 Chromophore Size o fLocus / Gene Sequence . r_______________________________________  marker_product*
Primers used for LOH analysis
D1S422 CATGGGGTATAGCAACAGAC
TGATTTCCTGCAAACATTTT
TET 160
DISI 58 GGGCCTTCTTATATTGCTTC
GGAAAGACTGGACCAAAGAG
TET 137-163
D1S305 CC AGNCTCGGT ATGTTTTT ACT A 
CTGAAACCTCTGTCCAAGCC
HEX 156-176
D1S414 GCACAGTTCAACATCCATT 
TCTCTGTC ATTTT AGGTCT ATTTCT
FAM 185-205
D2S222 ACAAATGCAGAAAAAGCATATG
CTGTCAGGCTGAGGAAATTT
HEX 118-138
D3S1263 CTGTTGACCCATTGATACCC 
T A A AATC AC AGC AGGGGTTC
FAM 231-249
D5S500 ACCTATTCGACCTAATGACTAAAGA 
ATCGGT G A A AT GC A ACT ACTT
HEX 188-214
D5S656 GCT AAG AAA AT ACGAC A ACT AA ATG 
CATAATAAACTGATGTTGACACAC
TET 185-203
D6S251 TTCCTAACCAGGTTTCAATG 
AT ATTTTT A A AGTAAGTTGC AC
FAM 150
D6S501 GCTGGAAACTGATAAGGGCT
GCCACCCTGGCTAAGTTACT
TET 166-182
D6S314 AAAATGACTTCTTTGGGTGGGC
GTGGGTAGCAACACTGTGGC
TET 243-259
D7S523 CTGATTCATAGCAGCACTTG
AAAACATTTCCATTACCACTG
FAM 224-240
D7S480 CTTGGGGACTGAACCATCTT 
AGCT ACC AT AGGGCTGGAGG
HEX 189-206
D8S549 AAATGAATCTCTGATTAGCCAAC 
TG AGAGCC AACCT ATTTCT ACC
FAM 166-172
D8S1991 GTGAAGGAGGGCAGTCAT
CAGGGTTGAAGCAATCTG
FAM 215
D8S136 GCCCAAAGAGGAGAATAAA 
CTGTTTCCACACCGAAGC
FAM 71-89
NEFL GCAGTAGTGCCGCAGTTTCA
TGCAATTCATCTTCCTTTCT
FAM 137-147
D8S255 TTTTGG AATTTCT AGCCTCC 
TG A AACCC AC AG AT ATTGGG
FAM 107-129
D8S133 CAGGTGGGAAAACTGAGGGA 
GTTT AGC AACTGTC AAC AT ATTGCTC
HEX 94-112
D8S137 A AAT ACCG AG ACTC AC ACT AT A 
GTTTGCTAATCAGGGAATCACCCAA
FAM 152-162
SFTP2 CAGCCCAGACAGGCTGGAA
GTTTACTTTTCTGGCCAAACTCCTG
FAM 111-157
221
D9S1748 CACCTCAGAAGTCAGTGAGT
GTGCTTGAAATACACCTTTCC
TET 130-150
D9S1679 CACCTCTGCCTGCCAA 
TGCTGTGG ACCT AAC AAAA A
FAM 135-145
D10S2491 GTT AGATAGAGTACCTGCACTC 
TT AT AAGGACTG AGTG AGGG A
HEX 130-150
D10S541 AAGC A AGTG A AGTCTT AG A ACC ACC 
CCACAAGTAACAGAAAGCCTGTCTC
FAM 272
D10S1246 CT ACGG ACTC ATTGA AGACT AGG 
AGCGTTTTCT AT AGCTCTG ACG
TET 210-234
D10S587 CCCAGATTCATGGCTTTC
TTCTGCTGACACGGGC
FAM 172-186
D10S211 CTCCTGGTCTCATGCG 
CAGGCTCCTACTACCGTC
FAM 195-211
D10S1765 AC ACTT AC AT AGTGCTTTCTGCG 
CAGCCTCCCAAAGTTGC
FAM 166
D11S903 AACACTTCGATGTTCCTTCC
AGCTGAGAGCGCATGTATAA
TET 99-109
D11S902 CCCGGCTGTGAATATACTTAATGC
CCCAACAGCAATGGGAAGTT
FAM 145-163
D11S916 CAGACTATTCTCATTGCTGC
GGACTTCTAAGCCTCCATAA
FAM 135-153
D11S990 CCTCTTATTCAGTCACAGCA
GAAATACTGTGGTGTACATC
TET 73-79
D11S2000 AGT AGAGAACAAA AC ACTGTGGC 
TTTGAAGATCTGTGAAATGTGC
TET 213
D12S89 ATTTGAGAGCAGCGTGTTTT 
CC ATT ATGGGG AGT AGGGGT
HEX 254-288
D12S1697 CATCTTGGCCCAGTCAAT
CCTTCTGTTTATAGCAATGGGA
HEX 218-234
D13S165 GTTTCGCCAAGCCTGTT
GTTGACAATAAAATACGCCACA
TET 183-195
D13S284 AAAATCAGGTGGAAACAGAAT 
A AAGGCT AAC ATCG AAGGG A
FAM 197-227
D13S171 CCTACCATTGACACTCTCAG
TAGGGCCATCCATTCT
TET 227-241
D13S269 TGTCTTCCAGCAGGGC
CAAAGTGGTTCATCTTGGTCT
FAM 116-134
D13S263 CCTGGCCTGTT AGTTTTT ATTGTT A 
CCC AGTCTTGGGT AT GTTTTT A
TET 144-160
D15S1232 CCAGAGAGATCTTTCCCCAT
TTGCTCCACTGTTTTCTCAC
TET 255-295
D16S505 GACTGTGTCTGCCCAA
TCTGCCTCCATACGTG
FAM 239-261
D16S422 C AGTGT AACCTGGGGGC 
CTTTCG ATT AGTTT AGC AG A ATG AG
HEX 188-212
D16S413 ACTCC AGCCCG AGT AA 
GGTCACAGGTGGGTTC
HEX 131-149
D17S938 CCGG ATT GCT AC ACCT A A AT HEX 164-182
222
AACAGTCTCTNCTGGAGCAG
D17S786 T ACAGGGATAGGTAGCCGAG 
GGATTTGGGCTCTTTTGTAA
FAM 135-157
D17S855 GG ATGGCCTTTT AGA A AGTGG 
AC AC AG ACTTGTCCT ACTGCC
HEX 143-155
D17S515 TT AGGCCC AGCTTCCTGGG AGA 
ACCTGGTTTG AGTT AGC AGCG AG
HEX 107-127
D18S364 AAATTGTGGGAAGTTCCTGG 
CCCCTGGTCTC AG AT ATGTC
TET 112-136
D18S363 TTGGG AACTGCTCT AC ATTC 
GCTTCATTCTCTCACTGGAT
HEX 177-247
D18S541 CTCCCAAATATGGAATGGAA 
TG AGCTGAG ATC AT ATC AATGC
FAM 272-283
D18S470 AGCTT ACC AC A AGGC AT A ACT 
AGGGT AG ACTGTT AACTGCNTT AGA
HEX 275
D19S223 CAAAATCGAGGTGCATAGAA 
ACCATGACTGGCTAATTGTG
TET 228-246
D21S156 GTC A AC AT AGTG AG ACCCC A 
ATCCAGCCTGTAACACATTC
HEX 77-107
Genomic CTTCATTGACCTCAACTACATG - 391
GAPDH TGTCATGGATGACCTTGGCCAG
Primers used for Reverse Transcription PCR
SNX10F TGTTGCTTTGTTACCCAGCCT
TGTGTTTTTCAAAACTGCTGT
- 440
KLK12 TGTTTGAGGGCACCAGCCT 
TGGC AGG AGTT AA AGTTCC A
- 509
BRPF1 TGACTCATTTCTGGTCTTGGG
CAAATGACTCTGGCGCGA
- 429
PHLDB2 TGTGCTCTTTTGGATGGAGAA
GGCTGGAGTATTTCTTTTCCA
- 435
ZBTB10 CATGGTTAGATGCATCTTTTG 
AAGGAAGGGGATAAATGGGA
- 264
PIM1 TCT ACTC AGGC ATCCGCGT 
AAGAAAACCTGGCCCCTGAT
- 610
AMACR TCGCTAGTGCTGGACCTGAA
AACAGCCATGAATTCCCCAT
- 546
EZH2 AAAAGCAGAAAGATCTGGAGG 
GGAGGTTC A AT ATTTGGCTTC
- 688
cDNA GAPDH TTTCCCATTCAAGACCTGTGG 
TGGC AC AG ATTTC AGCTCCT A
- 204
Hepsin AG A AC AGC A ACG AT ATTGCCC 
TTTATGGCCTGGAAGATCCA
756
* Product size information for LOH loci obtained from the G DB Human G enom e Database (w w w .gdb.org) 
when given.
223
